Processing 00000000.tx.1: Result of high-dose imatinib mesylate in patients with Philadelphia chromosomepositive chronic myeloid leukemia after failure of interferon- Jorge Cortes, Francis Giles, Susan O'Brien, Deborah Thomas, Guillermo Garcia-Manero, Mary Beth Rios, Stefan Faderl, Srdan Verstovsek, Alessandra Ferrajoli, Emil J. 

Phrase: "Result of high-dose imatinib mesylate"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C1274040:Result [Functional Concept]
   753   C1546471:Result [Idea or Concept]
   753   C2825142:Result [Finding]

Phrase: "in patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "with Philadelphia chromosomepositive chronic myeloid leukemia"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   884   C0023473:Chronic myeloid leukaemia [Neoplastic Process]
   884   C2984277:Chronic myeloid leukemia [Functional Concept]
   853   C1279296:Chronic leukaemia [Neoplastic Process]
   840   C0023470:Myeloid Leukemia [Neoplastic Process]
   804   C0023418:Leukaemia [Neoplastic Process]
   804   C0205191:chronic [Temporal Concept]
   804   C0439677:Myeloid [Qualitative Concept]

Phrase: "after failure"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0231174:Failure [Functional Concept]
  1000   C0680095:failure [Individual Behavior]

Phrase: "of interferon- Jorge Cortes,"

Phrase: "Francis Giles,"

Phrase: "Susan O'Brien,"

Phrase: "Deborah Thomas,"

Phrase: "Guillermo Garcia-Manero,"

Phrase: "Mary Beth Rios,"

Phrase: "Stefan Faderl,"

Phrase: "Srdan Verstovsek,"

Phrase: "Alessandra Ferrajoli,"

Phrase: "Emil J."
Processing 00000000.tx.2: Freireich, Moshe Talpaz, and Hagop Kantarjian From the Department of Leukemia and Bioimmunotherapy, University of Texas, M. 

Phrase: "Freireich,"

Phrase: "Moshe Talpaz,"

Phrase: "and"

Phrase: "Hagop Kantarjian From the Department of Leukemia"

Phrase: "and"

Phrase: "Bioimmunotherapy,"

Phrase: "University of Texas,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0039711:Texas [Geographic Area]
   827   C0041740:University [Manufactured Object,Organization]

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.3: D. 

Phrase: "D."
Processing 00000000.tx.4: Anderson Cancer Center, Houston, TX.  

Phrase: "Anderson Cancer Center,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C1513817:Cancer Center [Health Care Related Organization]
   827   C0205099:Center [Spatial Concept]

Phrase: "Houston,"

Phrase: "TX."
Processing 00000000.tx.5: Abstract Top Abstract Introduction Patients and methods Results Discussion References  Imatinib at 400 mg daily is effective in chronic-phase chronic myeloid leukemia (CML) after interferon failure, although only a few patients achieve a molecular remission. 

Phrase: "Abstract Top Abstract Introduction Patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C0030705:Patients [Patient or Disabled Group]

Phrase: "and"

Phrase: "methods Results Discussion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0557061:Discussion [Therapeutic or Preventive Procedure]
   827   C2584313:Discussion [Social Behavior]

Phrase: "References"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Imatinib at 400 mg daily"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   844   C1331284:imatinib 400 MG [Clinical Drug]
   760   C0935989:imatinib [Organic Chemical,Pharmacologic Substance]

Phrase: "is"

Phrase: "effective in chronic-phase chronic myeloid leukemia (CML)"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C1280519:effective [Qualitative Concept]
   748   C1704419:Effective [Qualitative Concept]
   731   C0023474:Chronic phase chronic myeloid leukaemia [Neoplastic Process]

Phrase: "after interferon failure,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0231174:Failure [Functional Concept]
   861   C0680095:failure [Individual Behavior]

Phrase: "although"

Phrase: "only"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205171:Only [Quantitative Concept]
  1000   C1720467:Only [Intellectual Product]

Phrase: "a few patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "achieve"

Phrase: "a molecular remission."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0544452:Remission [Finding]
   861   C0687702:remission [Neoplastic Process]
Processing 00000000.tx.6: We investigated whether higher doses of imatinib may be more effective. 

Phrase: "We"

Phrase: "investigated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1292732:investigated [Functional Concept]

Phrase: "whether"

Phrase: "higher doses of imatinib"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   799   C0444956:High dose [Quantitative Concept]
   770   C0178602:Doses [Quantitative Concept]
   737 E C0869039:Dose [Quantitative Concept]
   737 E C1114758:Dose # [Clinical Attribute]
   737 E C1428722:DOS [Gene or Genome]

Phrase: "may"

Phrase: "be"

Phrase: "more effective."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1280519:effective [Qualitative Concept]
   861   C1704419:Effective [Qualitative Concept]
Processing 00000000.tx.7: Thirty-six patients with chronic-phase CML after failure on interferon- were treated with 400 mg imatinib twice daily. 

Phrase: "Thirty-six patients with chronic-phase CML"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C0030705:Patients [Patient or Disabled Group]

Phrase: "after failure"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0231174:Failure [Functional Concept]
  1000   C0680095:failure [Individual Behavior]

Phrase: "on interferon-"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0021747:Interferon [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
  1000   C0733470:Interferon [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "were"

Phrase: "treated with 400 mg imatinib twice daily."
Meta Candidates (Total=13; Excluded=1; Pruned=0; Remaining=12)
   804   C1331284:imatinib 400 MG [Clinical Drug]
   778   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   778   C0585361:Twice daily [Temporal Concept]
   748   C0332173:Daily [Temporal Concept]
   748   C0439269:mg% [Quantitative Concept]
   748   C0935989:imatinib [Organic Chemical,Pharmacologic Substance]
   748   C1522326:Treated [Functional Concept]
   748   C1720725:Twice [Intellectual Product]
   748   C1948050:Twice [Quantitative Concept]
   748   C1960952:mg % [Quantitative Concept]
   748   C2346927:Mg++ [Element, Ion, or Isotope,Pharmacologic Substance]
   714 E C1292734:TREAT [Functional Concept]
Processing 00000000.tx.8: Median time from diagnosis was 25 months (range, 10-135 months); 

Phrase: "Median time from diagnosis"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   770   C0040223:Time [Temporal Concept]
   770   C3541383:Time [Temporal Concept]
   715 E C0442043:Temporal [Spatial Concept]
   715 E C2362314:Temporal [Temporal Concept]

Phrase: "was"

Phrase: "25 months"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0439231:months [Temporal Concept]
   827 E C0439507:/month [Temporal Concept]

Phrase: "(range,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1514721:Range [Quantitative Concept]
  1000   C2348147:Range [Quantitative Concept]
  1000   C3542016:Range [Intellectual Product]

Phrase: "10-135 months"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0439231:months [Temporal Concept]
   793 E C0439507:/month [Temporal Concept]

Phrase: ")"

Phrase: ";"
Processing 00000000.tx.9: 4 patients (11%) had clonal evolution. 

Phrase: "4 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "(11%"

Phrase: ")"

Phrase: "had"

Phrase: "clonal evolution."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1516669:Clonal Evolution [Neoplastic Process]
   861   C0015219:Evolution [Genetic Function]
Processing 00000000.tx.10: All 11 patients with active disease achieved complete hematologic response. 

Phrase: "All 11 patients with active disease"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0030705:Patients [Patient or Disabled Group]

Phrase: "achieved"

Phrase: "complete hematologic response."
Meta Candidates (Total=11; Excluded=2; Pruned=0; Remaining=9)
   913   C0677874:Complete Response [Finding]
   827   C0018943:Hematologic [Biomedical Occupation or Discipline]
   827   C0205197:Complete [Qualitative Concept]
   827   C0205488:Haematologic [Functional Concept]
   827   C0725685:COMPLEAT [Food]
   827   C0871261:Response [Organism Attribute]
   827   C1704632:Response [Finding]
   827   C1706817:Response [Intellectual Product]
   827   C2911692:Response [Mental Process]
   755 E C0200627:HEMATOLOGY [Laboratory Procedure]
   755 E C0439812:Completeness [Qualitative Concept]
Processing 00000000.tx.11: Excluding patients with fewer than 35% Ph-positive metaphases before the start of therapy, 19 (90%) of 21 evaluable patients achieved a major cytogenetic response. 

Phrase: "Excluding patients with fewer"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0030705:Patients [Patient or Disabled Group]

Phrase: "than 35% Ph-positive metaphases"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   812   C1621812:Metaphases [Cell Function]
   779 E C0025564:Metaphase [Cell Function]

Phrase: "before the start"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439659:Start [Temporal Concept]

Phrase: "of therapy,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039798:therapy [Functional Concept]
  1000   C0087111:Therapy [Therapeutic or Preventive Procedure]
  1000   C1363945:Therapy [Finding]

Phrase: "19"

Phrase: "(90%"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439083:>90 [Quantitative Concept]
  1000   C0439087:<90 [Quantitative Concept]

Phrase: ")"

Phrase: "of 21 evaluable patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C2986511:evaluable patients [Patient or Disabled Group]
   827   C0030705:Patients [Patient or Disabled Group]

Phrase: "achieved"

Phrase: "a major cytogenetic response."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   827   C0010802:Cytogenetic [Biomedical Occupation or Discipline]
   827   C0205164:Major [Qualitative Concept]
   827   C0871261:Response [Organism Attribute]
   827   C1704632:Response [Finding]
   827   C1706817:Response [Intellectual Product]
   827   C2911692:Response [Mental Process]
Processing 00000000.tx.12: Of 27 evaluable patients, 24 (89%) achieved a complete cytogenetic response. 

Phrase: "Of 27 evaluable patients,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C2986511:evaluable patients [Patient or Disabled Group]
   827   C0030705:Patients [Patient or Disabled Group]

Phrase: "24"

Phrase: "(89%"

Phrase: ")"

Phrase: "achieved"

Phrase: "a complete cytogenetic response."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   913   C0677874:Complete Response [Finding]
   827   C0871261:Response [Organism Attribute]
   827   C1704632:Response [Finding]
   827   C1706817:Response [Intellectual Product]
   827   C2911692:Response [Mental Process]
Processing 00000000.tx.13: Quantitative polymerase chain reaction was performed in bone marrow every 3 months. 

Phrase: "Quantitative polymerase chain reaction"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   923   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]
   812   C0337112:Chain [Manufactured Object]
   812   C0392762:Quantitative [Quantitative Concept]
   812   C0443286:Reaction [Functional Concept]
   812   C1114821:Reaction [Clinical Attribute]
   812   C1335439:Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   812   C1524075:Chain [Idea or Concept]

Phrase: "was"

Phrase: "performed in bone marrow"
Meta Candidates (Total=14; Excluded=5; Pruned=0; Remaining=9)
   833   C0005953:Bone Marrow [Tissue]
   791 E C1708973:Medullary Bone [Tissue]
   770   C0086590:Marrow [Food]
   770   C0262950:Bone, NOS [Body Part, Organ, or Organ Component]
   770   C0376152:Marrow [Body Part, Organ, or Organ Component]
   770   C0391978:Bone [Tissue]
   770   C0884358:Performed [Functional Concept]
   770   C1266908:Bone [Body Part, Organ, or Organ Component]
   770   C1266909:Bone [Body System]
   770   C1546708:Marrow [Intellectual Product]
   737 E C2947996:Perform [Pharmacologic Substance]
   715 E C0001629:Medullary [Body Part, Organ, or Organ Component]
   715 E C0025148:Medullary [Body Part, Organ, or Organ Component]
   715 E C1550278:Medullary [Body Part, Organ, or Organ Component]

Phrase: "every 3 months."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C1442461:3 Months [Temporal Concept]
   861   C0439231:months [Temporal Concept]
   827 E C0439507:/month [Temporal Concept]
Processing 00000000.tx.14: Of 32 evaluable patients, 18 (56%) showed BCR-ABL/ABL percentage ratios lower than 0.045%, including 13 (41%) with undetectable levels. 

Phrase: "Of 32 evaluable patients,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C2986511:evaluable patients [Patient or Disabled Group]
   827   C0030705:Patients [Patient or Disabled Group]

Phrase: "18"

Phrase: "(56%"

Phrase: ")"

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "BCR-ABL/ABL percentage ratios"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   804   C0456603:Ratios [Quantitative Concept]
   804   C1610540:*Ratios [Quantitative Concept]
   771 E C1547037:Ratio [Intellectual Product]

Phrase: "lower than 0.045%,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0441994:Lower [Spatial Concept]
   770   C1548802:Lower [Body Location or Region]
   770   C2003888:Lower [Activity]

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "13"

Phrase: "(41%"

Phrase: ")"

Phrase: "with undetectable levels."
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   861   C0441889:Levels [Qualitative Concept]
   827 E C0456079:Level [Classification]
   827 E C1547707:Level [Geographic Area]
   827 E C2946261:Level [Pharmacologic Substance]
Processing 00000000.tx.15: With a median follow-up of 15 months, all patients were alive in chronic phase. 

Phrase: "With a median"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0549183:Median [Spatial Concept]
  1000   C0876920:Median [Quantitative Concept]
  1000   C2347635:Median [Quantitative Concept]
  1000   C2348144:Median [Quantitative Concept]
  1000   C2939193:Median [Spatial Concept]

Phrase: "follow-up of 15 months,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   806   C0589120:Follow-up [Finding]
   806   C1522577:follow-up [Health Care Activity]
   806   C1704685:FOLLOW-UP [Intellectual Product]
   806   C3274571:FOLLOW-UP [Health Care Activity]
   760   C0332283:follow [Temporal Concept]
   760   C1719822:Follow [Intellectual Product]

Phrase: "all patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "were"

Phrase: "alive in chronic phase."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0376558:Alive [Idea or Concept]
   770   C2584946:Alive [Finding]
Processing 00000000.tx.16: Toxicities were similar to those reported with standard dose; 

Phrase: "Toxicities"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
  1000   C0600688:toxicities [Injury or Poisoning]
   966 E C0040539:toxicity [Qualitative Concept]
   916 E C1407029:Toxic [Qualitative Concept]
   900 E C0032346:Poison [Hazardous or Poisonous Substance]
   900 E C1548769:Poison [Intellectual Product]
   900 E C1550590:poison [Idea or Concept]

Phrase: "were"

Phrase: "similar to those"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C2348205:Similar [Qualitative Concept]

Phrase: "reported with standard dose"
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
   770   C0178602:Dose [Quantitative Concept]
   770   C0684224:Reported [Intellectual Product]
   770   C0700287:Reported [Health Care Activity]
   770   C0869039:Dose [Quantitative Concept]
   770   C1114758:Dose # [Clinical Attribute]
   770   C1442989:Standard [Qualitative Concept]
   770   C2828392:Standard [Intellectual Product]
   770   C3496591:Reported [Clinical Attribute]
   737 E C3273238:Report [Intellectual Product]

Phrase: ";"
Processing 00000000.tx.17: 71% of patients continue to receive 600 mg or more of imatinib daily. 

Phrase: "71% of patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0030705:Patients [Patient or Disabled Group]
   790   C0450389:71 [Intellectual Product]

Phrase: "continue"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0549178:Continue [Idea or Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "receive"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Receive [Qualitative Concept]

Phrase: "600 mg"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0439269:mg% [Quantitative Concept]
   861   C1960952:mg % [Quantitative Concept]
   861   C2346927:Mg++ [Element, Ion, or Isotope,Pharmacologic Substance]

Phrase: "or"

Phrase: "more of imatinib daily."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0205172:More [Functional Concept]
   770   C0332173:Daily [Temporal Concept]
   770   C0935989:imatinib [Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.18: In conclusion, high-dose imatinib induces complete cytogenetic responses in most patients with chronic-phase CML after interferon failure. 

Phrase: "In conclusion,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707478:Conclusion [Idea or Concept]

Phrase: "high-dose imatinib"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0935989:imatinib [Organic Chemical,Pharmacologic Substance]
   734   C0444956:High dose [Quantitative Concept]

Phrase: "induces"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205263:Induce [Functional Concept]

Phrase: "complete cytogenetic responses in most patients"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   767   C0677874:Complete Response [Finding]
   753   C0871261:responses [Organism Attribute]
   719 E C1704632:Response [Finding]
   719 E C1706817:Response [Intellectual Product]
   719 E C2911692:Response [Mental Process]

Phrase: "with chronic-phase CML"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
  1000   C0023474:Chronic phase chronic myeloid leukaemia [Neoplastic Process]
           Leukemia, Myeloid, Chronic-Phase
   911   C0023473:Chronic myeloid leukaemia [Neoplastic Process]
   911   C2984277:Chronic myeloid leukemia [Functional Concept]
   897   C1279296:Chronic leukaemia [Neoplastic Process]
   840   C0023470:Myeloid Leukemia [Neoplastic Process]
   840   C0457343:Chronic phase [Temporal Concept]
   804   C0023418:Leukaemia [Neoplastic Process]
   804   C0205191:chronic [Temporal Concept]
   804   C0205390:Phase [Temporal Concept]
   804   C0439677:Myeloid [Qualitative Concept]

Phrase: "after interferon failure."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0231174:Failure [Functional Concept]
   861   C0680095:failure [Individual Behavior]
Processing 00000000.tx.19: This is accompanied by a high rate of molecular remission. 

Phrase: "This"

Phrase: "is"

Phrase: "accompanied by a high rate of molecular remission."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   744   C0205250:High [Qualitative Concept]
   744   C0544452:Remission [Finding]
   744   C0687702:remission [Neoplastic Process]
   744   C0871208:Rate [Activity]
   744   C1299351:High [Qualitative Concept]
   744   C1521828:Rate [Quantitative Concept]
   744   C1521991:Molecular [Qualitative Concept]
   744   C2700149:HIGH [Intellectual Product]
Processing 00000000.tx.20: (Blood. 

Phrase: "(Blood."
Meta Candidates (Total=10; Excluded=7; Pruned=0; Remaining=3)
  1000   C0005767:Blood [Tissue]
  1000   C0005768:blood [Body Substance]
  1000   C0229664:Blood [Body Substance]
   928 E C0333275:Bloody [Qualitative Concept]
   916 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   916 E C0392895:Bloods [Population Group]
   916 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   916 E C1511228:VESSEL, BLOOD [Tissue]
   900 E C1558950:VASCULAR [Finding]
   900 E C1801960:Vascular [Qualitative Concept]
Processing 00000000.tx.21: 2003;102:83-86)  Introduction Top Abstract Introduction Patients and methods Results Discussion References  Imatinib mesylate (STI571; Gleevec) is a potent tyrosine kinase inhibitor with selectivity against c-abl and bcr/abl, as well as c-kit and platelet-derived growth factor receptor (PDGF-R).1,2 Significant activity has been demonstrated in patients with Philadelphia chromosome (Ph)positive chronic myeloid leukemia (CML) after failure of interferon-alpha (IFN-) therapy. 

Phrase: "2003"

Phrase: ";102"

Phrase: ":"

Phrase: "83-86"

Phrase: ")"

Phrase: "Introduction Top Abstract Introduction Patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C0030705:Patients [Patient or Disabled Group]

Phrase: "and"

Phrase: "methods Results Discussion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0557061:Discussion [Therapeutic or Preventive Procedure]
   827   C2584313:Discussion [Social Behavior]

Phrase: "References"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Imatinib mesylate"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0939537:Imatinib mesilate [Organic Chemical,Pharmacologic Substance]
   861   C0025619:Mesilate [Organic Chemical]
   861   C0066087:mesilate [Organic Chemical]
   861   C0935989:imatinib [Organic Chemical,Pharmacologic Substance]
   861   C3645051:mesylate [Organic Chemical]

Phrase: "(STI571"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0906802:STI-571 [Organic Chemical,Pharmacologic Substance]

Phrase: "; Gleevec"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0935987:Gleevec [Organic Chemical,Pharmacologic Substance]

Phrase: ")"

Phrase: "is"

Phrase: "a potent tyrosine kinase inhibitor with selectivity"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   814   C1268567:Tyrosine Kinase Inhibitor [Pharmacologic Substance]
   778   C0033681:Tyrosine Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   778   C1171350:Kinase Inhibitor [Pharmacologic Substance]
   778   C3537023:kinase inhibitor [Molecular Function]
   778   C3537035:kinase inhibitor [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   748   C0031727:Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   748   C0041485:Tyrosine [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]
   748   C1999216:Inhibitor [Qualitative Concept]

Phrase: "against c-abl"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0079050:c abl [Gene or Genome]
  1000   C1412097:c-ABL [Gene or Genome]
  1000   C1704928:c-Abl [Gene or Genome]
           ABL
   861   C1553033:[c] [Quantitative Concept]

Phrase: "and"

Phrase: "bcr/abl,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0004891:BCR/ABL [Amino Acid, Peptide, or Protein,Biologically Active Substance]
  1000   C1835417:BCR-ABL [Gene or Genome]
   861   C1704928:ABL [Gene or Genome]

Phrase: "as well as"

Phrase: "c-kit"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0072470:c kit [Amino Acid, Peptide, or Protein,Immunologic Factor,Receptor]
   861   C0812225:KIT [Medical Device]
   861   C1150635:KIT [Molecular Function]
   861   C1553033:[c] [Quantitative Concept]
   861   C1705212:Kit [Medical Device]
   861   C1705213:KIT [Medical Device]
   861   C3273202:Kit [Manufactured Object]

Phrase: "and"

Phrase: "platelet-derived growth factor receptor (PDGF-R).1,"
Meta Candidates (Total=18; Excluded=1; Pruned=0; Remaining=17)
  1000   C0290068:Platelet-Derived Growth Factor Receptor 1 [Amino Acid, Peptide, or Protein,Enzyme,Receptor]
   947   C0071253:Platelet-Derived Growth Factor Receptor [Amino Acid, Peptide, or Protein,Enzyme,Receptor]
   901   C0032200:Platelet-Derived Growth Factor [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   898   C0071241:platelet factor 1 [Amino Acid, Peptide, or Protein]
   861   C0206454:Growth Factor Receptor [Amino Acid, Peptide, or Protein,Receptor]
   858   C1979795:Platelet factor [Amino Acid, Peptide, or Protein]
   827   C0018284:Growth Factor [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0005821:Platelet [Cell]
   799   C0018270:'growth' NOS [Organism Function]
   799   C0220844:growth [Physiologic Function]
   799   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   799   C1441547:Derived [Qualitative Concept]
   799   C1521761:Factor [Functional Concept]
   799   C1621966:Growth [Organ or Tissue Function]
   799   C2827422:Factor [Conceptual Entity]
   799   C2911660:Growth [Activity]
   799   C3245521:derived [Idea or Concept]
   716 E C1963076:Platelets [Finding]

Phrase: "2 Significant activity"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0205177:Activity [Functional Concept]
   827   C0439167:% activity [Quantitative Concept]
   827   C0441655:Activity [Activity]
   827   C1561536:*Activity [Idea or Concept]

Phrase: "has"

Phrase: "been"

Phrase: "demonstrated in patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0030705:Patients [Patient or Disabled Group]

Phrase: "with Philadelphia chromosome"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0031526:Philadelphia Chromosome [Pathologic Function]
   861   C0008633:Chromosome [Cell Component]
   861   C0031525:Philadelphia [Geographic Area]

Phrase: "(Ph)positive chronic myeloid leukemia"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   884   C0023473:Chronic myeloid leukaemia [Neoplastic Process]
   884   C2984277:Chronic myeloid leukemia [Functional Concept]
   853   C1279296:Chronic leukaemia [Neoplastic Process]
   840   C0023470:Myeloid Leukemia [Neoplastic Process]
   804   C0023418:Leukaemia [Neoplastic Process]
   804   C0205191:chronic [Temporal Concept]
   804   C0439677:Myeloid [Qualitative Concept]

Phrase: "(CML"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0023473:Chronic myeloid leukaemia [Neoplastic Process]
  1000   C2984277:Chronic myeloid leukemia [Functional Concept]
   913   C1279296:Chronic leukaemia [Neoplastic Process]
   901   C0023470:Myeloid Leukemia [Neoplastic Process]
   827   C0023418:Leukaemia [Neoplastic Process]
   827   C0205191:chronic [Temporal Concept]
   827   C0439677:Myeloid [Qualitative Concept]

Phrase: ")"

Phrase: "after"

Phrase: "failure of interferon-alpha"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0231174:Failure [Functional Concept]
   770   C0680095:failure [Individual Behavior]

Phrase: "(IFN-) therapy."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039798:therapy [Functional Concept]
   861   C0087111:Therapy [Therapeutic or Preventive Procedure]
   861   C1363945:Therapy [Finding]
Processing 00000000.tx.22: The standard dose recommended for chronic-phase CML is 400 mg daily. 

Phrase: "The standard dose"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   861   C0178602:Dose [Quantitative Concept]
   861   C0869039:Dose [Quantitative Concept]
   861   C1114758:Dose # [Clinical Attribute]
   861   C1442989:Standard [Qualitative Concept]
   861   C2828392:Standard [Intellectual Product]

Phrase: "recommended for chronic-phase CML"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   897   C0023474:Chronic phase chronic myeloid leukaemia [Neoplastic Process]
           Leukemia, Myeloid, Chronic-Phase
   804   C0023473:Chronic myeloid leukaemia [Neoplastic Process]
   804   C2984277:Chronic myeloid leukemia [Functional Concept]
   778   C0023470:Myeloid Leukemia [Neoplastic Process]
   778   C0457343:Chronic phase [Temporal Concept]
   774   C1279296:Chronic leukaemia [Neoplastic Process]
   748   C0023418:Leukaemia [Neoplastic Process]
   748   C0034866:Recommended [Idea or Concept]
   748   C0205191:chronic [Temporal Concept]
   748   C0205390:Phase [Temporal Concept]
   748   C0439677:Myeloid [Qualitative Concept]

Phrase: "is"

Phrase: "400 mg daily."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0439269:mg% [Quantitative Concept]
   827   C1960952:mg % [Quantitative Concept]
   827   C2346927:Mg++ [Element, Ion, or Isotope,Pharmacologic Substance]
Processing 00000000.tx.23: With these doses, more than 90% of patients treated in chronic-phase CML after IFN- failure achieve a complete hematologic response (CHR),3,4 and 60% achieve a major cytogenetic (CG) response, which is complete in 40%.3,4 After a median follow-up of 18 months, 90% of patients have not transformed to the accelerated or blastic phase. 

Phrase: "With these doses,"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0178602:Doses [Quantitative Concept]
   966 E C0869039:Dose [Quantitative Concept]
   966 E C1114758:Dose # [Clinical Attribute]
   966 E C1428722:DOS [Gene or Genome]

Phrase: "more than 90% of patients"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0030705:Patients [Patient or Disabled Group]
   760   C0205172:More [Functional Concept]
   760   C0439083:>90 [Quantitative Concept]
   760   C0439087:<90 [Quantitative Concept]

Phrase: "treated in chronic-phase CML"
Meta Candidates (Total=14; Excluded=1; Pruned=0; Remaining=13)
   897   C0023474:Chronic phase chronic myeloid leukaemia [Neoplastic Process]
           Leukemia, Myeloid, Chronic-Phase
   804   C0023473:Chronic myeloid leukaemia [Neoplastic Process]
   804   C2984277:Chronic myeloid leukemia [Functional Concept]
   778   C0023470:Myeloid Leukemia [Neoplastic Process]
   778   C0457343:Chronic phase [Temporal Concept]
   774   C1279296:Chronic leukaemia [Neoplastic Process]
   748   C0023418:Leukaemia [Neoplastic Process]
   748   C0205191:chronic [Temporal Concept]
   748   C0205390:Phase [Temporal Concept]
   748   C0332293:treated [Therapeutic or Preventive Procedure]
   748   C0439677:Myeloid [Qualitative Concept]
   748   C1522326:Treated [Functional Concept]
   714 E C1292734:TREAT [Functional Concept]

Phrase: "after IFN- failure"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0231174:Failure [Functional Concept]
   861   C0680095:failure [Individual Behavior]

Phrase: "achieve"

Phrase: "a complete hematologic response (CHR),"
Meta Candidates (Total=11; Excluded=2; Pruned=0; Remaining=9)
   913   C0677874:Complete Response [Finding]
   827   C0018943:Hematologic [Biomedical Occupation or Discipline]
   827   C0205197:Complete [Qualitative Concept]
   827   C0205488:Haematologic [Functional Concept]
   827   C0725685:COMPLEAT [Food]
   827   C0871261:Response [Organism Attribute]
   827   C1704632:Response [Finding]
   827   C1706817:Response [Intellectual Product]
   827   C2911692:Response [Mental Process]
   755 E C0200627:HEMATOLOGY [Laboratory Procedure]
   755 E C0439812:Completeness [Qualitative Concept]

Phrase: "3,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]

Phrase: "4"

Phrase: "and"

Phrase: "60%"

Phrase: "achieve"

Phrase: "a major cytogenetic (CG) response,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   827   C0010802:Cytogenetic [Biomedical Occupation or Discipline]
   827   C0205164:Major [Qualitative Concept]
   827   C0871261:Response [Organism Attribute]
   827   C1704632:Response [Finding]
   827   C1706817:Response [Intellectual Product]
   827   C2911692:Response [Mental Process]

Phrase: "which"

Phrase: "is"

Phrase: "complete in 40%.3,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0205197:Complete [Qualitative Concept]
   770   C0725685:COMPLEAT [Food]

Phrase: "4 After a median"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0549183:Median [Spatial Concept]
   770   C0876920:Median [Quantitative Concept]
   770   C2347635:Median [Quantitative Concept]
   770   C2348144:Median [Quantitative Concept]
   770   C2939193:Median [Spatial Concept]

Phrase: "follow-up of 18 months,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   806   C0589120:Follow-up [Finding]
   806   C1522577:follow-up [Health Care Activity]
   806   C1704685:FOLLOW-UP [Intellectual Product]
   806   C3274571:FOLLOW-UP [Health Care Activity]
   760   C0332283:follow [Temporal Concept]
   760   C1719822:Follow [Intellectual Product]

Phrase: "90% of patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0030705:Patients [Patient or Disabled Group]
   790   C0439083:>90 [Quantitative Concept]
   790   C0439087:<90 [Quantitative Concept]

Phrase: "have"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "transformed to the accelerated"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0521110:Accelerated [Functional Concept]
   770   C1510411:Transformed [Pathologic Function]

Phrase: "or"

Phrase: "blastic phase."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   964   C0005699:Blast Phase [Neoplastic Process]
   861   C0205390:Phase [Temporal Concept]
Processing 00000000.tx.24: As significant as these responses are, most patients still do not achieve a complete CG response, and 8% have lost their major CG response.3 Achievement of a complete CG response has been associated with 10-year survival rates of 70% to 85%5-8 with IFN-based therapy. 

Phrase: "As significant"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0237881:significant [Quantitative Concept]
  1000   C0750502:Significant [Idea or Concept]
  1000   C1546944:Significant [Qualitative Concept]

Phrase: "as these responses"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0871261:responses [Organism Attribute]
   966 E C1704632:Response [Finding]
   966 E C1706817:Response [Intellectual Product]
   966 E C2911692:Response [Mental Process]

Phrase: "are"

Phrase: ","

Phrase: "most patients still"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "do"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "achieve"

Phrase: "a complete CG response,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   913   C0677874:Complete Response [Finding]
   827   C0871261:Response [Organism Attribute]
   827   C1704632:Response [Finding]
   827   C1706817:Response [Intellectual Product]
   827   C2911692:Response [Mental Process]

Phrase: "and"

Phrase: "8%"

Phrase: "have"

Phrase: "lost"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0745777:Lost [Functional Concept]

Phrase: "their major CG response.3 Achievement of a complete CG response"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   738   C0001072:Achievement [Behavior]

Phrase: "has"

Phrase: "been"

Phrase: "associated with 10-year survival rates of 70%"
Meta Candidates (Total=11; Excluded=2; Pruned=0; Remaining=9)
   770   C0038954:Survival Rates [Quantitative Concept]
   770   C0332281:Associated with [Qualitative Concept]
           Associated
   744   C0038952:Survival [Activity]
   744   C0220921:survival [Functional Concept]
   744   C0439234:year [Temporal Concept]
   744   C0439508:/year [Temporal Concept]
   711 E C0750490:Associate [Idea or Concept]
   711   C0871208:Rate [Activity]
   711   C1521828:Rate [Quantitative Concept]
   711 E C1706221:Associate [Professional or Occupational Group]

Phrase: "to 85%5-8"

Phrase: "with IFN-based therapy."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0039798:therapy [Functional Concept]
   827   C0087111:Therapy [Therapeutic or Preventive Procedure]
   827   C1363945:Therapy [Finding]
Processing 00000000.tx.25: Thus, achievement of a complete CG remission is the most important short-term objective of CML therapy. 

Phrase: "Thus,"

Phrase: "achievement of a complete CG remission"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0001072:Achievement [Behavior]

Phrase: "is"

Phrase: "the most important short-term objective of CML therapy."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   738   C0018017:Objective [Intellectual Product]
   738   C1571702:Objective [Qualitative Concept]
Processing 00000000.tx.26: Furthermore, molecular remissions have been rare among patients treated with standard-dose imatinib.9 Data from imatinib trials suggest that higher doses of imatinib may be more effective. 

Phrase: "Furthermore,"

Phrase: "molecular remissions"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0544452:remissions [Finding]
   861   C0687702:remissions [Neoplastic Process]

Phrase: "have"

Phrase: "been"

Phrase: "rare among patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0521114:Rare [Temporal Concept]
   790   C0522498:Rare [Qualitative Concept]
   790   C1514917:RARE [Gene or Genome]

Phrase: "treated with standard-dose imatinib.9 Data"
Meta Candidates (Total=12; Excluded=1; Pruned=0; Remaining=11)
   778   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   748   C0178602:Dose [Quantitative Concept]
   748   C0869039:Dose [Quantitative Concept]
   748   C0935989:imatinib [Organic Chemical,Pharmacologic Substance]
   748   C1114758:Dose # [Clinical Attribute]
   748   C1442989:Standard [Qualitative Concept]
   748   C1511726:Data [Idea or Concept]
   748   C1522326:Treated [Functional Concept]
   748   C2828392:Standard [Intellectual Product]
   748   C3245479:data [Medical Device]
   714 E C1292734:TREAT [Functional Concept]

Phrase: "from imatinib trials"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0008976:Trial [Research Activity]

Phrase: "suggest"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that higher doses of imatinib"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   773   C0444956:High dose [Quantitative Concept]
   760   C0178602:Doses [Quantitative Concept]
   726 E C0869039:Dose [Quantitative Concept]
   726 E C1114758:Dose # [Clinical Attribute]
   726 E C1428722:DOS [Gene or Genome]

Phrase: "may"

Phrase: "be"

Phrase: "more effective."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1280519:effective [Qualitative Concept]
   861   C1704419:Effective [Qualitative Concept]
Processing 00000000.tx.27: The initial dose-finding phase 1 trial reported a clear relationship between dose and response.10 Complete hematologic responses were achieved in 98% of patients treated at daily doses of 300 mg or higher, compared with 56% in patients treated with 200 or 250 mg daily, and lower responses at doses of less than 200 mg daily. 

Phrase: "The initial dose-"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   861   C0178602:Dose [Quantitative Concept]
   861   C0205265:Initial [Temporal Concept]
   861   C0869039:Dose [Quantitative Concept]
   861   C1114758:Dose # [Clinical Attribute]
   861   C1279901:Initial [Qualitative Concept]
   861   C1555582:Initial [Idea or Concept]
   861   C1705685:INITIAL [Functional Concept]

Phrase: "finding"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0037088:Finding [Sign or Symptom]
  1000   C0243095:Finding [Finding]
  1000   C2825141:Finding [Finding]

Phrase: "phase 1 trial"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0008976:Trial [Research Activity]
   734   C0439559:Phase 1 [Temporal Concept]

Phrase: "reported"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0684224:Reported [Intellectual Product]
  1000   C0700287:Reported [Health Care Activity]
  1000   C3496591:Reported [Clinical Attribute]
   966 E C3273238:Report [Intellectual Product]

Phrase: "a clear relationship between dose"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0439849:Relationship [Qualitative Concept]
   760   C1705630:Relationship [Idea or Concept]
   760   C1706279:Relationship [Idea or Concept]
   760   C3540605:Relationship [Intellectual Product]

Phrase: "and"

Phrase: "response.10 Complete hematologic responses"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   804   C0018943:Hematologic [Biomedical Occupation or Discipline]
   804   C0205197:Complete [Qualitative Concept]
   804   C0205488:Haematologic [Functional Concept]
   804   C0725685:COMPLEAT [Food]
   804   C0871261:responses [Organism Attribute]
   733 E C0200627:HEMATOLOGY [Laboratory Procedure]
   733 E C0439812:Completeness [Qualitative Concept]

Phrase: "were"

Phrase: "achieved in 98% of patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0030705:Patients [Patient or Disabled Group]

Phrase: "treated at daily doses of 300 mg"
Meta Candidates (Total=12; Excluded=4; Pruned=0; Remaining=8)
   748   C0178602:Doses [Quantitative Concept]
   748   C0332173:Daily [Temporal Concept]
   748   C0332293:treated [Therapeutic or Preventive Procedure]
   748   C0439269:mg% [Quantitative Concept]
   748   C1522326:Treated [Functional Concept]
   748   C1960952:mg % [Quantitative Concept]
   748   C2346927:Mg++ [Element, Ion, or Isotope,Pharmacologic Substance]
   745   C2348070:Daily Dose [Quantitative Concept]
   714 E C0869039:Dose [Quantitative Concept]
   714 E C1114758:Dose # [Clinical Attribute]
   714 E C1292734:TREAT [Functional Concept]
   714 E C1428722:DOS [Gene or Genome]

Phrase: "or"

Phrase: "higher,"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   966   C0205250:High [Qualitative Concept]
   966   C1299351:High [Qualitative Concept]
   966   C2700149:HIGH [Intellectual Product]
   916 E C0489786:Height [Organism Attribute]

Phrase: "compared with 56%"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1707455:Compared [Activity]

Phrase: "in patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "treated with 200"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   882   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   790   C1522326:Treated [Functional Concept]
   756 E C1292734:TREAT [Functional Concept]

Phrase: "or"

Phrase: "250 mg daily,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0439269:mg% [Quantitative Concept]
   827   C1960952:mg % [Quantitative Concept]
   827   C2346927:Mg++ [Element, Ion, or Isotope,Pharmacologic Substance]

Phrase: "and"

Phrase: "lower responses at doses of less"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   753   C0871261:responses [Organism Attribute]
   719 E C1704632:Response [Finding]
   719 E C1706817:Response [Intellectual Product]
   719 E C2911692:Response [Mental Process]

Phrase: "than 200 mg daily."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0439269:mg% [Quantitative Concept]
   827   C1960952:mg % [Quantitative Concept]
   827   C2346927:Mg++ [Element, Ion, or Isotope,Pharmacologic Substance]
Processing 00000000.tx.28: Cytogenetic response occurred in 29 (54%) of 54 patients treated at 300 mg/d or higher, while only 2 patients treated at lower doses had such a response.10 In the phase 2 studies, patients in accelerated phase were treated with a daily starting dose of either 400 mg or 600 mg.11 The higher dose induced higher response rates and longer response durations and survival compared with the lower dose. 

Phrase: "Cytogenetic response"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0871261:Response [Organism Attribute]
   861   C1704632:Response [Finding]
   861   C1706817:Response [Intellectual Product]
   861   C2911692:Response [Mental Process]

Phrase: "occurred in 29"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   790   C1709305:Occurred [Activity]
   756 E C2745955:OCCUR [Temporal Concept]

Phrase: "(54%"

Phrase: ")"

Phrase: "of 54 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "treated at 300 mg/d"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   806   C0439423:mg/d [Quantitative Concept]
   760   C0332293:treated [Therapeutic or Preventive Procedure]
   760   C0439269:mg% [Quantitative Concept]
   760   C1522326:Treated [Functional Concept]
   760   C1960952:mg % [Quantitative Concept]
   760   C2346927:Mg++ [Element, Ion, or Isotope,Pharmacologic Substance]
   726 E C1292734:TREAT [Functional Concept]

Phrase: "or"

Phrase: "higher,"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   966   C0205250:High [Qualitative Concept]
   966   C1299351:High [Qualitative Concept]
   966   C2700149:HIGH [Intellectual Product]
   916 E C0489786:Height [Organism Attribute]

Phrase: "while"

Phrase: "only 2 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0030705:Patients [Patient or Disabled Group]

Phrase: "treated at lower doses"
Meta Candidates (Total=10; Excluded=4; Pruned=0; Remaining=6)
   770   C0178602:Doses [Quantitative Concept]
   770   C0332293:treated [Therapeutic or Preventive Procedure]
   770   C0441994:Lower [Spatial Concept]
   770   C1522326:Treated [Functional Concept]
   770   C1548802:Lower [Body Location or Region]
   770   C2003888:Lower [Activity]
   737 E C0869039:Dose [Quantitative Concept]
   737 E C1114758:Dose # [Clinical Attribute]
   737 E C1292734:TREAT [Functional Concept]
   737 E C1428722:DOS [Gene or Genome]

Phrase: "had"

Phrase: "such a response.10 In the phase 2 studies,"
Meta Candidates (Total=10; Excluded=2; Pruned=0; Remaining=8)
   779   C0282460:Phase 2 Study [Research Activity]
   764   C0439560:Phase 2 [Temporal Concept]
   742   C0205390:Phase [Temporal Concept]
   742   C0871261:Response [Organism Attribute]
   742   C0947630:studies [Laboratory Procedure]
   742   C1704632:Response [Finding]
   742   C1706817:Response [Intellectual Product]
   742   C2911692:Response [Mental Process]
   708 E C0557651:Study [Manufactured Object]
   708 E C2603343:Study [Research Activity]

Phrase: "patients in accelerated phase"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0030705:Patients [Patient or Disabled Group]

Phrase: "were"

Phrase: "treated with a daily starting dose of either 400 mg"
Meta Candidates (Total=13; Excluded=1; Pruned=0; Remaining=12)
   760   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   757   C2348070:Daily Dose [Quantitative Concept]
   739   C0178602:Dose [Quantitative Concept]
   739   C0332173:Daily [Temporal Concept]
   739   C0439269:mg% [Quantitative Concept]
   739   C0869039:Dose [Quantitative Concept]
   739   C1114758:Dose # [Clinical Attribute]
   739   C1522326:Treated [Functional Concept]
   739   C1960952:mg % [Quantitative Concept]
   739   C2346927:Mg++ [Element, Ion, or Isotope,Pharmacologic Substance]
   706   C0439659:Start [Temporal Concept]
   706 E C1292734:TREAT [Functional Concept]

Phrase: "or"

Phrase: "600 mg.11"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0439269:mg% [Quantitative Concept]
   827   C1960952:mg % [Quantitative Concept]
   827   C2346927:Mg++ [Element, Ion, or Isotope,Pharmacologic Substance]

Phrase: "The higher dose"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   983   C0444956:High dose [Quantitative Concept]
   861   C0178602:Dose [Quantitative Concept]
   861   C0869039:Dose [Quantitative Concept]
   861   C1114758:Dose # [Clinical Attribute]

Phrase: "induced"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205263:Induced [Functional Concept]

Phrase: "higher response rates"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   867   C0237629:Response Rate [Temporal Concept]
   827   C0871261:Response [Organism Attribute]
   827   C1704632:Response [Finding]
   827   C1706817:Response [Intellectual Product]
   827   C2911692:Response [Mental Process]
   793   C0871208:Rate [Activity]
   793   C1521828:Rate [Quantitative Concept]

Phrase: "and"

Phrase: "longer response durations"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   884   C0237585:Response Duration [Temporal Concept]
   880   C0439591:Long duration [Qualitative Concept]
   827   C0449238:Durations [Temporal Concept]
   793 E C2926735:Duration [Pharmacologic Substance]

Phrase: "and"

Phrase: "survival"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0038952:Survival [Activity]
  1000   C0220921:survival [Functional Concept]

Phrase: "compared with the lower dose."
Meta Candidates (Total=12; Excluded=3; Pruned=0; Remaining=9)
   790   C0445550:Low dose [Quantitative Concept]
   790   C1708745:Low-Dose [Research Activity]
   760   C0178602:Dose [Quantitative Concept]
   760   C0441994:Lower [Spatial Concept]
   760   C0869039:Dose [Quantitative Concept]
   760   C1114758:Dose # [Clinical Attribute]
   760   C1548802:Lower [Body Location or Region]
   760   C1707455:Compared [Activity]
   760   C2003888:Lower [Activity]
   726 E C0205251:low [Qualitative Concept]
   726 E C1299352:Low [Qualitative Concept]
   726 E C1550472:low [Idea or Concept]
Processing 00000000.tx.29: In the chronic-phase trials, imatinib dose escalation to 800 mg daily in patients not responding to 400 mg recaptured CHR in 2 of 3 patients and improved cytogenetic response to a major one in 40%. 

Phrase: "In the chronic-phase trials,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   793   C0008976:Trial [Research Activity]
   734   C0457343:Chronic phase [Temporal Concept]

Phrase: "imatinib dose escalation to 800 mg daily"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   774   C2348070:Daily Dose [Quantitative Concept]
   748   C0178602:Dose [Quantitative Concept]
   748   C0869039:Dose [Quantitative Concept]
   748   C1114758:Dose # [Clinical Attribute]

Phrase: "in patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "responding to 400 mg recaptured CHR"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   767   C0677874:Complete Response [Finding]
   744   C0018943:Hematologic [Biomedical Occupation or Discipline]
   744   C0205197:Complete [Qualitative Concept]
   744   C0205488:Haematologic [Functional Concept]
   744   C0439269:mg% [Quantitative Concept]
   744   C0725685:COMPLEAT [Food]
   744   C0871261:Response [Organism Attribute]
   744   C1704632:Response [Finding]
   744   C1706817:Response [Intellectual Product]
   744   C1960952:mg % [Quantitative Concept]
   744   C2346927:Mg++ [Element, Ion, or Isotope,Pharmacologic Substance]
   744   C2911692:Response [Mental Process]

Phrase: "in 2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: "of 3 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "and"

Phrase: "improved cytogenetic response to a major one"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   748   C0871261:Response [Organism Attribute]
   748   C1704632:Response [Finding]
   748   C1706817:Response [Intellectual Product]
   748   C2911692:Response [Mental Process]

Phrase: "in 40%."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439509:/40 [Temporal Concept]
Processing 00000000.tx.30: Finally, amplification of the BCR/ABL gene or overexpression of its protein product is one of the known mechanisms of resistance.12-15 In this study we investigated the efficacy and toxicity profile of high-dose imatinib in patients with CML after IFN- failure. 

Phrase: "Finally,"

Phrase: "amplification of the BCR/ABL gene"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   783   C0017256:Gene Amplification [Genetic Function]
   783   C1705759:Gene Amplification [Cell or Molecular Dysfunction]
           Amplification
   753   C1517480:Amplification [Molecular Biology Research Technique]
   753   C1521871:Amplification [Phenomenon or Process]

Phrase: "or"

Phrase: "overexpression of its protein product"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   797   C1514559:Protein Overexpression [Genetic Function]
           Overexpression

Phrase: "is"

Phrase: "one of the known mechanisms of resistance.12-15"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C0205447:One [Quantitative Concept]

Phrase: "In this study"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0557651:Study [Manufactured Object]
  1000   C2603343:Study [Research Activity]

Phrase: "we"

Phrase: "investigated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1292732:investigated [Functional Concept]

Phrase: "the efficacy"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1280519:Efficacy [Qualitative Concept]
  1000   C1707887:EFFICACY [Research Activity]

Phrase: "and"

Phrase: "toxicity profile of high-dose imatinib"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C1979963:Profile [Laboratory Procedure]
   753   C2003903:Profile [Functional Concept]

Phrase: "in patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "with CML"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0023473:Chronic myeloid leukaemia [Neoplastic Process]
  1000   C2984277:Chronic myeloid leukemia [Functional Concept]
   913   C1279296:Chronic leukaemia [Neoplastic Process]
   901   C0023470:Myeloid Leukemia [Neoplastic Process]
   827   C0023418:Leukaemia [Neoplastic Process]
   827   C0205191:chronic [Temporal Concept]
   827   C0439677:Myeloid [Qualitative Concept]

Phrase: "after IFN- failure."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0231174:Failure [Functional Concept]
   861   C0680095:failure [Individual Behavior]
Processing 00000000.tx.31: We observed a high rate of major and complete cytogenetic responses and, more important, a high rate of complete molecular remission.  

Phrase: "We"

Phrase: "observed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1441672:Observed [Functional Concept]

Phrase: "a high rate of major"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0205250:High [Qualitative Concept]
   760   C0871208:Rate [Activity]
   760   C1299351:High [Qualitative Concept]
   760   C1521828:Rate [Quantitative Concept]
   760   C2700149:HIGH [Intellectual Product]

Phrase: "and"

Phrase: "complete cytogenetic responses"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   896   C0677874:Complete Response [Finding]
   827   C0871261:responses [Organism Attribute]
   793 E C1704632:Response [Finding]
   793 E C1706817:Response [Intellectual Product]
   793 E C2911692:Response [Mental Process]

Phrase: "and"

Phrase: ","

Phrase: "more important,"

Phrase: "a high rate of complete molecular remission."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   748   C0205250:High [Qualitative Concept]
   748   C0871208:Rate [Activity]
   748   C1299351:High [Qualitative Concept]
   748   C1521828:Rate [Quantitative Concept]
   748   C2700149:HIGH [Intellectual Product]
Processing 00000000.tx.32: Patients and methods Top Abstract Introduction Patients and methods Results Discussion References  Patients with chronic-phase CML were eligible for this study if their disease did not respond to IFN- therapy (according to hematologic or cytogenetic response criteria) or if they could not tolerate IFN- therapy. 

Phrase: "Patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "and"

Phrase: "methods Top Abstract Introduction Patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C0030705:Patients [Patient or Disabled Group]

Phrase: "and"

Phrase: "methods Results Discussion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0557061:Discussion [Therapeutic or Preventive Procedure]
   827   C2584313:Discussion [Social Behavior]

Phrase: "References"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Patients with chronic-phase CML"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0030705:Patients [Patient or Disabled Group]
   731   C0023474:Chronic phase chronic myeloid leukaemia [Neoplastic Process]

Phrase: "were"

Phrase: "eligible for this study"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1548635:eligible [Idea or Concept]

Phrase: "if"

Phrase: "their disease"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0012634:Disease [Disease or Syndrome]
   944 E C1836721:MALS [Finding]
   944 E C3538764:MALS [Gene or Genome]
   944 E C3540595:MAL [Gene or Genome]

Phrase: "did"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "respond to IFN- therapy"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0039798:therapy [Functional Concept]
   770   C0087111:Therapy [Therapeutic or Preventive Procedure]
   770   C1363945:Therapy [Finding]

Phrase: "("

Phrase: "according to hematologic"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0018943:Hematologic [Biomedical Occupation or Discipline]
  1000   C0205488:Haematologic [Functional Concept]
   928 E C0200627:HEMATOLOGY [Laboratory Procedure]

Phrase: "or"

Phrase: "cytogenetic response criteria"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0243161:criteria [Intellectual Product]

Phrase: ")"

Phrase: "or"

Phrase: "if"

Phrase: "they"

Phrase: "could"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "tolerate"

Phrase: "IFN- therapy."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039798:therapy [Functional Concept]
   861   C0087111:Therapy [Therapeutic or Preventive Procedure]
   861   C1363945:Therapy [Finding]
Processing 00000000.tx.33: In addition, to be eligible, patients were required to be 18 years or older and to have adequate performance status (Eastern Cooperative Oncology Group [ECOG] 0 to 3), serum creatinine levels lower than 176.8 M, total bilirubin levels less than 34.2 M, and normal cardiac function (New York Heart Association grades 3-4 cardiac disease excluded). 

Phrase: "In addition,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1883712:Addition [Functional Concept]
   928 E C1524062:Additional [Functional Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "eligible, patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "were"

Phrase: "required"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514873:Required [Functional Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "18 years"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0439234:years [Temporal Concept]
   827 E C0439508:/year [Temporal Concept]

Phrase: "or"

Phrase: "older"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0580836:Old [Temporal Concept]

Phrase: "and"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "have"

Phrase: "adequate performance status"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C1518965:Performance Status [Clinical Attribute]
   827   C0449438:Status [Qualitative Concept]
   827   C0597198:Performance [Individual Behavior]
   827   C1882330:Performance [Activity]

Phrase: "(Eastern Cooperative Oncology Group [ECOG] 0 to 3"
Meta Candidates (Total=13; Excluded=0; Pruned=0; Remaining=13)
   853   C1512162:Eastern Cooperative Oncology Group [Health Care Related Organization]
   778   C1518578:Oncology Group [Professional or Occupational Group]
   774   C0441869:Group 3 [Intellectual Product]
   774   C1521808:Cooperative Group [Professional or Occupational Group]
   748   C0278627:Oncology [Biomedical Occupation or Discipline]
   748   C0441833:Group [Idea or Concept]
   748   C0679729:cooperative [Organization]
   748   C0687744:group [Population Group]
   748   C1257890:Group [Population Group]
   748   C1552516:Group [Health Care Related Organization]
   748   C1705428:Group [Conceptual Entity]
   748   C1705429:Group [Population Group]
   748   C1707877:Eastern [Spatial Concept]

Phrase: ")"

Phrase: ","

Phrase: "serum creatinine levels"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   983   C0600061:Serum creatinine level [Laboratory or Test Result]
           serum creatinine
   901   C0428279:creatinine levels [Laboratory or Test Result]
   827   C0441889:Levels [Qualitative Concept]
   793 E C0456079:Level [Classification]
   793 E C1547707:Level [Geographic Area]
   793 E C2946261:Level [Pharmacologic Substance]
   734   C0201976:Serum creatinine [Laboratory Procedure]

Phrase: "lower than 176.8 M,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0441994:Lower [Spatial Concept]
   760   C1548802:Lower [Body Location or Region]
   760   C2003888:Lower [Activity]

Phrase: "total bilirubin levels less than 34.2 M,"
Meta Candidates (Total=15; Excluded=4; Pruned=0; Remaining=11)
   770   C0005437:Total bilirubin [Biologically Active Substance,Organic Chemical]
           Bilirubin
   770   C0344395:bilirubin levels [Laboratory Procedure]
   770   C0368753:total bilirubin [Laboratory or Test Result]
           Total bilirubin level
   770   C1287365:bilirubin levels [Laboratory or Test Result]
   767   C0201913:Total bilirubin level [Laboratory Procedure]
   767 E C1442893:Bilirubin.total [Laboratory or Test Result]
   750   C0456948:Level 2 [Intellectual Product]
   744   C0439175:% total [Quantitative Concept]
   744   C0439810:Total [Qualitative Concept]
   744   C0441889:Levels [Qualitative Concept]
   711 E C0456079:Level [Classification]
   711 E C1547707:Level [Geographic Area]
   711 E C2946261:Level [Pharmacologic Substance]

Phrase: "and"

Phrase: "normal cardiac function"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   901   C0232164:Cardiac function [Organ or Tissue Function]
   827   C0031843:function [Physiologic Function]
   827   C0542341:Function [Functional Concept]
   827   C0700205:FUNCTION [Classification]
   827   C1705273:Function [Intellectual Product]
   755 E C0205245:Functional [Functional Concept]
   755 E C2700217:Functional [Conceptual Entity]

Phrase: "(New York Heart Association"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   861   C0027976:New York [Geographic Area]
   812   C0004083:Association [Mental Process]
   812   C0018787:Heart [Body Part, Organ, or Organ Component]
   812   C0205314:New [Temporal Concept]
   812   C0439849:Association [Qualitative Concept]
   812   C0596306:Association [Phenomenon or Process]
   812   C0699792:association [Social Behavior]
   812   C1281570:Heart [Body Part, Organ, or Organ Component]

Phrase: "grades"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0441800:Grade [Classification]
  1000   C0919553:Grade [Classification]
  1000   C3244287:grade [Finding]

Phrase: "3-4 cardiac disease"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   875   C0629789:3-MAL [Organic Chemical]
   861   C0018799:Disease, Cardiac [Disease or Syndrome]
   812   C0012634:Disease [Disease or Syndrome]
   812   C0018787:Cardiac [Body Part, Organ, or Organ Component]
   812   C1522601:Cardiac [Spatial Concept]
   756 E C1836721:MALS [Finding]
   756 E C3538764:MALS [Gene or Genome]
   756 E C3540595:MAL [Gene or Genome]

Phrase: "excluded"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C1554077:Excluded [Idea or Concept]
  1000   C2828389:Excluded [Activity]
   966 E C0332196:Exclude [Functional Concept]

Phrase: ")."
Processing 00000000.tx.34: Patients previously treated with imatinib at any dose for any length of time were not eligible, but patients could have received and failed other therapies for CML besides IFN-. 

Phrase: "Patients previously"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "treated with imatinib"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   882   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   790   C0935989:imatinib [Organic Chemical,Pharmacologic Substance]
   790   C1522326:Treated [Functional Concept]
   756 E C1292734:TREAT [Functional Concept]

Phrase: "at any dose"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0178602:Dose [Quantitative Concept]
  1000   C0869039:Dose [Quantitative Concept]
  1000   C1114758:Dose # [Clinical Attribute]

Phrase: "for any length"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C1444754:Length [Quantitative Concept]
  1000   C1706316:LENGTH [Research Activity]
   928 E C0205166:Long [Qualitative Concept]
   928 E C1522425:Longest [Qualitative Concept]
   928 E C1706317:Long [Qualitative Concept]

Phrase: "of time"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0040223:Time [Temporal Concept]
  1000   C3541383:Time [Temporal Concept]
   944 E C0442043:Temporal [Spatial Concept]
   944 E C2362314:Temporal [Temporal Concept]
   916 E C1632851:Times [Quantitative Concept]

Phrase: "were"

Phrase: "not eligible,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1555471:not eligible [Intellectual Product]
   861   C1548635:eligible [Idea or Concept]

Phrase: "but"

Phrase: "patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "could"

Phrase: "have"

Phrase: "received"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Received [Qualitative Concept]

Phrase: "and"

Phrase: "failed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0231175:Failed [Functional Concept]

Phrase: "other therapies for CML"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   790   C0418967:Other therapies [Therapeutic or Preventive Procedure]
   753   C0087111:therapies [Therapeutic or Preventive Procedure]
   719 E C0039798:therapy [Functional Concept]
   719 E C1363945:Therapy [Finding]

Phrase: "besides IFN-."
Processing 00000000.tx.35: Women of childbearing age were required to have a negative pregnancy test before starting imatinib, and all patients at risk were required to use barrier contraception during therapy. 

Phrase: "Women of childbearing age"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0043210:Women [Population Group]

Phrase: "were"

Phrase: "required"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514873:Required [Functional Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "have"

Phrase: "a negative pregnancy test before starting imatinib,"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   814   C0427780:Negative Pregnancy Test [Laboratory or Test Result]
   778   C0032976:Test, Pregnancy [Diagnostic Procedure]
   778   C1880076:Pregnancy Test [Laboratory Procedure]
   748   C0022885:Test [Laboratory Procedure]
   748   C0032961:Pregnancy [Organism Function]
   748   C0039593:Test [Functional Concept]
   748   C0392366:test [Intellectual Product]
   748   C3484365:Pregnancy [Clinical Attribute]

Phrase: "and"

Phrase: "all patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "at risk"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1444641:At risk [Qualitative Concept]
   861   C0035647:Risk [Qualitative Concept]
   861   C1516077:At [Spatial Concept]

Phrase: "were"

Phrase: "required"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514873:Required [Functional Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "use"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0042153:use [Functional Concept]
  1000   C0457083:Use [Functional Concept]
  1000   C1947944:Use [Intellectual Product]

Phrase: "barrier contraception during therapy."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C0004764:Contraception, Barrier [Therapeutic or Preventive Procedure]
   770   C0700589:Contraception [Therapeutic or Preventive Procedure]
Processing 00000000.tx.36: Patients provided written informed consent before entry into the study; 

Phrase: "Patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "provided"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1999230:Provided [Activity]

Phrase: "written informed consent before entry"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   806   C0021430:Informed Consent [Regulation or Law]
   760   C1511481:Consent [Functional Concept]
   760   C1522154:Informed [Qualitative Concept]
   760   C1554192:consent [Idea or Concept]
   726 E C0537670:Inform [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   726 E C0700287:inform [Health Care Activity]
   726 E C1552002:inform [Idea or Concept]

Phrase: "into the study"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0557651:Study [Manufactured Object]
  1000   C2603343:Study [Research Activity]

Phrase: ";"
Processing 00000000.tx.37: the study was reviewed and approved by the internal review board of the institution and performed in accordance with the Declaration of Helsinki. 

Phrase: "the study"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0557651:Study [Manufactured Object]
  1000   C2603343:Study [Research Activity]

Phrase: "was"

Phrase: "reviewed"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0282443:reviewed [Intellectual Product]
  1000   C1709940:Reviewed [Qualitative Concept]
   966 E C1552617:Review [Idea or Concept]

Phrase: "and"

Phrase: "approved by the internal review board of the institution"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   760   C0086911:Review Board, Institutional [Professional or Occupational Group]
   742   C0018704:Institution [Health Care Related Organization,Manufactured Object]
   742   C0205102:Internal [Spatial Concept]
   742   C0205540:Approved [Qualitative Concept]
   742   C0282443:Review [Intellectual Product]
   742   C0972401:board [Medical Device]
   742   C1272753:Institution [Idea or Concept]
   742   C1552617:Review [Idea or Concept]
   742   C1553872:Internal [Intellectual Product]
   742   C1619620:Internal [Intellectual Product]
   742   C1948070:Board [Organization]
   742   C2607850:Institution [Health Care Related Organization]

Phrase: "and"

Phrase: "performed in accordance with the Declaration of Helsinki."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   800   C0018898:Declaration of Helsinki [Regulation or Law]
           Helsinki Declaration
   744   C0884358:Performed [Functional Concept]
   711 E C2947996:Perform [Pharmacologic Substance]
Processing 00000000.tx.38: Patients with accelerated- or blastic-phase CML, as previously defined,16 were excluded. 

Phrase: "Patients with accelerated-"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0030705:Patients [Patient or Disabled Group]

Phrase: "or"

Phrase: "blastic-phase CML,"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C0005699:Blastic phase chronic myeloid leukaemia [Neoplastic Process]
   897   C1378512:Blastic leukemia [Neoplastic Process]
   884   C0023473:Chronic myeloid leukaemia [Neoplastic Process]
   884   C2984277:Chronic myeloid leukemia [Functional Concept]
   853   C1279296:Chronic leukaemia [Neoplastic Process]
   840   C0023470:Myeloid Leukemia [Neoplastic Process]
   804   C0023418:Leukaemia [Neoplastic Process]
   804   C0205191:chronic [Temporal Concept]
   804   C0439677:Myeloid [Qualitative Concept]

Phrase: "as"

Phrase: "previously"

Phrase: "defined"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1704788:Defined [Conceptual Entity]
  1000   C3539106:Defined [Intellectual Product]

Phrase: ","

Phrase: "16"

Phrase: "were"

Phrase: "excluded."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C1554077:Excluded [Idea or Concept]
  1000   C2828389:Excluded [Activity]
   966 E C0332196:Exclude [Functional Concept]
Processing 00000000.tx.39: Patients with cytogenetic clonal evolution were eligible only if there were no other criteria of accelerated-phase CML. 

Phrase: "Patients with cytogenetic clonal evolution"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0030705:Patients [Patient or Disabled Group]

Phrase: "were"

Phrase: "eligible only"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205171:Only [Quantitative Concept]
   861   C1548635:eligible [Idea or Concept]
   861   C1720467:Only [Intellectual Product]

Phrase: "if"

Phrase: "there"

Phrase: "were"

Phrase: "no other criteria of accelerated-phase CML."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C0243161:criteria [Intellectual Product]
Processing 00000000.tx.40: Hematologic and cytogenetic failure to IFN-, and IFN- intolerance were as previously defined.3,4 After initial evaluation of the results of this study, the study was modified to include patients in late chronic phase who had not received and refused therapy with IFN-, and patients who had not achieved a molecular remission after 2 years or longer of IFN- therapy. 

Phrase: "Hematologic"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0018943:Hematologic [Biomedical Occupation or Discipline]
  1000   C0205488:Haematologic [Functional Concept]
   928 E C0200627:HEMATOLOGY [Laboratory Procedure]

Phrase: "and"

Phrase: "cytogenetic failure to IFN-,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0231174:Failure [Functional Concept]
   770   C0680095:failure [Individual Behavior]

Phrase: "and"

Phrase: "IFN- intolerance"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   861   C0231199:Intolerance [Organism Function]
   861   C1744706:intolerance [Intellectual Product]
   861   C2355652:Intolerance [Organism Attribute]
   789 E C0231200:Intolerant [Functional Concept]

Phrase: "were"

Phrase: "as"

Phrase: "previously"

Phrase: "defined.3,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1704788:Defined [Conceptual Entity]
   861   C3539106:Defined [Intellectual Product]

Phrase: "4 After initial evaluation of the results of this study,"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
   757   C0015196:evaluation study [Intellectual Product]
   757   C0683954:results study [Finding]
   741   C1707704:EVALUATION RESULT [Idea or Concept]
   739   C0205265:Initial [Temporal Concept]
   739   C0220825:Evaluation [Functional Concept]
   739   C0557651:Study [Manufactured Object]
   739   C1261322:Evaluation [Health Care Activity]
   739   C1279901:Initial [Qualitative Concept]
   739   C1555582:Initial [Idea or Concept]
   739   C1705685:INITIAL [Functional Concept]
   739   C2603343:Study [Research Activity]
   706   C1274040:Result [Functional Concept]
   706   C1546471:Result [Idea or Concept]
   706   C2825142:Result [Finding]

Phrase: "the study"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0557651:Study [Manufactured Object]
  1000   C2603343:Study [Research Activity]

Phrase: "was"

Phrase: "modified"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0392747:Modified [Functional Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "include"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0332257:include [Functional Concept]
  1000   C1552866:include [Idea or Concept]
  1000   C2700399:Include [Activity]

Phrase: "patients in late chronic phase"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0030705:Patients [Patient or Disabled Group]

Phrase: "who"

Phrase: "had"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "received"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Received [Qualitative Concept]

Phrase: "and"

Phrase: "refused therapy with IFN-,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0039798:therapy [Functional Concept]
   770   C0087111:Therapy [Therapeutic or Preventive Procedure]
   770   C1363945:Therapy [Finding]

Phrase: "and"

Phrase: "patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "who"

Phrase: "had"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "achieved"

Phrase: "a molecular remission after 2 years"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0544452:Remission [Finding]
   753   C0687702:remission [Neoplastic Process]

Phrase: "or"

Phrase: "longer of IFN- therapy."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   737   C0205166:Long [Qualitative Concept]
   737   C1706317:Long [Qualitative Concept]
Processing 00000000.tx.41: Treatment and dose modifications Imatinib was given as an oral dose of 400 mg twice daily. 

Phrase: "Treatment"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0039798:treatment [Functional Concept]
  1000   C0087111:Treatment [Therapeutic or Preventive Procedure]
  1000   C1522326:Treatment [Functional Concept]
  1000   C1533734:Treatment [Therapeutic or Preventive Procedure]
  1000   C1705169:Treatment [Conceptual Entity]
  1000   C3538994:TREATMENT [Research Activity]

Phrase: "and"

Phrase: "dose modifications Imatinib"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0935989:imatinib [Organic Chemical,Pharmacologic Substance]
   717   C1707811:Dose Modification [Research Activity]

Phrase: "was"

Phrase: "given as an oral dose of 400 mg twice daily."
Meta Candidates (Total=16; Excluded=1; Pruned=0; Remaining=15)
   760   C0585361:Twice daily [Temporal Concept]
   757   C2348070:Daily Dose [Quantitative Concept]
   739   C0178602:Dose [Quantitative Concept]
   739   C0332173:Daily [Temporal Concept]
   739   C0439269:mg% [Quantitative Concept]
   739   C0442027:Oral [Spatial Concept]
   739   C0869039:Dose [Quantitative Concept]
   739   C1114758:Dose # [Clinical Attribute]
   739   C1442162:GIVEN [Conceptual Entity]
   739   C1550718:given [Idea or Concept]
   739   C1720725:Twice [Intellectual Product]
   739   C1948050:Twice [Quantitative Concept]
   739   C1960952:mg % [Quantitative Concept]
   739   C2346927:Mg++ [Element, Ion, or Isotope,Pharmacologic Substance]
   739   C3244317:given [Intellectual Product]
   706 E C1947971:Give [Functional Concept]
Processing 00000000.tx.42: Hydroxyurea was allowed for debulking during the first 6 weeks of therapy. 

Phrase: "Hydroxyurea"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0020402:Urea, hydroxy- [Organic Chemical,Pharmacologic Substance]
   944 E C0591617:Hydrea [Organic Chemical,Pharmacologic Substance]

Phrase: "was"

Phrase: "allowed for debulking"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0439805:debulking [Therapeutic or Preventive Procedure]
   790   C0683607:allowed [Social Behavior]
   790   C1706406:Debulking [Therapeutic or Preventive Procedure]

Phrase: "during the first 6 weeks"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0439230:weeks [Temporal Concept]
   793 E C0332174:/week [Temporal Concept]

Phrase: "of therapy."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039798:therapy [Functional Concept]
  1000   C0087111:Therapy [Therapeutic or Preventive Procedure]
  1000   C1363945:Therapy [Finding]
Processing 00000000.tx.43: Anagrelide and leukapheresis (a maximum of 1 procedure per week) were permitted for up to 3 weeks. 

Phrase: "Anagrelide"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0051809:anagrelide [Organic Chemical,Pharmacologic Substance]

Phrase: "and"

Phrase: "leukapheresis"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0023416:Leucapheresis [Therapeutic or Preventive Procedure]

Phrase: "("

Phrase: "a maximum of 1 procedure"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0806909:Maximum [Quantitative Concept]
   760   C1552615:maximum [Quantitative Concept]
   760   C2826546:MAXIMUM [Quantitative Concept]

Phrase: "per week"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332174:/week [Temporal Concept]
  1000   C0439230:week [Temporal Concept]

Phrase: ")"

Phrase: "were"

Phrase: "permitted for"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   833   C0329040:permitted [Fish]
   799 E C0023636:Permit [Regulation or Law]

Phrase: "up to 3 weeks."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C1442462:3 Weeks [Temporal Concept]
   861   C0439230:weeks [Temporal Concept]
   827 E C0332174:/week [Temporal Concept]
Processing 00000000.tx.44: Dose reductions of imatinib for nonhematologic or hematologic toxic effects were as follows. 

Phrase: "Dose reductions of imatinib"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   770   C0301630:reductions [Natural Phenomenon or Process]
   770   C0441610:reductions [Therapeutic or Preventive Procedure]
   737 E C0392756:Reduction [Qualitative Concept]

Phrase: "for nonhematologic"

Phrase: "or"

Phrase: "hematologic toxic effects"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   867   C0600688:Toxic effect [Injury or Poisoning]
           toxic
   827   C1280500:effects [Qualitative Concept]
   827   C1407029:Toxic [Qualitative Concept]
   793 E C2348382:Effect [Qualitative Concept]

Phrase: "were"

Phrase: "as"

Phrase: "follows."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332283:follow [Temporal Concept]
  1000   C1719822:Follow [Intellectual Product]
Processing 00000000.tx.45: For grade 2 persistent nonhematologic toxic effects, therapy was interrupted until recovery to grade 1 or less and resumed at the original dose level. 

Phrase: "For grade 2 persistent nonhematologic toxic effects,"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   799   C0600688:toxic [Injury or Poisoning]
           Toxic effect
   799   C1280500:effects [Qualitative Concept]
   799   C1407029:Toxic [Qualitative Concept]
   766 E C2348382:Effect [Qualitative Concept]

Phrase: "therapy"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039798:therapy [Functional Concept]
  1000   C0087111:Therapy [Therapeutic or Preventive Procedure]
  1000   C1363945:Therapy [Finding]

Phrase: "was"

Phrase: "interrupted until recovery to"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0237820:Recovery [Activity]
   770   C0443239:Interrupted [Qualitative Concept]
   770   C1512900:Interrupted [Temporal Concept]
   770   C1555688:recovery [Idea or Concept]
   770   C2004454:Recovery [Organism Function]

Phrase: "grade"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0441800:Grade [Classification]
  1000   C0919553:Grade [Classification]
  1000   C3244287:grade [Finding]

Phrase: "1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: "or"

Phrase: "less"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439092:less [Intellectual Product]
  1000   C0547044:Less [Qualitative Concept]

Phrase: "and"

Phrase: "resumed at the original dose level."
Meta Candidates (Total=13; Excluded=0; Pruned=0; Remaining=13)
   790   C0178602:Dose Level [Quantitative Concept]
           Dose
   753   C0205313:Original [Idea or Concept]
   753   C0441889:Level [Qualitative Concept]
   753   C0456079:Level [Classification]
   753   C0869039:Dose [Quantitative Concept]
   753   C1114758:Dose # [Clinical Attribute]
   753   C1547707:Level [Geographic Area]
   753   C2347409:Original [Occupational Activity]
   753   C2946261:Level [Pharmacologic Substance]
   719   C1550028:Resume [Idea or Concept]
   719   C1880201:Resume [Intellectual Product]
   719   C3242342:resume [Functional Concept]
Processing 00000000.tx.46: If grade 2 toxicity reappeared, treatment was interrupted again until recovery and resumed at a daily dose of 600 mg. 

Phrase: "If"

Phrase: "grade 2 toxicity"
Meta Candidates (Total=8; Excluded=4; Pruned=0; Remaining=4)
   827   C0040539:toxicity [Qualitative Concept]
   827   C0600688:Toxicity [Injury or Poisoning]
   755 E C1407029:Toxic [Qualitative Concept]
   734 E C0032346:Poison [Hazardous or Poisonous Substance]
   734   C0687696:grade 2 [Intellectual Product]
   734   C1522446:Grade 2 [Qualitative Concept]
   734 E C1548769:Poison [Intellectual Product]
   734 E C1550590:poison [Idea or Concept]

Phrase: "reappeared"

Phrase: ","

Phrase: "treatment"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0039798:treatment [Functional Concept]
  1000   C0087111:Treatment [Therapeutic or Preventive Procedure]
  1000   C1522326:Treatment [Functional Concept]
  1000   C1533734:Treatment [Therapeutic or Preventive Procedure]
  1000   C1705169:Treatment [Conceptual Entity]
  1000   C3538994:TREATMENT [Research Activity]

Phrase: "was"

Phrase: "interrupted"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0443239:Interrupted [Qualitative Concept]
  1000   C1512900:Interrupted [Temporal Concept]

Phrase: "again"

Phrase: "until"

Phrase: "recovery"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0237820:Recovery [Activity]
  1000   C1555688:recovery [Idea or Concept]
  1000   C2004454:Recovery [Organism Function]

Phrase: "and"

Phrase: "resumed at a daily dose of 600 mg."
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   770   C2348070:Daily Dose [Quantitative Concept]
   744   C0178602:Dose [Quantitative Concept]
   744   C0332173:Daily [Temporal Concept]
   744   C0439269:mg% [Quantitative Concept]
   744   C0869039:Dose [Quantitative Concept]
   744   C1114758:Dose # [Clinical Attribute]
   744   C1960952:mg % [Quantitative Concept]
   744   C2346927:Mg++ [Element, Ion, or Isotope,Pharmacologic Substance]
   711   C1550028:Resume [Idea or Concept]
   711   C1880201:Resume [Intellectual Product]
   711   C3242342:resume [Functional Concept]
Processing 00000000.tx.47: For grades 3 or 4 nonhematologic toxicity, therapy was interrupted until recovery to grade 1 or less and resumed at a daily dose of 600 mg. 

Phrase: "For grades 3"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   983   C0450094:Grade 3 [Qualitative Concept]
   983   C0687697:grade 3 [Intellectual Product]
   861   C0441800:Grades [Classification]
   827 E C0919553:Grade [Classification]
   827 E C3244287:grade [Finding]

Phrase: "or"

Phrase: "4 nonhematologic toxicity,"
Meta Candidates (Total=6; Excluded=4; Pruned=0; Remaining=2)
   827   C0040539:toxicity [Qualitative Concept]
   827   C0600688:Toxicity [Injury or Poisoning]
   755 E C1407029:Toxic [Qualitative Concept]
   734 E C0032346:Poison [Hazardous or Poisonous Substance]
   734 E C1548769:Poison [Intellectual Product]
   734 E C1550590:poison [Idea or Concept]

Phrase: "therapy"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039798:therapy [Functional Concept]
  1000   C0087111:Therapy [Therapeutic or Preventive Procedure]
  1000   C1363945:Therapy [Finding]

Phrase: "was"

Phrase: "interrupted until recovery to"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0237820:Recovery [Activity]
   770   C0443239:Interrupted [Qualitative Concept]
   770   C1512900:Interrupted [Temporal Concept]
   770   C1555688:recovery [Idea or Concept]
   770   C2004454:Recovery [Organism Function]

Phrase: "grade"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0441800:Grade [Classification]
  1000   C0919553:Grade [Classification]
  1000   C3244287:grade [Finding]

Phrase: "1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: "or"

Phrase: "less"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439092:less [Intellectual Product]
  1000   C0547044:Less [Qualitative Concept]

Phrase: "and"

Phrase: "resumed at a daily dose of 600 mg."
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   770   C2348070:Daily Dose [Quantitative Concept]
   744   C0178602:Dose [Quantitative Concept]
   744   C0332173:Daily [Temporal Concept]
   744   C0439269:mg% [Quantitative Concept]
   744   C0869039:Dose [Quantitative Concept]
   744   C1114758:Dose # [Clinical Attribute]
   744   C1960952:mg % [Quantitative Concept]
   744   C2346927:Mg++ [Element, Ion, or Isotope,Pharmacologic Substance]
   711   C1550028:Resume [Idea or Concept]
   711   C1880201:Resume [Intellectual Product]
   711   C3242342:resume [Functional Concept]
Processing 00000000.tx.48: For grades 3 to 4 hematologic toxicity (granulocyte count of < 0.5 x 109/L or a platelet count of < 40 x 109/L), therapy was interrupted until the neutrophils recovered to 109/L or higher and/or platelets to 60 x 109/L or higher. 

Phrase: "For grades 3"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   983   C0450094:Grade 3 [Qualitative Concept]
   983   C0687697:grade 3 [Intellectual Product]
   861   C0441800:Grades [Classification]
   827 E C0919553:Grade [Classification]
   827 E C3244287:grade [Finding]

Phrase: "to 4 hematologic toxicity"
Meta Candidates (Total=6; Excluded=4; Pruned=0; Remaining=2)
   827   C0040539:toxicity [Qualitative Concept]
   827   C0600688:Toxicity [Injury or Poisoning]
   755 E C1407029:Toxic [Qualitative Concept]
   734 E C0032346:Poison [Hazardous or Poisonous Substance]
   734 E C1548769:Poison [Intellectual Product]
   734 E C1550590:poison [Idea or Concept]

Phrase: "(granulocyte count of < 0.5 x 109/L"

Phrase: "or"

Phrase: "a platelet count of < 40 x 109/L), therapy"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   793   C0039798:therapy [Functional Concept]
   793   C0087111:Therapy [Therapeutic or Preventive Procedure]
   793   C1363945:Therapy [Finding]

Phrase: "was"

Phrase: "interrupted until the neutrophils"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0027950:Neutrophils [Cell]
   770   C0443239:Interrupted [Qualitative Concept]
   770   C1512900:Interrupted [Temporal Concept]

Phrase: "recovered to 109/L"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C0521108:recovered [Qualitative Concept]
   737 E C2004454:recover [Organism Function]

Phrase: "or"

Phrase: "higher"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   966   C0205250:High [Qualitative Concept]
   966   C1299351:High [Qualitative Concept]
   966   C2700149:HIGH [Intellectual Product]
   916 E C0489786:Height [Organism Attribute]

Phrase: "and/or"

Phrase: "platelets to 60 x 109/L"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   783   C0456525:platelets/L [Quantitative Concept]
   753   C0005821:Platelets [Cell]
   753   C1963076:Platelets [Finding]

Phrase: "or"

Phrase: "higher."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   966   C0205250:High [Qualitative Concept]
   966   C1299351:High [Qualitative Concept]
   966   C2700149:HIGH [Intellectual Product]
   916 E C0489786:Height [Organism Attribute]
Processing 00000000.tx.49: If the toxicity resolved within 2 weeks, treatment was resumed at the original dose of 400 mg twice daily. 

Phrase: "If"

Phrase: "the toxicity"
Meta Candidates (Total=6; Excluded=4; Pruned=0; Remaining=2)
  1000   C0040539:toxicity [Qualitative Concept]
  1000   C0600688:Toxicity [Injury or Poisoning]
   928 E C1407029:Toxic [Qualitative Concept]
   907 E C0032346:Poison [Hazardous or Poisonous Substance]
   907 E C1548769:Poison [Intellectual Product]
   907 E C1550590:poison [Idea or Concept]

Phrase: "resolved within 2 weeks,"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   770   C0439230:weeks [Temporal Concept]
   770   C1514893:Resolved [Idea or Concept]
   770   C2699488:Resolved [Conceptual Entity]
   737 E C0332174:/week [Temporal Concept]

Phrase: "treatment"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0039798:treatment [Functional Concept]
  1000   C0087111:Treatment [Therapeutic or Preventive Procedure]
  1000   C1522326:Treatment [Functional Concept]
  1000   C1533734:Treatment [Therapeutic or Preventive Procedure]
  1000   C1705169:Treatment [Conceptual Entity]
  1000   C3538994:TREATMENT [Research Activity]

Phrase: "was"

Phrase: "resumed at the original dose of 400 mg twice daily."
Meta Candidates (Total=16; Excluded=0; Pruned=0; Remaining=16)
   760   C0585361:Twice daily [Temporal Concept]
   757   C2348070:Daily Dose [Quantitative Concept]
   739   C0178602:Dose [Quantitative Concept]
   739   C0205313:Original [Idea or Concept]
   739   C0332173:Daily [Temporal Concept]
   739   C0439269:mg% [Quantitative Concept]
   739   C0869039:Dose [Quantitative Concept]
   739   C1114758:Dose # [Clinical Attribute]
   739   C1720725:Twice [Intellectual Product]
   739   C1948050:Twice [Quantitative Concept]
   739   C1960952:mg % [Quantitative Concept]
   739   C2346927:Mg++ [Element, Ion, or Isotope,Pharmacologic Substance]
   739   C2347409:Original [Occupational Activity]
   706   C1550028:Resume [Idea or Concept]
   706   C1880201:Resume [Intellectual Product]
   706   C3242342:resume [Functional Concept]
Processing 00000000.tx.50: If toxicity resolved after more than 2 weeks, or if it recurred after resuming therapy, the dose was reduced to 600 mg. 

Phrase: "If"

Phrase: "toxicity"
Meta Candidates (Total=6; Excluded=4; Pruned=0; Remaining=2)
  1000   C0040539:toxicity [Qualitative Concept]
  1000   C0600688:Toxicity [Injury or Poisoning]
   928 E C1407029:Toxic [Qualitative Concept]
   907 E C0032346:Poison [Hazardous or Poisonous Substance]
   907 E C1548769:Poison [Intellectual Product]
   907 E C1550590:poison [Idea or Concept]

Phrase: "resolved"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514893:Resolved [Idea or Concept]
  1000   C2699488:Resolved [Conceptual Entity]

Phrase: "after"

Phrase: "more than 2 weeks,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   770   C0205172:More [Functional Concept]
   770   C0439230:weeks [Temporal Concept]
   737 E C0332174:/week [Temporal Concept]

Phrase: "or"

Phrase: "if"

Phrase: "it"

Phrase: "recurred after resuming therapy,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   770   C0034897:recurred [Phenomenon or Process]
   770   C0039798:therapy [Functional Concept]
   770   C0087111:Therapy [Therapeutic or Preventive Procedure]
   770   C1363945:Therapy [Finding]
   737   C1550028:Resume [Idea or Concept]
   737   C1880201:Resume [Intellectual Product]
   737   C3242342:resume [Functional Concept]

Phrase: "the dose"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0178602:Dose [Quantitative Concept]
  1000   C0869039:Dose [Quantitative Concept]
  1000   C1114758:Dose # [Clinical Attribute]

Phrase: "was"

Phrase: "reduced to 600 mg."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   819   C0240291:mg reduced [Finding]
   770   C0392756:Reduced [Qualitative Concept]
   770   C0439269:mg% [Quantitative Concept]
   770   C1960952:mg % [Quantitative Concept]
   770   C2346927:Mg++ [Element, Ion, or Isotope,Pharmacologic Substance]
Processing 00000000.tx.51: Further dose reductions to 400 mg or 300 mg daily were allowed using the same guidelines for hematologic and nonhematologic toxicity. 

Phrase: "Further dose reductions to 400 mg"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   753   C0301630:reductions [Natural Phenomenon or Process]
   753   C0441610:reductions [Therapeutic or Preventive Procedure]
   719 E C0392756:Reduction [Qualitative Concept]

Phrase: "or"

Phrase: "300 mg daily"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0439269:mg% [Quantitative Concept]
   827   C1960952:mg % [Quantitative Concept]
   827   C2346927:Mg++ [Element, Ion, or Isotope,Pharmacologic Substance]

Phrase: "were"

Phrase: "allowed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0683607:allowed [Social Behavior]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the same guidelines for hematologic"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0162791:Guidelines [Intellectual Product]
   760   C0220845:guidelines [Intellectual Product]
   760   C0282423:guidelines [Intellectual Product]

Phrase: "and"

Phrase: "nonhematologic toxicity."
Meta Candidates (Total=6; Excluded=4; Pruned=0; Remaining=2)
   861   C0040539:toxicity [Qualitative Concept]
   861   C0600688:Toxicity [Injury or Poisoning]
   789 E C1407029:Toxic [Qualitative Concept]
   768 E C0032346:Poison [Hazardous or Poisonous Substance]
   768 E C1548769:Poison [Intellectual Product]
   768 E C1550590:poison [Idea or Concept]
Processing 00000000.tx.52: Patients developing anemia received packed red blood cell transfusions or blood products at the discretion of the investigator, or erythropoietin, 40 000 units given subcutaneously once a week until the hemoglobin level increased to 120 g/L or more. 

Phrase: "Patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "developing"

Phrase: "anemia"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0002871:Anaemia [Disease or Syndrome]
  1000   C1000483:Anemia [Plant]
   928 E C0857322:anaemic [Finding]

Phrase: "received"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Received [Qualitative Concept]

Phrase: "packed red blood cell transfusions"
Meta Candidates (Total=37; Excluded=15; Pruned=0; Remaining=22)
   966   C0199962:packed red blood cell transfusion [Therapeutic or Preventive Procedure]
       E   Red Blood Cell Transfusion
   937   C0086252:Transfusions, Red Blood Cell [Therapeutic or Preventive Procedure]
   922   C0178192:Packed blood cell transfusion [Therapeutic or Preventive Procedure]
           Packed cell transfusion
   884   C0014792:Red blood cell [Cell]
           Red Cell
   884   C0565531:blood cell transfusions [Therapeutic or Preventive Procedure]
   853   C0005841:Blood Transfusions [Therapeutic or Preventive Procedure]
           Transfusions
   840   C0005773:Blood cell [Cell]
   836 E C0455012:Blood Transfusion [Therapeutic or Preventive Procedure]
       E   Transfusion
   812 E C2328697:Hemal cell [Cell]
   804   C0005767:Blood [Tissue]
   804   C0005768:blood [Body Substance]
   804   C0007634:Cell [Cell]
   804   C0184967:Packed [Therapeutic or Preventive Procedure]
   804   C0199960:transfusions [Functional Concept]
   804   C0229664:Blood [Body Substance]
   804   C0332575:Red [Finding]
   804   C1260956:Red [Qualitative Concept]
   804   C1269647:Cell [Cell]
   804   C1704653:Cell [Medical Device]
   804   C1879316:Transfusions [Therapeutic or Preventive Procedure]
   804   C1948049:Cell [Spatial Concept]
   771 E C1968515:Pack [Medical Device]
   771 E C2825051:Pack [Drug Delivery Device]
   771 E C2828395:Pack [Activity]
   733 E C0333275:Bloody [Qualitative Concept]
   721 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   721 E C0392895:Bloods [Population Group]
   721 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   721 E C1511228:VESSEL, BLOOD [Tissue]
   721 E C1549003:Transfused [Idea or Concept]
   704 E C1558950:VASCULAR [Finding]
   704 E C1801960:Vascular [Qualitative Concept]

Phrase: "or"

Phrase: "blood products at the discretion of the investigator,"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   770   C0456388:Blood products [Pharmacologic Substance]
   754 E C1547007:Blood product [Idea or Concept]
   744   C1514468:Products [Entity]
   711 E C1704444:Product [Quantitative Concept]

Phrase: "or"

Phrase: "erythropoietin,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0014822:Erythropoietin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C0357126:ERYTHROPOIETIN [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
  1000   C0376541:Erythropoietin [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
  1000   C1755594:erythropoietin [Molecular Function]

Phrase: "40 000 units"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   827   C0439148:Units [Quantitative Concept]
   827   C1519795:Units [Quantitative Concept]
   793 E C1704753:Unit [Manufactured Object]
   793 E C1880519:Unit [Quantitative Concept]

Phrase: "given"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C1442162:GIVEN [Conceptual Entity]
  1000   C1550718:given [Idea or Concept]
  1000   C3244317:given [Intellectual Product]
   966 E C1947971:Give [Functional Concept]

Phrase: "subcutaneously once"

Phrase: "a week until the hemoglobin level"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0332174:/week [Temporal Concept]
   753   C0439230:week [Temporal Concept]

Phrase: "increased to 120 g/L"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   806   C0439294:g l [Quantitative Concept]
   760   C0205217:Increased [Quantitative Concept]
   760   C0439267:g% [Quantitative Concept]
   760   C0442805:Increased [Functional Concept]

Phrase: "or"

Phrase: "more."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205172:More [Functional Concept]
Processing 00000000.tx.53: Complete blood counts and serum chemistry were performed weekly during the first 4 weeks, every other week for the next 3 months, and every 6 weeks thereafter. 

Phrase: "Complete blood counts"
Meta Candidates (Total=17; Excluded=10; Pruned=0; Remaining=7)
  1000   C0009555:Counts, Complete Blood [Laboratory Procedure]
   827   C0005767:Blood [Tissue]
   827   C0005768:blood [Body Substance]
   827   C0205197:Complete [Qualitative Concept]
   827   C0229664:Blood [Body Substance]
   827   C0439157:counts [Quantitative Concept]
   827   C0725685:COMPLEAT [Food]
   793 E C0750480:Count [Activity]
   793 E C1705566:Count [Quantitative Concept]
   755 E C0333275:Bloody [Qualitative Concept]
   755 E C0439812:Completeness [Qualitative Concept]
   743 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   743 E C0392895:Bloods [Population Group]
   743 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   743 E C1511228:VESSEL, BLOOD [Tissue]
   727 E C1558950:VASCULAR [Finding]
   727 E C1801960:Vascular [Qualitative Concept]

Phrase: "and"

Phrase: "serum chemistry"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0007996:Chemistry [Occupation or Discipline]
   861   C0079107:chemistry [Classification]
   861   C0201682:Chemistry [Laboratory Procedure]

Phrase: "were"

Phrase: "performed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0884358:Performed [Functional Concept]
   966 E C2947996:Perform [Pharmacologic Substance]

Phrase: "weekly during the first 4 weeks,"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   753   C0205435:First [Quantitative Concept]
   753   C0332174:Weekly [Temporal Concept]
       E   /week
   753   C0439230:weeks [Temporal Concept]
   753   C1279901:First [Qualitative Concept]

Phrase: "every"

Phrase: "other week for the next 3 months,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0332174:/week [Temporal Concept]
   748   C0439230:week [Temporal Concept]

Phrase: "and"

Phrase: "every 6 weeks thereafter."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0439230:weeks [Temporal Concept]
   793 E C0332174:/week [Temporal Concept]
Processing 00000000.tx.54: Bone marrow studies, including morphologic and cytogenetic or fluorescent in situ hybridization (iFISH) analysis, were performed every 3 months. 

Phrase: "Bone marrow studies,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   913   C0841669:bone studies [Diagnostic Procedure]
   827   C0947630:studies [Laboratory Procedure]
   793 E C0557651:Study [Manufactured Object]
   793 E C2603343:Study [Research Activity]
   734   C0005953:Bone Marrow [Tissue]

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "morphologic"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   928   C0332437:Morphology [Qualitative Concept]
   928   C0543482:morphology [Spatial Concept]
   928   C0700329:Morphology, NOS [Finding]
   928   C0700619:Morphology [Biomedical Occupation or Discipline]

Phrase: "and"

Phrase: "cytogenetic"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0010802:Cytogenetic [Biomedical Occupation or Discipline]

Phrase: "or"

Phrase: "fluorescent in situ hybridization"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0162789:Fluorescent in Situ Hybridization [Molecular Biology Research Technique]
   923   C0162788:In Situ Hybridization [Laboratory Procedure,Molecular Biology Research Technique]
           situ hybridization
   861   C0444498:In situ [Spatial Concept]
   812   C0020202:Hybridisation [Genetic Function]
   812   C0303920:Fluorescent [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]
   812   C1300517:Hybridization [Laboratory Procedure]

Phrase: "(iFISH"

Phrase: ")"

Phrase: "analysis,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0002778:Analysis [Laboratory Procedure]
  1000   C0936012:Analysis [Research Activity]
  1000   C1524024:analysis [Functional Concept]

Phrase: "were"

Phrase: "performed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0884358:Performed [Functional Concept]
   966 E C2947996:Perform [Pharmacologic Substance]

Phrase: "every 3 months."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C1442461:3 Months [Temporal Concept]
   861   C0439231:months [Temporal Concept]
   827 E C0439507:/month [Temporal Concept]
Processing 00000000.tx.55: Patients were followed for survival at least every 3 months. 

Phrase: "Patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "were"

Phrase: "followed for survival"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   790   C0038952:Survival [Activity]
   790   C0220921:survival [Functional Concept]
   790   C0332283:followed [Temporal Concept]
   756 E C1719822:Follow [Intellectual Product]

Phrase: "at least"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0439092:less [Intellectual Product]
   966   C0547044:Less [Qualitative Concept]

Phrase: "every 3 months."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C1442461:3 Months [Temporal Concept]
   861   C0439231:months [Temporal Concept]
   827 E C0439507:/month [Temporal Concept]
Processing 00000000.tx.56: Drug safety parameters were evaluated at each visit and graded according to the National Cancer Institute (NCI) Common Toxicity Criteria (CTC), version 2.0. 

Phrase: "Drug safety parameters"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   827   C0449381:Parameters [Finding]
   793 E C0549193:Parameter [Spatial Concept]
   793 E C1704769:Parameter [Conceptual Entity]
   793 E C2350001:Parameter [Quantitative Concept]
   734   C0678800:drug safety [Qualitative Concept]

Phrase: "were"

Phrase: "evaluated at each visit"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0220825:Evaluated [Functional Concept]
   770   C0545082:Visit [Behavior]
   770   C1512346:visit [Health Care Activity]
   770   C2826704:VISIT [Intellectual Product]

Phrase: "and"

Phrase: "graded according to the National Cancer Institute (NCI) Common Toxicity Criteria (CTC),"
Meta Candidates (Total=20; Excluded=0; Pruned=0; Remaining=20)
   782   C1513882:National Cancer Institute [Health Care Related Organization]
   782   C1516728:Common Toxicity Criteria [Intellectual Product]
   741   C0804646:Grade Cancer [Clinical Attribute]
   741   C2826262:Toxicity Grade [Quantitative Concept]
   739   C0006826:Cancer [Neoplastic Process]
   739   C0021622:institute [Organization]
   739   C0040539:toxicity [Qualitative Concept]
   739   C0205214:Common [Quantitative Concept]
   739   C0243161:criteria [Intellectual Product]
   739   C0600688:Toxicity [Injury or Poisoning]
   739   C0680240:according [Social Behavior]
   739   C0998265:Cancer [Eukaryote]
   739   C1272753:Institute [Idea or Concept]
   739   C1306459:Cancer [Finding]
   739   C1522138:Common [Functional Concept]
   739   C3245503:national [Intellectual Product]
   739   C3245511:common [Intellectual Product]
   706   C0441800:Grade [Classification]
   706   C0919553:Grade [Classification]
   706   C3244287:grade [Finding]

Phrase: "version 2.0."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0333052:Version [Functional Concept]
   827   C2607870:Version [Spatial Concept]
Processing 00000000.tx.57: Response criteria were as previously described.8 A CHR was defined as a white blood cell count of less than 10 x 109/L, a platelet count of less than 450 x 109/L, no immature cells (blasts, promyelocytes, myelocytes) in the peripheral blood, and disappearance of all signs and symptoms related to leukemia (including palpable splenomegaly) lasting for at least 4 weeks. 

Phrase: "Response criteria"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0243161:criteria [Intellectual Product]

Phrase: "were"

Phrase: "as"

Phrase: "previously"

Phrase: "described.8"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1552738:described [Idea or Concept]

Phrase: "A CHR"
Meta Candidates (Total=11; Excluded=2; Pruned=0; Remaining=9)
   913   C0677874:Complete Response [Finding]
   827   C0018943:Hematologic [Biomedical Occupation or Discipline]
   827   C0205197:Complete [Qualitative Concept]
   827   C0205488:Haematologic [Functional Concept]
   827   C0725685:COMPLEAT [Food]
   827   C0871261:Response [Organism Attribute]
   827   C1704632:Response [Finding]
   827   C1706817:Response [Intellectual Product]
   827   C2911692:Response [Mental Process]
   755 E C0200627:HEMATOLOGY [Laboratory Procedure]
   755 E C0439812:Completeness [Qualitative Concept]

Phrase: "was"

Phrase: "defined as a white blood cell count of less"
Meta Candidates (Total=23; Excluded=1; Pruned=0; Remaining=22)
   818   C0023508:Blood Cell Count, White [Laboratory Procedure]
   818   C0427512:white blood cell count [Laboratory or Test Result]
   790   C0005771:Blood Cell Count [Laboratory Procedure]
   790   C0009555:Blood Cell Count [Laboratory Procedure]
   790   C0023516:White blood cell [Cell]
           White Cell
   764   C0005773:Blood cell [Cell]
   764   C0007584:Cell Count [Laboratory Procedure]
   742   C0005767:Blood [Tissue]
   742   C0005768:blood [Body Substance]
   742   C0007457:White [Population Group]
   742   C0007634:Cell [Cell]
   742   C0043157:White [Population Group]
   742   C0220938:White [Qualitative Concept]
   742   C0229664:Blood [Body Substance]
   742   C0750480:Count [Activity]
   742   C1269647:Cell [Cell]
   742   C1704653:Cell [Medical Device]
   742   C1704788:Defined [Conceptual Entity]
   742   C1705566:Count [Quantitative Concept]
   742   C1948049:Cell [Spatial Concept]
   742   C3539106:Defined [Intellectual Product]
   736 E C2328697:Hemal cell [Cell]

Phrase: "than 10 x 109/L,"

Phrase: "a platelet count of less"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   806   C0032181:Platelet Count [Laboratory Procedure]
   806   C1287267:Platelet count [Laboratory or Test Result]
   760   C0005821:Platelet [Cell]
   760   C0750480:Count [Activity]
   760   C1705566:Count [Quantitative Concept]

Phrase: "than 450 x 109/L,"

Phrase: "no immature cells"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
  1000   C2708700:Immature cells [Cell]
  1000   C3272950:Immature Cells [Laboratory Procedure]
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "(blasts,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0337026:blasts [Natural Phenomenon or Process]
  1000   C0368761:Blasts [Cell]
  1000   C0523113:Blasts [Laboratory Procedure]

Phrase: "promyelocytes,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0033416:Promyelocytes [Cell]
  1000   C0455279:Promyelocytes [Laboratory Procedure]

Phrase: "myelocytes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369715:Myelocytes [Cell]
  1000   C0455284:Myelocytes [Laboratory Procedure]

Phrase: ")"

Phrase: "in the peripheral blood,"
Meta Candidates (Total=13; Excluded=8; Pruned=0; Remaining=5)
  1000   C0229664:peripheral blood [Body Substance]
           Blood
   958 E C0150936:Peripheral Blood Vessel [Body Part, Organ, or Organ Component]
   861   C0005767:Blood [Tissue]
   861   C0005768:blood [Body Substance]
   861   C0205100:Peripheral [Spatial Concept]
   789 E C0333275:Bloody [Qualitative Concept]
   777 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   777 E C0392895:Bloods [Population Group]
   777 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   777 E C1511228:VESSEL, BLOOD [Tissue]
   761 E C1558950:VASCULAR [Finding]
   761 E C1801960:Vascular [Qualitative Concept]

Phrase: "and"

Phrase: "disappearance of all signs"

Phrase: "and"

Phrase: "symptoms"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0683368:symptoms [Functional Concept]
  1000   C1457887:Symptoms [Sign or Symptom]

Phrase: "related to leukemia"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   790   C0023418:Leukaemia [Neoplastic Process]
   790   C0439849:Related [Qualitative Concept]
   790   C0445223:Related [Finding]
   756 E C0163712:Relate [Organic Chemical]

Phrase: "("

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "palpable splenomegaly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0038002:Splenomegaly [Finding]

Phrase: ")"

Phrase: "lasting for"

Phrase: "at least 4 weeks."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0439230:weeks [Temporal Concept]
   793 E C0332174:/week [Temporal Concept]
Processing 00000000.tx.58: Response was further categorized by the best CG response: complete if no Ph-positive cells were present, partial if Ph-positive cells were 1% to 34%, and minor if Ph-positive cells were 35% to 90%. 

Phrase: "Response"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0871261:Response [Organism Attribute]
  1000   C1704632:Response [Finding]
  1000   C1706817:Response [Intellectual Product]
  1000   C2911692:Response [Mental Process]

Phrase: "was"

Phrase: "further"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1517331:Further [Spatial Concept]
   966 E C0205108:far [Spatial Concept]

Phrase: "categorized by the best CG response"
Meta Candidates (Total=10; Excluded=2; Pruned=0; Remaining=8)
   783   C2986560:Best Response [Finding]
   753   C0010802:Cytogenetic [Biomedical Occupation or Discipline]
   753   C0871261:Response [Organism Attribute]
   753   C0871968:categorized [Activity]
   753   C1522427:Best [Qualitative Concept]
   753   C1704632:Response [Finding]
   753   C1706817:Response [Intellectual Product]
   753   C2911692:Response [Mental Process]
   719 E C0205170:Well [Qualitative Concept]
   719 E C3146287:Well [Manufactured Object]

Phrase: ":"

Phrase: "complete"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205197:Complete [Qualitative Concept]

Phrase: "if"

Phrase: "no Ph-positive cells"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   901   C0439178:% positive cells [Quantitative Concept]
   827   C0007634:Cells [Cell]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]

Phrase: "were"

Phrase: "present, partial"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0728938:Partial [Quantitative Concept]
   861   C1550516:partial [Idea or Concept]

Phrase: "if"

Phrase: "Ph-positive cells"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   901   C0439178:% positive cells [Quantitative Concept]
   827   C0007634:Cells [Cell]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]

Phrase: "were"

Phrase: "1% to 34%,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C2827734:1+ [Quantitative Concept]
   790   C2981698:1+ [Classification]

Phrase: "and"

Phrase: "minor"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0026193:Minor [Population Group]
  1000   C0205165:Minor [Qualitative Concept]

Phrase: "if"

Phrase: "Ph-positive cells"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   901   C0439178:% positive cells [Quantitative Concept]
   827   C0007634:Cells [Cell]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]

Phrase: "were"

Phrase: "35% to 90%."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0439083:>90 [Quantitative Concept]
   790   C0439087:<90 [Quantitative Concept]
Processing 00000000.tx.59: Major CG response included complete plus partial cytogenetic responses (ie, Ph-positive cells 0% to 34%). 

Phrase: "Major CG response"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   827   C0010802:Cytogenetic [Biomedical Occupation or Discipline]
   827   C0205164:Major [Qualitative Concept]
   827   C0871261:Response [Organism Attribute]
   827   C1704632:Response [Finding]
   827   C1706817:Response [Intellectual Product]
   827   C2911692:Response [Mental Process]

Phrase: "included"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0332257:included [Functional Concept]
  1000   C3538986:INCLUDED [Gene or Genome]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "complete plus partial cytogenetic responses"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   781   C0677874:Complete Response [Finding]
   760   C0205197:Complete [Qualitative Concept]
   760   C0725685:COMPLEAT [Food]

Phrase: "("

Phrase: "ie"

Phrase: ","

Phrase: "Ph-positive cells 0% to 34%"
Meta Candidates (Total=14; Excluded=3; Pruned=0; Remaining=11)
   790   C0439178:% positive cells [Quantitative Concept]
           % Positive
   753   C0007634:Cells [Cell]
   753   C0020283:[pH] [Quantitative Concept]
   753   C0450407:ph+ [Finding]
   753   C0450408:ph++ [Finding]
   753   C0450409:ph+++ [Finding]
   753   C1446409:Positive [Qualitative Concept]
   753   C1514241:Positive [Finding]
   753   C2825490:Positive [Qualitative Concept]
   753   C3282337:Cells [Cell]
   719 E C1269647:Cell [Cell]
   719 E C1704653:Cell [Medical Device]
   719 E C1948049:Cell [Spatial Concept]

Phrase: ")."
Processing 00000000.tx.60: Cytogenetic response was judged by standard CG analysis of metaphase spreads, not by iFISH. 

Phrase: "Cytogenetic response"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0871261:Response [Organism Attribute]
   861   C1704632:Response [Finding]
   861   C1706817:Response [Intellectual Product]
   861   C2911692:Response [Mental Process]

Phrase: "was"

Phrase: "judged by standard CG analysis of metaphase spreads,"
Meta Candidates (Total=13; Excluded=0; Pruned=0; Remaining=13)
   770   C0752095:Cytogenetic Analysis [Molecular Biology Research Technique]
   754   C1513166:Metaphase Spread [Laboratory Procedure]
   744   C0002778:Analysis [Laboratory Procedure]
   744   C0010802:Cytogenetic [Biomedical Occupation or Discipline]
   744   C0025564:Metaphase [Cell Function]
   744   C0936012:Analysis [Research Activity]
   744   C1442989:Standard [Qualitative Concept]
   744   C1524024:analysis [Functional Concept]
   744   C1621812:Metaphase [Cell Function]
   744   C2828392:Standard [Intellectual Product]
   711   C0221191:Judge [Professional or Occupational Group]
   711   C0332261:Spread [Qualitative Concept]
   711   C1947932:Spread [Activity]

Phrase: "not by iFISH."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1518422:Not [Functional Concept]
Processing 00000000.tx.61: Time to disease progression was calculated from the time treatment began until appearance of accelerated- or blastic-phase disease, discontinuation of therapy for unsatisfactory response, or death. 

Phrase: "Time to disease progression"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   881   C2985467:Time to Progression [Temporal Concept]
   770   C0040223:Time [Temporal Concept]
   770   C3541383:Time [Temporal Concept]
   715 E C0442043:Temporal [Spatial Concept]
   715 E C2362314:Temporal [Temporal Concept]

Phrase: "was"

Phrase: "calculated from the time treatment"
Meta Candidates (Total=13; Excluded=2; Pruned=0; Remaining=11)
   760   C0039798:treatment [Functional Concept]
   760   C0040223:Time [Temporal Concept]
   760   C0087111:Treatment [Therapeutic or Preventive Procedure]
   760   C0444686:Calculated [Functional Concept]
   760   C1441506:Calculated [Activity]
   760   C1443182:Calculated [Laboratory Procedure]
   760   C1522326:Treatment [Functional Concept]
   760   C1533734:Treatment [Therapeutic or Preventive Procedure]
   760   C1705169:Treatment [Conceptual Entity]
   760   C3538994:TREATMENT [Research Activity]
   760   C3541383:Time [Temporal Concept]
   704 E C0442043:Temporal [Spatial Concept]
   704 E C2362314:Temporal [Temporal Concept]

Phrase: "began until appearance of accelerated-"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0233426:Appearance [Organism Attribute]
   760   C0521110:Accelerated [Functional Concept]
   760   C0700364:Appearance [Qualitative Concept]
   726   C0439659:Begin [Temporal Concept]

Phrase: "or"

Phrase: "blastic-phase disease,"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   827   C0012634:Disease [Disease or Syndrome]
   771 E C1836721:MALS [Finding]
   771 E C3538764:MALS [Gene or Genome]
   771 E C3540595:MAL [Gene or Genome]

Phrase: "discontinuation of therapy"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0457454:Discontinuation [Health Care Activity]
   790   C1444662:Discontinuation [Finding]

Phrase: "for unsatisfactory response,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0871261:Response [Organism Attribute]
   861   C1704632:Response [Finding]
   861   C1706817:Response [Intellectual Product]
   861   C2911692:Response [Mental Process]

Phrase: "or"

Phrase: "death."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0011065:Death [Organism Function]
  1000   C1306577:Death, NOS [Finding]
Processing 00000000.tx.62: Survival was calculated from the time treatment began until death from any cause. 

Phrase: "Survival"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0038952:Survival [Activity]
  1000   C0220921:survival [Functional Concept]

Phrase: "was"

Phrase: "calculated from the time treatment"
Meta Candidates (Total=13; Excluded=2; Pruned=0; Remaining=11)
   760   C0039798:treatment [Functional Concept]
   760   C0040223:Time [Temporal Concept]
   760   C0087111:Treatment [Therapeutic or Preventive Procedure]
   760   C0444686:Calculated [Functional Concept]
   760   C1441506:Calculated [Activity]
   760   C1443182:Calculated [Laboratory Procedure]
   760   C1522326:Treatment [Functional Concept]
   760   C1533734:Treatment [Therapeutic or Preventive Procedure]
   760   C1705169:Treatment [Conceptual Entity]
   760   C3538994:TREATMENT [Research Activity]
   760   C3541383:Time [Temporal Concept]
   704 E C0442043:Temporal [Spatial Concept]
   704 E C2362314:Temporal [Temporal Concept]

Phrase: "began until death"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0011065:Death [Organism Function]
   790   C1306577:Death, NOS [Finding]
   756   C0439659:Begin [Temporal Concept]

Phrase: "from any cause."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0015127:cause [Functional Concept]
  1000   C1524003:Cause [Conceptual Entity]
Processing 00000000.tx.63: Cytogenetic and polymerase chain reaction (PCR) analysis Cytogenetic analysis was performed by the G-banding technique. 

Phrase: "Cytogenetic"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0010802:Cytogenetic [Biomedical Occupation or Discipline]

Phrase: "and"

Phrase: "polymerase chain reaction (PCR) analysis Cytogenetic analysis"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   734   C0200931:Polymerase chain reaction analysis [Laboratory Procedure]

Phrase: "was"

Phrase: "performed by the G-banding technique."
Meta Candidates (Total=10; Excluded=4; Pruned=0; Remaining=6)
   790   C1517334:G-Banding [Laboratory Procedure]
   790   C1550369:Performed By [Qualitative Concept]
   753   C0185014:Banding [Therapeutic or Preventive Procedure]
   753   C0439267:g% [Quantitative Concept]
   753   C0449851:Technique [Functional Concept]
   753   C0884358:Performed [Functional Concept]
   719 E C0175723:Band [Medical Device]
   719 E C0439645:Band [Spatial Concept]
   719 E C1521913:band [Cell Component]
   719 E C2947996:Perform [Pharmacologic Substance]
Processing 00000000.tx.64: For chromosome analysis, bone marrow specimens were examined on direct or short-term (24-hour) cultures. 

Phrase: "For chromosome analysis,"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0200867:Chromosome analysis [Laboratory Procedure]
   964 E C0853259:chromosomal analysis [Laboratory Procedure]
   861   C0002778:Analysis [Laboratory Procedure]
   861   C0008633:Chromosome [Cell Component]
   861   C0936012:Analysis [Research Activity]
   861   C1524024:analysis [Functional Concept]

Phrase: "bone marrow specimens"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   983   C0438737:Bone marrow specimen [Body Substance]
   827   C0370003:specimens [Substance]
   793 E C2347026:Specimen [Conceptual Entity]
   734   C0005953:Bone Marrow [Tissue]

Phrase: "were"

Phrase: "examined on direct"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0332128:Examined [Finding]
   790   C0439851:Direct [Qualitative Concept]
   790   C1947931:Direct [Qualitative Concept]

Phrase: "or"

Phrase: "short-term"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0443303:Short-term [Temporal Concept]
   861   C1282927:short [Qualitative Concept]
   861   C1515273:Term [Temporal Concept]
   861   C1705313:Term [Idea or Concept]
   861   C1806781:Short [Quantitative Concept]
   861   C2350002:Short [Quantitative Concept]
   861   C2826302:TERM [Intellectual Product]

Phrase: "(24-hour"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439227:Hour [Temporal Concept]
   861   C0564385:/hour [Quantitative Concept]

Phrase: ")"

Phrase: "cultures."
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0010453:Cultures [Idea or Concept]
   966 E C0220814:culture [Functional Concept]
   966 E C0430400:Culture [Laboratory Procedure]
   966 E C2242979:Culture [Laboratory Procedure]
Processing 00000000.tx.65: At least 20 metaphases were analyzed. 

Phrase: "At least 20 metaphases"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C1621812:Metaphases [Cell Function]
   793 E C0025564:Metaphase [Cell Function]

Phrase: "were"

Phrase: "analyzed."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0936012:Analyzed [Research Activity]
Processing 00000000.tx.66: PCR was done by real-time quantitative reverse transcription (RT)PCR, and negative results (ie, undetectable transcript) were confirmed by nested PCR as previously reported.17  Results Top Abstract Introduction Patients and methods Results Discussion References  There were 36 patients who were treated and were evaluable. 

Phrase: "PCR"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]
   827   C0337112:Chain [Manufactured Object]
   827   C0443286:Reaction [Functional Concept]
   827   C1114821:Reaction [Clinical Attribute]
   827   C1335439:Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   827   C1524075:Chain [Idea or Concept]

Phrase: "was"

Phrase: "done by real-time quantitative reverse transcription (RT)PCR,"
Meta Candidates (Total=21; Excluded=0; Pruned=0; Remaining=21)
   837   C3179034:Quantitative Real-Time Polymerase Chain Reaction [Molecular Biology Research Technique]
   833   C0814037:reverse transcription polymerase chain reaction [Genetic Function]
   820   C1709846:Real-Time Polymerase Chain Reaction [Molecular Biology Research Technique]
   782   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]
   760   C0035380:Reverse Transcription [Genetic Function]
   760   C1550177:Real Time [Idea or Concept]
   757   C0034746:Reaction Time [Temporal Concept]
   739   C0040223:Time [Temporal Concept]
   739   C0040649:Transcription [Genetic Function]
   739   C0237400:Real [Qualitative Concept]
   739   C0337112:Chain [Manufactured Object]
   739   C0392762:Quantitative [Quantitative Concept]
   739   C0443286:Reaction [Functional Concept]
   739   C1114821:Reaction [Clinical Attribute]
   739   C1272695:Done [Qualitative Concept]
   739   C1335439:Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   739   C1524075:Chain [Idea or Concept]
   739   C1555029:Reverse [Idea or Concept]
   739   C2746065:Done [Temporal Concept]
   739   C3272377:REAL [Intellectual Product]
   739   C3541383:Time [Temporal Concept]

Phrase: "and"

Phrase: "negative results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C1274040:Result [Functional Concept]
   827   C1546471:Result [Idea or Concept]
   827   C2825142:Result [Finding]

Phrase: "("

Phrase: "ie"

Phrase: ","

Phrase: "undetectable transcript"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1519595:Transcript [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: ")"

Phrase: "were"

Phrase: "confirmed by nested PCR"
Meta Candidates (Total=11; Excluded=1; Pruned=0; Remaining=10)
   882   C0242574:Nested Polymerase Chain Reaction [Molecular Biology Research Technique]
   833   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]
   790   C0521093:Confirmed by [Qualitative Concept]
           confirmed
   753   C0337112:Chain [Manufactured Object]
   753   C0443286:Reaction [Functional Concept]
   753   C0750484:Confirmed [Idea or Concept]
   753   C1114821:Reaction [Clinical Attribute]
   753   C1335439:Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   753   C1524075:Chain [Idea or Concept]
   719 E C1456348:Confirm [Qualitative Concept]

Phrase: "as"

Phrase: "previously"

Phrase: "reported.17  Results Top Abstract Introduction Patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   795   C0030705:Patients [Patient or Disabled Group]

Phrase: "and"

Phrase: "methods Results Discussion References  There"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   771   C1514811:Reference [Idea or Concept]
   771   C1706462:Reference [Conceptual Entity]

Phrase: "were"

Phrase: "36 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "who"

Phrase: "were"

Phrase: "treated"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0332293:treated [Therapeutic or Preventive Procedure]
  1000   C1522326:Treated [Functional Concept]
   966 E C1292734:TREAT [Functional Concept]

Phrase: "and"

Phrase: "were"

Phrase: "evaluable."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1516986:Evaluable [Disease or Syndrome]
Processing 00000000.tx.67: Of them, 2 patients belonged to the categories added late into the study: 1 patient with late chronic-phase CML who had not received prior IFN- and 1 patient who was not in molecular remission after 3 years of IFN-. 

Phrase: "Of them,"

Phrase: "2 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "belonged to the categories"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C0683312:Categories [Intellectual Product]
   737 E C1555713:category [Idea or Concept]

Phrase: "added"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1524062:Added [Functional Concept]
   966 E C1883712:Add [Functional Concept]

Phrase: "late into the study"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0205087:Late [Temporal Concept]
   770   C0557651:Study [Manufactured Object]
   770   C2603343:Study [Research Activity]

Phrase: ":"

Phrase: "1 patient with late chronic-phase CML"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C0030705:*^patient [Patient or Disabled Group]

Phrase: "who"

Phrase: "had"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "received"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Received [Qualitative Concept]

Phrase: "prior IFN-"

Phrase: "and"

Phrase: "1 patient"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:*^patient [Patient or Disabled Group]

Phrase: "who"

Phrase: "was"

Phrase: "not in molecular remission"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0544452:Remission [Finding]
   770   C0687702:remission [Neoplastic Process]
   770   C1518422:Not [Functional Concept]
   770   C1521991:Molecular [Qualitative Concept]

Phrase: "after 3 years"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0439234:years [Temporal Concept]
   827 E C0439508:/year [Temporal Concept]

Phrase: "of IFN-."
Processing 00000000.tx.68: The other 34 patients had late chronic-phase CML that failed to respond to IFN-, or were intolerant to IFN-. 

Phrase: "The"

Phrase: "other 34 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "had"

Phrase: "late chronic-phase CML"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   947   C0023474:Chronic phase chronic myeloid leukaemia [Neoplastic Process]
           Leukemia, Myeloid, Chronic-Phase
   885   C0023473:Chronic myeloid leukaemia [Neoplastic Process]
   885   C2984277:Chronic myeloid leukemia [Functional Concept]
   876   C1279296:Chronic leukaemia [Neoplastic Process]
   827   C0023470:Myeloid Leukemia [Neoplastic Process]
   827   C0457343:Chronic phase [Temporal Concept]
   799   C0023418:Leukaemia [Neoplastic Process]
   799   C0205191:chronic [Temporal Concept]
   799   C0205390:Phase [Temporal Concept]
   799   C0439677:Myeloid [Qualitative Concept]

Phrase: "that"

Phrase: "failed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0231175:Failed [Functional Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "respond to IFN-,"

Phrase: "or"

Phrase: "were"

Phrase: "intolerant to IFN-."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0231200:Intolerant [Functional Concept]
Processing 00000000.tx.69: Their clinical characteristics are summarized in Table 1. 

Phrase: "Their clinical characteristics"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0683325:clinical characteristics [Clinical Attribute]
   861   C1521970:Characteristics [Qualitative Concept]

Phrase: "are"

Phrase: "summarized in Table 1."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0039224:Table [Manufactured Object]
   770   C1706073:Table [Medical Device]
   770   C1706074:Table [Intellectual Product]
Processing 00000000.tx.70: Of the patients, 13 (36%) had active disease, and 23 (64%) were in CHR. 

Phrase: "Of the patients,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "13"

Phrase: "(36%"

Phrase: ")"

Phrase: "had"

Phrase: "active disease,"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0012634:Disease [Disease or Syndrome]
   861   C0205177:Active [Functional Concept]
   805 E C1836721:MALS [Finding]
   805 E C3538764:MALS [Gene or Genome]
   805 E C3540595:MAL [Gene or Genome]

Phrase: "and"

Phrase: "23"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450348:23 [Quantitative Concept]

Phrase: "(64%"

Phrase: ")"

Phrase: "were in CHR."
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   797   C0677874:Complete Response [Finding]
   760   C0018943:Hematologic [Biomedical Occupation or Discipline]
   760   C0205197:Complete [Qualitative Concept]
   760   C0205488:Haematologic [Functional Concept]
   760   C0725685:COMPLEAT [Food]
   760   C0871261:Response [Organism Attribute]
   760   C1704632:Response [Finding]
   760   C1706817:Response [Intellectual Product]
   760   C2911692:Response [Mental Process]
Processing 00000000.tx.71: The median age was 47 years (range, 30-75 years); 

Phrase: "The median age"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0001779:Age [Organism Attribute]

Phrase: "was"

Phrase: "47 years"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0439234:years [Temporal Concept]
   827 E C0439508:/year [Temporal Concept]

Phrase: "(range,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1514721:Range [Quantitative Concept]
  1000   C2348147:Range [Quantitative Concept]
  1000   C3542016:Range [Intellectual Product]

Phrase: "30-75 years"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0439234:years [Temporal Concept]
   793 E C0439508:/year [Temporal Concept]

Phrase: ")"

Phrase: ";"
Processing 00000000.tx.72: the median time from diagnosis to start of high-dose imatinib was 25 months (range, 10-135 months). 

Phrase: "the median time from diagnosis to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0040223:Time [Temporal Concept]
   753   C3541383:Time [Temporal Concept]

Phrase: "start of high-dose imatinib"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   806   C0444956:High dose [Quantitative Concept]
   760   C0178602:Dose [Quantitative Concept]
   760   C0205250:High [Qualitative Concept]
   760   C0439659:Start [Temporal Concept]
   760   C0869039:Dose [Quantitative Concept]
   760   C0935989:imatinib [Organic Chemical,Pharmacologic Substance]
   760   C1114758:Dose # [Clinical Attribute]
   760   C1299351:High [Qualitative Concept]
   760   C2700149:HIGH [Intellectual Product]

Phrase: "was"

Phrase: "25 months"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0439231:months [Temporal Concept]
   827 E C0439507:/month [Temporal Concept]

Phrase: "(range,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1514721:Range [Quantitative Concept]
  1000   C2348147:Range [Quantitative Concept]
  1000   C3542016:Range [Intellectual Product]

Phrase: "10-135 months"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0439231:months [Temporal Concept]
   793 E C0439507:/month [Temporal Concept]

Phrase: ")."
Processing 00000000.tx.73: There were 13 (36%) patients who had received other therapies besides IFN-, including homoharringtonine (n = 10) and R11577 [GenBank] 7 (Zarnestra, a farnesyl transferase inhibitor; n = 3). 

Phrase: "There"

Phrase: "were"

Phrase: "13"

Phrase: "(36%"

Phrase: ")"

Phrase: "patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "who"

Phrase: "had"

Phrase: "received"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Received [Qualitative Concept]

Phrase: "other therapies besides IFN-,"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   833   C0418967:Other therapies [Therapeutic or Preventive Procedure]
   770   C0087111:therapies [Therapeutic or Preventive Procedure]
   737 E C0039798:therapy [Functional Concept]
   737 E C1363945:Therapy [Finding]

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "homoharringtonine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0062941:homoharringtonine [Organic Chemical,Pharmacologic Substance]

Phrase: "(n = 10"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441922:N+ [Intellectual Product]
   861   C1553036:[n] [Quantitative Concept]

Phrase: ")"

Phrase: "and"

Phrase: "R11577"

Phrase: "[GenBank"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0598211:GenBank [Intellectual Product]

Phrase: "] 7"

Phrase: "(Zarnestra,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1174783:Zarnestra [Organic Chemical,Pharmacologic Substance]

Phrase: "a farnesyl transferase inhibitor"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
  1000   C1517132:Farnesyl Transferase Inhibitor [Pharmacologic Substance]
   901   C0138837:Farnesyl Transferase [Amino Acid, Peptide, or Protein,Enzyme]
   901   C0210158:Farnesyltransferase [Amino Acid, Peptide, or Protein,Enzyme]
   901   C0597790:Farnesyltransferase [Amino Acid, Peptide, or Protein,Enzyme]
   901   C1532411:Transferase inhibitor [Pharmacologic Substance]
   901   C1658753:transferase inhibitor [Molecular Function]
   827   C0040676:Transferase [Amino Acid, Peptide, or Protein,Enzyme]
   827   C1999216:Inhibitor [Qualitative Concept]

Phrase: "; n = 3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441922:N+ [Intellectual Product]
   861   C1553036:[n] [Quantitative Concept]

Phrase: ")."
Processing 00000000.tx.74: There were 4 patients (11%) who had cytogenetic clonal evolution. 

Phrase: "There"

Phrase: "were"

Phrase: "4 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "(11%"

Phrase: ")"

Phrase: "who"

Phrase: "had"

Phrase: "cytogenetic clonal evolution."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C1516669:Clonal Evolution [Neoplastic Process]
   827   C0015219:Evolution [Genetic Function]
Processing 00000000.tx.75: Having received fewer than 3 months of imatinib therapy, 3 patients were inevaluable for response because of poor compliance. 

Phrase: "Having"

Phrase: "received"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Received [Qualitative Concept]

Phrase: "fewer than 3 months of imatinib therapy,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   714   C0205388:Few [Quantitative Concept]

Phrase: "3 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "were"

Phrase: "inevaluable for response"

Phrase: "because of poor compliance."
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0032646:POOR COMPLIANCE [Finding]
   861   C0009563:Compliance [Quantitative Concept]
   861   C1321605:Compliance [Individual Behavior]
   861   C3244300:compliance [Activity]
   789 E C0566588:Compliant [Qualitative Concept]
Processing 00000000.tx.76: Results are described for 33 evaluable patients. 

Phrase: "Results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "are"

Phrase: "described for 33 evaluable patients."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   806   C2986511:evaluable patients [Patient or Disabled Group]
   760   C0030705:Patients [Patient or Disabled Group]
   760   C1516986:Evaluable [Disease or Syndrome]
   760   C1552738:described [Idea or Concept]
Processing 00000000.tx.77: View this table: [in this window] [in a new window]  Table 1. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "this table"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039224:Table [Manufactured Object]
  1000   C1706073:Table [Medical Device]
  1000   C1706074:Table [Intellectual Product]

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Table 1."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]
Processing 00000000.tx.78: Patient characteristics of the study group (36 patients)  Response to therapy All 11 patients with abnormal peripheral blood counts when treatment was started achieved a CHR (Table 2). 

Phrase: "Patient characteristics of the study group"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0815172:patient characteristics [Clinical Attribute]
   783   C1568011:Study Characteristics [Intellectual Product]
   753   C1521970:Characteristics [Qualitative Concept]

Phrase: "(36 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: ")"

Phrase: "Response to therapy"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0871261:Response [Organism Attribute]
   790   C1704632:Response [Finding]
   790   C1706817:Response [Intellectual Product]
   790   C2911692:Response [Mental Process]

Phrase: "All 11 patients with abnormal peripheral blood counts"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0030705:Patients [Patient or Disabled Group]

Phrase: "when"

Phrase: "treatment"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0039798:treatment [Functional Concept]
  1000   C0087111:Treatment [Therapeutic or Preventive Procedure]
  1000   C1522326:Treatment [Functional Concept]
  1000   C1533734:Treatment [Therapeutic or Preventive Procedure]
  1000   C1705169:Treatment [Conceptual Entity]
  1000   C3538994:TREATMENT [Research Activity]

Phrase: "was"

Phrase: "started"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1272689:Started [Qualitative Concept]
   966 E C0439659:Start [Temporal Concept]

Phrase: "achieved"

Phrase: "a CHR"
Meta Candidates (Total=11; Excluded=2; Pruned=0; Remaining=9)
   913   C0677874:Complete Response [Finding]
   827   C0018943:Hematologic [Biomedical Occupation or Discipline]
   827   C0205197:Complete [Qualitative Concept]
   827   C0205488:Haematologic [Functional Concept]
   827   C0725685:COMPLEAT [Food]
   827   C0871261:Response [Organism Attribute]
   827   C1704632:Response [Finding]
   827   C1706817:Response [Intellectual Product]
   827   C2911692:Response [Mental Process]
   755 E C0200627:HEMATOLOGY [Laboratory Procedure]
   755 E C0439812:Completeness [Qualitative Concept]

Phrase: "(Table 2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.79: At the start of therapy, 12 patients had fewer than 34% Ph-positive metaphases, including 6 who had 0% Ph-positive. 

Phrase: "At the start"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439659:Start [Temporal Concept]

Phrase: "of therapy,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039798:therapy [Functional Concept]
  1000   C0087111:Therapy [Therapeutic or Preventive Procedure]
  1000   C1363945:Therapy [Finding]

Phrase: "12 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "had"

Phrase: "fewer than 34% Ph-positive metaphases,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   719   C0205388:Few [Quantitative Concept]

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "6"

Phrase: "who"

Phrase: "had"

Phrase: "0% Ph-positive."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0439178:% Positive [Quantitative Concept]
   827   C1446409:Positive [Qualitative Concept]
   827   C1514241:Positive [Finding]
   827   C2825490:Positive [Qualitative Concept]
Processing 00000000.tx.80: A major CG response was achieved in 19 (90%) of 21 other patients (complete in 18, partial in 1). 

Phrase: "A major CG response"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   827   C0010802:Cytogenetic [Biomedical Occupation or Discipline]
   827   C0205164:Major [Qualitative Concept]
   827   C0871261:Response [Organism Attribute]
   827   C1704632:Response [Finding]
   827   C1706817:Response [Intellectual Product]
   827   C2911692:Response [Mental Process]

Phrase: "was"

Phrase: "achieved in 19"

Phrase: "(90%"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439083:>90 [Quantitative Concept]
  1000   C0439087:<90 [Quantitative Concept]

Phrase: ")"

Phrase: "of 21"

Phrase: "other patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "(complete in 18,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   790   C0205197:Complete [Qualitative Concept]
   790   C0725685:COMPLEAT [Food]
   718 E C0439812:Completeness [Qualitative Concept]

Phrase: "partial in 1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0728938:Partial [Quantitative Concept]
   790   C1550516:partial [Idea or Concept]

Phrase: ")."
Processing 00000000.tx.81: Complete CG response was achieved in 24 (89%) of 27 patients with Ph-positive metaphases at the start of imatinib. 

Phrase: "Complete"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205197:Complete [Qualitative Concept]

Phrase: "CG response"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0871261:Response [Organism Attribute]
   861   C1704632:Response [Finding]
   861   C1706817:Response [Intellectual Product]
   861   C2911692:Response [Mental Process]

Phrase: "was"

Phrase: "achieved in 24"

Phrase: "(89%"

Phrase: ")"

Phrase: "of 27 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "with Ph-positive metaphases"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C1621812:Metaphases [Cell Function]
   793 E C0025564:Metaphase [Cell Function]

Phrase: "at the start"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439659:Start [Temporal Concept]

Phrase: "of imatinib."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0935989:imatinib [Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.82: Responses occurred early: 19 (73%) of 26 patients evaluable at 3 months had already achieved a complete CG response at this time. 

Phrase: "Responses"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0871261:responses [Organism Attribute]
   966 E C1704632:Response [Finding]
   966 E C1706817:Response [Intellectual Product]
   966 E C2911692:Response [Mental Process]

Phrase: "occurred"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1709305:Occurred [Activity]
   966 E C2745955:OCCUR [Temporal Concept]

Phrase: "early"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1279919:Early [Temporal Concept]

Phrase: ":"

Phrase: "19"

Phrase: "(73%"

Phrase: ")"

Phrase: "of 26 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "evaluable at 3 months"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1516986:Evaluable [Disease or Syndrome]

Phrase: "had"

Phrase: "already"

Phrase: "achieved"

Phrase: "a complete CG response at this time."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   774   C0034746:Response Time [Temporal Concept]
   774   C0677874:Complete Response [Finding]
   748   C0871261:Response [Organism Attribute]
   748   C1704632:Response [Finding]
   748   C1706817:Response [Intellectual Product]
   748   C2911692:Response [Mental Process]
Processing 00000000.tx.83: Within the small number of patients in each group, there was no significant difference in the response rate according to previous IFN- response. 

Phrase: "Within the small number"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0237753:*Number [Quantitative Concept]
   861   C0449788:Number [Quantitative Concept]

Phrase: "of patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "in each group,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0441833:Group [Idea or Concept]
  1000   C0687744:group [Population Group]
  1000   C1257890:Group [Population Group]
  1000   C1552516:Group [Health Care Related Organization]
  1000   C1705428:Group [Conceptual Entity]
  1000   C1705429:Group [Population Group]

Phrase: "there"

Phrase: "was"

Phrase: "no significant difference in the response rate"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C1705241:*Difference [Quantitative Concept]
   748   C1705242:Difference [Qualitative Concept]

Phrase: "according to previous IFN- response."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0871261:Response [Organism Attribute]
   827   C1704632:Response [Finding]
   827   C1706817:Response [Intellectual Product]
   827   C2911692:Response [Mental Process]
Processing 00000000.tx.84: View this table: [in this window] [in a new window]  Table 2. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "this table"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039224:Table [Manufactured Object]
  1000   C1706073:Table [Medical Device]
  1000   C1706074:Table [Intellectual Product]

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Table 2."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]
Processing 00000000.tx.85: Response to imatinib mesylate therapy (33 patients)  Figure 1 shows the values of BCR-ABL/ABL percentage ratio during imatinib therapy. 

Phrase: "Response to imatinib mesylate therapy"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0871261:Response [Organism Attribute]
   760   C1704632:Response [Finding]
   760   C1706817:Response [Intellectual Product]
   760   C2911692:Response [Mental Process]

Phrase: "(33 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: ")"

Phrase: "Figure 1"

Phrase: "shows"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1547282:Show [Intellectual Product]

Phrase: "the values of BCR-ABL/ABL percentage ratio"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   750   C1532109:Ratio value [Quantitative Concept]
   744   C0042295:Values [Qualitative Concept]
   711 E C1522609:Value [Quantitative Concept]

Phrase: "during imatinib therapy."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039798:therapy [Functional Concept]
   861   C0087111:Therapy [Therapeutic or Preventive Procedure]
   861   C1363945:Therapy [Finding]
Processing 00000000.tx.86: There was a consistent and significant decline of these ratios over time. 

Phrase: "There"

Phrase: "was"

Phrase: "a consistent"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332290:Consistent [Idea or Concept]
   928 E C0332529:Consistencies [Qualitative Concept]
   928 E C1547017:Consistency [Quantitative Concept]

Phrase: "and"

Phrase: "significant decline of these ratios"

Phrase: "over time."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0040223:Time [Temporal Concept]
  1000   C3541383:Time [Temporal Concept]
   944 E C0442043:Temporal [Spatial Concept]
   944 E C2362314:Temporal [Temporal Concept]
   916 E C1632851:Times [Quantitative Concept]
Processing 00000000.tx.87: The median BCR-ABL/ABL percentage ratio decreased from 0.169% (range, .005%-12.281%) after 3 months to .026% (range, 0%-63.454%) after 12 months of therapy (P = .60). 

Phrase: "The median BCR-ABL/ABL percentage ratio"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   799   C0456603:Ratio [Quantitative Concept]
   799   C1547037:Ratio [Intellectual Product]

Phrase: "decreased from 0.169%"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   770   C0205216:Decreased [Quantitative Concept]
   770   C0392756:Decreased [Qualitative Concept]
   770   C0442797:decreased [Qualitative Concept]
   737 E C0547047:Decrease [Quantitative Concept]

Phrase: "(range,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1514721:Range [Quantitative Concept]
  1000   C2348147:Range [Quantitative Concept]
  1000   C3542016:Range [Intellectual Product]

Phrase: ".005%-12.281%"

Phrase: ")"

Phrase: "after 3 months to .026%"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   861   C1442461:3 Months [Temporal Concept]
   812   C0439086:<3 [Quantitative Concept]
   812   C0439231:months [Temporal Concept]
   812   C2827736:3+ [Quantitative Concept]
   812   C2981702:3+ [Classification]
   779 E C0439507:/month [Temporal Concept]

Phrase: "(range,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1514721:Range [Quantitative Concept]
  1000   C2348147:Range [Quantitative Concept]
  1000   C3542016:Range [Intellectual Product]

Phrase: "0%-63.454%"

Phrase: ")"

Phrase: "after 12 months"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0439231:months [Temporal Concept]
   827 E C0439507:/month [Temporal Concept]

Phrase: "of therapy"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039798:therapy [Functional Concept]
  1000   C0087111:Therapy [Therapeutic or Preventive Procedure]
  1000   C1363945:Therapy [Finding]

Phrase: "(P = .60"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C2603361:P' [Clinical Attribute]

Phrase: ")."
Processing 00000000.tx.88: Significantly, 18 (56%) of 32 patients evaluable for molecular response have achieved ratios lower than 0.045%, including 13 patients (41%) who had undetectable transcripts (confirmed by nested PCR). 

Phrase: "Significantly,"

Phrase: "18"

Phrase: "(56%"

Phrase: ")"

Phrase: "of 32 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "evaluable for molecular response"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1516986:Evaluable [Disease or Syndrome]

Phrase: "have"

Phrase: "achieved ratios"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0456603:Ratios [Quantitative Concept]
   861   C1610540:*Ratios [Quantitative Concept]
   827 E C1547037:Ratio [Intellectual Product]

Phrase: "lower than 0.045%,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0441994:Lower [Spatial Concept]
   770   C1548802:Lower [Body Location or Region]
   770   C2003888:Lower [Activity]

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "13 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "(41%"

Phrase: ")"

Phrase: "who"

Phrase: "had"

Phrase: "undetectable transcripts"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1519595:Transcripts [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "("

Phrase: "confirmed by nested PCR"
Meta Candidates (Total=11; Excluded=1; Pruned=0; Remaining=10)
   882   C0242574:Nested Polymerase Chain Reaction [Molecular Biology Research Technique]
   833   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]
   790   C0521093:Confirmed by [Qualitative Concept]
           confirmed
   753   C0337112:Chain [Manufactured Object]
   753   C0443286:Reaction [Functional Concept]
   753   C0750484:Confirmed [Idea or Concept]
   753   C1114821:Reaction [Clinical Attribute]
   753   C1335439:Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   753   C1524075:Chain [Idea or Concept]
   719 E C1456348:Confirm [Qualitative Concept]

Phrase: ")."
Processing 00000000.tx.89: There were 16 patients who have had at least 2 consecutive PCR values lower than 0.045%, and 4 patients had at least 2 consecutive analyses with undetectable transcripts. 

Phrase: "There"

Phrase: "were"

Phrase: "16 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "who"

Phrase: "have"

Phrase: "had at least 2 consecutive PCR values"
Meta Candidates (Total=12; Excluded=1; Pruned=0; Remaining=11)
   790   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]
   742   C0042295:Values [Qualitative Concept]
   742   C0062074:HAD [Therapeutic or Preventive Procedure]
   742   C0337112:Chain [Manufactured Object]
   742   C0443286:Reaction [Functional Concept]
   742   C1114821:Reaction [Clinical Attribute]
   742   C1335439:Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   742   C1415458:HAD [Gene or Genome]
   742   C1524075:Chain [Idea or Concept]
   742   C1707491:Consecutive [Qualitative Concept]
   742   C3539897:Had [Qualitative Concept]
   708 E C1522609:Value [Quantitative Concept]

Phrase: "lower than 0.045%,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0441994:Lower [Spatial Concept]
   770   C1548802:Lower [Body Location or Region]
   770   C2003888:Lower [Activity]

Phrase: "and"

Phrase: "4 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "had at least 2 consecutive analyses"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   753   C0062074:HAD [Therapeutic or Preventive Procedure]
   753   C1415458:HAD [Gene or Genome]
   753   C1707491:Consecutive [Qualitative Concept]
   753   C3539897:Had [Qualitative Concept]
   719   C0002778:Analysis [Laboratory Procedure]
   719   C0936012:Analysis [Research Activity]
   719   C1524024:analysis [Functional Concept]

Phrase: "with undetectable transcripts."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1519595:Transcripts [Nucleic Acid, Nucleoside, or Nucleotide]
Processing 00000000.tx.90: View larger version (19K): [in this window] [in a new window]  Figure 1. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(19K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Figure 1."
Processing 00000000.tx.91: BCR-ABL/ABL percentage ratio over the course of therapy. 

Phrase: "BCR-ABL/ABL percentage ratio over the course of therapy."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   739   C0456603:Ratio [Quantitative Concept]
   739   C1547037:Ratio [Intellectual Product]
Processing 00000000.tx.92: Results are expressed for each evaluable patient at each 3-month period. 

Phrase: "Results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "are"

Phrase: "expressed for each evaluable patient"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   806   C2986511:Evaluable Patient [Patient or Disabled Group]
   760   C0030705:*^patient [Patient or Disabled Group]
   760   C1516986:Evaluable [Disease or Syndrome]

Phrase: "at each 3-month period."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   827   C0439531:/period [Temporal Concept]
   827   C1948053:Period [Temporal Concept]
   755 E C0332182:Periodic [Temporal Concept]
   755 E C1706381:PERIODIC [Intellectual Product]
   727 E C0031084:Periodicities [Temporal Concept]
Processing 00000000.tx.93: Number of evaluable patients is shown on top. 

Phrase: "Number of evaluable patients"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   881   C2360800:Number of patients [Finding]
   802   C1830427:Patient number [Intellectual Product]
   770   C0237753:*Number [Quantitative Concept]
   770   C0449788:Number [Quantitative Concept]

Phrase: "is"

Phrase: "shown on top."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C1704458:Top [Spatial Concept]
   756   C1547282:Show [Intellectual Product]
Processing 00000000.tx.94: The dotted line represents a percentage ratio of 0.045%. 

Phrase: "The dotted line"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205132:Line [Spatial Concept]
   861   C1550648:Line [Substance]
   861   C1552960:Line [Quantitative Concept]

Phrase: "represents"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1882932:Represent [Activity]

Phrase: "a percentage ratio of 0.045%."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0456603:Ratio [Quantitative Concept]
   753   C1547037:Ratio [Intellectual Product]
Processing 00000000.tx.95: Percentages shown under this line represent the proportion of patients below this threshold at each time point. 

Phrase: "Percentages"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C0439165:Percentage [Quantitative Concept]
   966   C1549488:Percentage [Idea or Concept]
   966   C1561533:Percentage [Idea or Concept]

Phrase: "shown under this line"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0205132:Line [Spatial Concept]
   770   C1550648:Line [Substance]
   770   C1552960:Line [Quantitative Concept]
   737   C1547282:Show [Intellectual Product]

Phrase: "represent"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1882932:Represent [Activity]

Phrase: "the proportion of patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1709707:Proportion [Quantitative Concept]

Phrase: "below this threshold"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449864:Threshold [Qualitative Concept]

Phrase: "at each time point."
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
  1000   C2348792:Time Point [Temporal Concept]
   861   C0040223:Time [Temporal Concept]
   861   C1552961:Point [Quantitative Concept]
   861   C2347617:point [Quantitative Concept]
   861   C3541383:Time [Temporal Concept]
   805 E C0442043:Temporal [Spatial Concept]
   805 E C2362314:Temporal [Temporal Concept]
   777 E C1632851:Times [Quantitative Concept]
Processing 00000000.tx.96: The horizontal bar at each time point represents the median value for all evaluable patients.  

Phrase: "The horizontal bar at each time point"

Phrase: "represents"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1882932:Represent [Activity]

Phrase: "the median value for all evaluable patients."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   748   C0549183:Median [Spatial Concept]
   748   C0876920:Median [Quantitative Concept]
   748   C1522609:Value [Quantitative Concept]
   748   C2347635:Median [Quantitative Concept]
   748   C2348144:Median [Quantitative Concept]
   748   C2939193:Median [Spatial Concept]
Processing 00000000.tx.97: Time to progression and survival Of the 33 patients treated for at least 3 months, 31 (94%) remain alive in chronic phase on imatinib therapy. 

Phrase: "Time to progression"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C2985467:Time to Progression [Temporal Concept]
   790   C0040223:Time [Temporal Concept]
   790   C3541383:Time [Temporal Concept]
   734 E C0442043:Temporal [Spatial Concept]
   734 E C2362314:Temporal [Temporal Concept]
   706 E C1632851:Times [Quantitative Concept]

Phrase: "and"

Phrase: "survival Of the 33 patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0038952:Survival [Activity]
   760   C0220921:survival [Functional Concept]

Phrase: "treated for"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   833   C0332293:treated [Therapeutic or Preventive Procedure]
   833   C1522326:Treated [Functional Concept]
   799 E C1292734:TREAT [Functional Concept]

Phrase: "at least 3 months,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0439231:months [Temporal Concept]
   793 E C0439507:/month [Temporal Concept]

Phrase: "31"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450355:31 [Intellectual Product]

Phrase: "(94%"

Phrase: ")"

Phrase: "remain"

Phrase: "alive in chronic phase"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0376558:Alive [Idea or Concept]
   770   C2584946:Alive [Finding]

Phrase: "on imatinib therapy."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039798:therapy [Functional Concept]
   861   C0087111:Therapy [Therapeutic or Preventive Procedure]
   861   C1363945:Therapy [Finding]
Processing 00000000.tx.98: The other 2 patients stopped therapy because of noncompliance (n = 1) and intercurrent illness (arthritis, n = 1). 

Phrase: "The"

Phrase: "other 2 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "stopped"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C1272691:stopped [Qualitative Concept]
   966 E C1947925:Stop [Activity]
   966 E C2746065:Stop [Temporal Concept]

Phrase: "therapy because of noncompliance"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0039798:therapy [Functional Concept]
   770   C0087111:Therapy [Therapeutic or Preventive Procedure]
   770   C1363945:Therapy [Finding]

Phrase: "(n = 1"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441922:N+ [Intellectual Product]
   861   C1553036:[n] [Quantitative Concept]

Phrase: ")"

Phrase: "and"

Phrase: "intercurrent illness"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
   861   C0221423:Illness [Finding]
   789 E C0231218:Ill [Sign or Symptom]
   789 E C0332271:worse [Qualitative Concept]
   789 E C1279889:Worse [Finding]
   789 E C1457868:Worse [Qualitative Concept]
   789 E C1522166:Worst [Qualitative Concept]

Phrase: "(arthritis,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0003864:Arthritis [Disease or Syndrome]
   907 E C0018099:Gout [Disease or Syndrome]

Phrase: "n = 1"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441922:N+ [Intellectual Product]
   861   C1553036:[n] [Quantitative Concept]

Phrase: ")."
Processing 00000000.tx.99: After a median follow-up of 16 months (range, 5-16 months), all patients are alive in chronic phase. 

Phrase: "After a median"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0549183:Median [Spatial Concept]
  1000   C0876920:Median [Quantitative Concept]
  1000   C2347635:Median [Quantitative Concept]
  1000   C2348144:Median [Quantitative Concept]
  1000   C2939193:Median [Spatial Concept]

Phrase: "follow-up of 16 months"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   806   C0589120:Follow-up [Finding]
   806   C1522577:follow-up [Health Care Activity]
   806   C1704685:FOLLOW-UP [Intellectual Product]
   806   C3274571:FOLLOW-UP [Health Care Activity]
   760   C0332283:follow [Temporal Concept]
   760   C1719822:Follow [Intellectual Product]

Phrase: "(range,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1514721:Range [Quantitative Concept]
  1000   C2348147:Range [Quantitative Concept]
  1000   C3542016:Range [Intellectual Product]

Phrase: "5-16 months"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0439231:months [Temporal Concept]
   793 E C0439507:/month [Temporal Concept]

Phrase: ")"

Phrase: ","

Phrase: "all patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "are"

Phrase: "alive in chronic phase."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0376558:Alive [Idea or Concept]
   770   C2584946:Alive [Finding]
Processing 00000000.tx.100: Response duration Of the 31 patients with a major cytogenetic response, 30 (97%) continue to have durable major response. 

Phrase: "Response duration Of the 31 patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0237585:Response Duration [Temporal Concept]
   753   C0449238:Duration [Temporal Concept]
   753   C2926735:Duration [Pharmacologic Substance]

Phrase: "with a major cytogenetic response,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   827   C0010802:Cytogenetic [Biomedical Occupation or Discipline]
   827   C0205164:Major [Qualitative Concept]
   827   C0871261:Response [Organism Attribute]
   827   C1704632:Response [Finding]
   827   C1706817:Response [Intellectual Product]
   827   C2911692:Response [Mental Process]

Phrase: "30"

Phrase: "(97%"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439073:97 [Intellectual Product]
  1000   C0439082:>97 [Quantitative Concept]

Phrase: ")"

Phrase: "continue"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0549178:Continue [Idea or Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "have"

Phrase: "durable major response."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0871261:Response [Organism Attribute]
   827   C1704632:Response [Finding]
   827   C1706817:Response [Intellectual Product]
   827   C2911692:Response [Mental Process]
Processing 00000000.tx.101: One patient had disease relapse (defined as an increase of Ph-positive cells by 30% or more documented on 2 occasions, or an increase to 65% or more documented once) after 6 months from the time the major CG response was achieved. 

Phrase: "One patient"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:*^patient [Patient or Disabled Group]

Phrase: "had"

Phrase: "disease relapse"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0277556:DISEASE RELAPSE [Disease or Syndrome]
           Relapse
   861   C0035020:Relapse [Phenomenon or Process]
   861   C0205336:relapse [Temporal Concept]

Phrase: "("

Phrase: "defined as an increase of Ph-positive cells"
Meta Candidates (Total=18; Excluded=3; Pruned=0; Remaining=15)
   770   C0439178:% positive cells [Quantitative Concept]
           % Positive
   767   C0221106:increase ph [Disease or Syndrome]
   744   C0007634:Cells [Cell]
   744   C0020283:[pH] [Quantitative Concept]
   744   C0442805:Increase [Functional Concept]
   744   C0450407:ph+ [Finding]
   744   C0450408:ph++ [Finding]
   744   C0450409:ph+++ [Finding]
   744   C1446409:Positive [Qualitative Concept]
   744   C1514241:Positive [Finding]
   744   C1704788:Defined [Conceptual Entity]
   744   C2825490:Positive [Qualitative Concept]
   744   C3282337:Cells [Cell]
   744   C3539106:Defined [Intellectual Product]
   711 E C1269647:Cell [Cell]
   711 E C1704653:Cell [Medical Device]
   711 E C1948049:Cell [Spatial Concept]

Phrase: "by 30%"

Phrase: "or"

Phrase: "more"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205172:More [Functional Concept]

Phrase: "documented on 2 occasions,"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   770   C1301725:Documented [Health Care Activity]
   770   C1609436:documented [Idea or Concept]
   737 E C1301746:document [Intellectual Product]
   737 E C1547673:Document [Intellectual Product]

Phrase: "or"

Phrase: "an increase to 65%"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0442805:Increase [Functional Concept]

Phrase: "or"

Phrase: "more"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205172:More [Functional Concept]

Phrase: "documented"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C1301725:Documented [Health Care Activity]
  1000   C1609436:documented [Idea or Concept]
   966 E C1301746:document [Intellectual Product]
   966 E C1547673:Document [Intellectual Product]

Phrase: "once"

Phrase: ")"

Phrase: "after 6 months"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0439231:months [Temporal Concept]
   827 E C0439507:/month [Temporal Concept]

Phrase: "from the time"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0040223:Time [Temporal Concept]
  1000   C3541383:Time [Temporal Concept]
   944 E C0442043:Temporal [Spatial Concept]
   944 E C2362314:Temporal [Temporal Concept]
   916 E C1632851:Times [Quantitative Concept]

Phrase: "the major CG response"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   827   C0010802:Cytogenetic [Biomedical Occupation or Discipline]
   827   C0205164:Major [Qualitative Concept]
   827   C0871261:Response [Organism Attribute]
   827   C1704632:Response [Finding]
   827   C1706817:Response [Intellectual Product]
   827   C2911692:Response [Mental Process]

Phrase: "was"

Phrase: "achieved."
Processing 00000000.tx.102: After a median follow-up time of 9 months from best response (range, 1-12 months), 3 patients who achieved a complete CG response have lost their response (complete CG response duration of 3 [1 patient] and 9 [2 patients] months). 

Phrase: "After a median follow-up time"
Meta Candidates (Total=11; Excluded=3; Pruned=0; Remaining=8)
   861   C0589120:Follow-up [Finding]
   861   C1522577:follow-up [Health Care Activity]
   861   C1704685:FOLLOW-UP [Intellectual Product]
   861   C3274571:FOLLOW-UP [Health Care Activity]
   812   C0040223:Time [Temporal Concept]
   812   C0332283:follow [Temporal Concept]
   812   C1719822:Follow [Intellectual Product]
   812   C3541383:Time [Temporal Concept]
   756 E C0442043:Temporal [Spatial Concept]
   756 E C2362314:Temporal [Temporal Concept]
   729 E C1632851:Times [Quantitative Concept]

Phrase: "of 9 months"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0439231:months [Temporal Concept]
   827 E C0439507:/month [Temporal Concept]

Phrase: "from best response"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C2986560:Best Response [Finding]
   861   C0871261:Response [Organism Attribute]
   861   C1704632:Response [Finding]
   861   C1706817:Response [Intellectual Product]
   861   C2911692:Response [Mental Process]

Phrase: "(range,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1514721:Range [Quantitative Concept]
  1000   C2348147:Range [Quantitative Concept]
  1000   C3542016:Range [Intellectual Product]

Phrase: "1-12 months"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   896   C1442451:1 Month [Temporal Concept]
   827   C0439231:months [Temporal Concept]
   793 E C0439507:/month [Temporal Concept]

Phrase: ")"

Phrase: ","

Phrase: "3 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "who"

Phrase: "achieved"

Phrase: "a complete CG response"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   913   C0677874:Complete Response [Finding]
   827   C0871261:Response [Organism Attribute]
   827   C1704632:Response [Finding]
   827   C1706817:Response [Intellectual Product]
   827   C2911692:Response [Mental Process]

Phrase: "have"

Phrase: "lost"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0745777:Lost [Functional Concept]

Phrase: "their response"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0871261:Response [Organism Attribute]
  1000   C1704632:Response [Finding]
  1000   C1706817:Response [Intellectual Product]
  1000   C2911692:Response [Mental Process]

Phrase: "(complete CG response duration of 3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0237585:Response Duration [Temporal Concept]
   753   C0449238:Duration [Temporal Concept]
   753   C2926735:Duration [Pharmacologic Substance]

Phrase: "[1 patient"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:*^patient [Patient or Disabled Group]

Phrase: "]"

Phrase: "and"

Phrase: "9"

Phrase: "[2 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "] months"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0439231:months [Temporal Concept]
   966 E C0439507:/month [Temporal Concept]

Phrase: ")."
Processing 00000000.tx.103: At their latest follow-up these patients had 20%, 16%, and 5% Ph-positive metaphases, but continue on therapy. 

Phrase: "At their latest follow-up"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   901   C0589120:Follow-up [Finding]
   901   C1522577:follow-up [Health Care Activity]
   901   C1704685:FOLLOW-UP [Intellectual Product]
   901   C3274571:FOLLOW-UP [Health Care Activity]
   827   C0332283:follow [Temporal Concept]
   827   C1719822:Follow [Intellectual Product]

Phrase: "these patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "had"

Phrase: "20%,"

Phrase: "16%,"

Phrase: "and"

Phrase: "5% Ph-positive metaphases,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   812   C1621812:Metaphases [Cell Function]
   779 E C0025564:Metaphase [Cell Function]

Phrase: "but"

Phrase: "continue on therapy."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0039798:therapy [Functional Concept]
   790   C0087111:Therapy [Therapeutic or Preventive Procedure]
   790   C0549178:Continue [Idea or Concept]
   790   C1363945:Therapy [Finding]
Processing 00000000.tx.104: All 6 patients who started with 0% Ph-positive continue in complete CG response. 

Phrase: "All 6 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "who"

Phrase: "started with 0% Ph-positive"
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
   760   C0020283:[pH] [Quantitative Concept]
   760   C0439178:% Positive [Quantitative Concept]
   760   C0450407:ph+ [Finding]
   760   C0450408:ph++ [Finding]
   760   C0450409:ph+++ [Finding]
   760   C1272689:Started [Qualitative Concept]
   760   C1446409:Positive [Qualitative Concept]
   760   C1514241:Positive [Finding]
   760   C2825490:Positive [Qualitative Concept]
   726 E C0439659:Start [Temporal Concept]

Phrase: "continue in complete CG response."
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   797   C0677874:Complete Response [Finding]
   760   C0010802:Cytogenetic [Biomedical Occupation or Discipline]
   760   C0205197:Complete [Qualitative Concept]
   760   C0549178:Continue [Idea or Concept]
   760   C0725685:COMPLEAT [Food]
   760   C0871261:Response [Organism Attribute]
   760   C1704632:Response [Finding]
   760   C1706817:Response [Intellectual Product]
   760   C2911692:Response [Mental Process]
Processing 00000000.tx.105: The median follow-up time from achievement of BCR-ABL/ABL percentage ratio lower than 0.045% is 3 months (range, 1-9 months); 

Phrase: "The median follow-up time from achievement"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   778   C0589120:Follow-up [Finding]
   778   C1522577:follow-up [Health Care Activity]
   778   C1704685:FOLLOW-UP [Intellectual Product]
   778   C3274571:FOLLOW-UP [Health Care Activity]
   748   C0040223:Time [Temporal Concept]
   748   C0332283:follow [Temporal Concept]
   748   C1719822:Follow [Intellectual Product]
   748   C3541383:Time [Temporal Concept]

Phrase: "of BCR-ABL/ABL percentage ratio"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   804   C0456603:Ratio [Quantitative Concept]
   804   C1547037:Ratio [Intellectual Product]

Phrase: "lower than 0.045%"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0441994:Lower [Spatial Concept]
   770   C1548802:Lower [Body Location or Region]
   770   C2003888:Lower [Activity]

Phrase: "is"

Phrase: "3 months"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C1442461:3 Months [Temporal Concept]
   861   C0439231:months [Temporal Concept]
   827 E C0439507:/month [Temporal Concept]

Phrase: "(range,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1514721:Range [Quantitative Concept]
  1000   C2348147:Range [Quantitative Concept]
  1000   C3542016:Range [Intellectual Product]

Phrase: "1-9 months"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   896   C1442451:1 Month [Temporal Concept]
   827   C0439231:months [Temporal Concept]
   793 E C0439507:/month [Temporal Concept]

Phrase: ")"

Phrase: ";"
Processing 00000000.tx.106: none of the 18 patients who have achieved these ratios has relapsed. 

Phrase: "none of the 18 patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0030705:Patients [Patient or Disabled Group]
   760   C0456148:None [Quantitative Concept]
   760   C0549184:None [Quantitative Concept]

Phrase: "who"

Phrase: "have"

Phrase: "achieved"

Phrase: "these ratios"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0456603:Ratios [Quantitative Concept]
  1000   C1610540:*Ratios [Quantitative Concept]
   966 E C1547037:Ratio [Intellectual Product]

Phrase: "has"

Phrase: "relapsed."
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0205336:relapsed [Temporal Concept]
   966 E C0035020:Relapse [Phenomenon or Process]
   966 E C0277556:Relapse [Disease or Syndrome]
Processing 00000000.tx.107: One patient who achieved a minor cytogenetic response has lost the cytogenetic response (defined as an increase of Ph-positive cells to more than 90%) after 9 months from best response. 

Phrase: "One patient"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:*^patient [Patient or Disabled Group]

Phrase: "who"

Phrase: "achieved"

Phrase: "a minor cytogenetic response"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0871261:Response [Organism Attribute]
   827   C1704632:Response [Finding]
   827   C1706817:Response [Intellectual Product]
   827   C2911692:Response [Mental Process]

Phrase: "has"

Phrase: "lost"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0745777:Lost [Functional Concept]

Phrase: "the cytogenetic response"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0871261:Response [Organism Attribute]
   861   C1704632:Response [Finding]
   861   C1706817:Response [Intellectual Product]
   861   C2911692:Response [Mental Process]

Phrase: "("

Phrase: "defined as an increase of Ph-positive cells"
Meta Candidates (Total=18; Excluded=3; Pruned=0; Remaining=15)
   770   C0439178:% positive cells [Quantitative Concept]
           % Positive
   767   C0221106:increase ph [Disease or Syndrome]
   744   C0007634:Cells [Cell]
   744   C0020283:[pH] [Quantitative Concept]
   744   C0442805:Increase [Functional Concept]
   744   C0450407:ph+ [Finding]
   744   C0450408:ph++ [Finding]
   744   C0450409:ph+++ [Finding]
   744   C1446409:Positive [Qualitative Concept]
   744   C1514241:Positive [Finding]
   744   C1704788:Defined [Conceptual Entity]
   744   C2825490:Positive [Qualitative Concept]
   744   C3282337:Cells [Cell]
   744   C3539106:Defined [Intellectual Product]
   711 E C1269647:Cell [Cell]
   711 E C1704653:Cell [Medical Device]
   711 E C1948049:Cell [Spatial Concept]

Phrase: "to more"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205172:More [Functional Concept]

Phrase: "than 90%"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439083:>90 [Quantitative Concept]
  1000   C0439087:<90 [Quantitative Concept]

Phrase: ")"

Phrase: "after 9 months"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0439231:months [Temporal Concept]
   827 E C0439507:/month [Temporal Concept]

Phrase: "from best response."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C2986560:Best Response [Finding]
   861   C0871261:Response [Organism Attribute]
   861   C1704632:Response [Finding]
   861   C1706817:Response [Intellectual Product]
   861   C2911692:Response [Mental Process]
Processing 00000000.tx.108: Toxicity and dose intensity Common adverse events are listed in Table 3. 

Phrase: "Toxicity"
Meta Candidates (Total=6; Excluded=4; Pruned=0; Remaining=2)
  1000   C0040539:toxicity [Qualitative Concept]
  1000   C0600688:Toxicity [Injury or Poisoning]
   928 E C1407029:Toxic [Qualitative Concept]
   907 E C0032346:Poison [Hazardous or Poisonous Substance]
   907 E C1548769:Poison [Intellectual Product]
   907 E C1550590:poison [Idea or Concept]

Phrase: "and"

Phrase: "dose intensity Common adverse events"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   840   C0877248:adverse events [Finding]
   840   C1705413:Adverse Events [Idea or Concept]
   804   C0441471:Events [Event]
   804   C3541888:Events [Classification]

Phrase: "are"

Phrase: "listed in Table 3."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0039224:Table [Manufactured Object]
   770   C1706073:Table [Medical Device]
   770   C1706074:Table [Intellectual Product]
   737   C0745732:List [Conceptual Entity]
   737   C3272378:LIST [Intellectual Product]
Processing 00000000.tx.109: Fluid retention, skin rash, nausea, diarrhea, and muscle cramps were common, but not more frequent than what has been reported with standard-dose imatinib. 

Phrase: "Fluid retention,"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
  1000   C0268000:fluid retention [Pathologic Function]
   861   C0005889:FLUID [Body Substance]
   861   C0035280:Retention [Mental Process]
   861   C0302908:fluid [Substance]
   861   C0333117:Retention [Functional Concept]
   861   C0444611:Fluid [Qualitative Concept]
   861   C1704353:Fluid [Substance]
   861   C1753315:retention [Cell Function]

Phrase: "skin rash,"
Meta Candidates (Total=9; Excluded=4; Pruned=0; Remaining=5)
  1000   C0015230:Skin Rash [Disease or Syndrome]
           Rash
   861   C0444099:Skin [Body Substance]
   861   C1123023:Skin [Body System]
   861   C1278993:Skin [Body System]
   805 E C0221912:Cutaneous [Spatial Concept]
   805 E C0221928:Dermal [Qualitative Concept]
   805 E C1522447:Cutaneous [Functional Concept]
   738 E C0011646:Dermis [Tissue]

Phrase: "nausea,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0027497:Nausea [Sign or Symptom]
  1000   C1963179:Nausea [Finding]

Phrase: "diarrhea,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0011991:Diarrhea [Sign or Symptom]
  1000   C1963091:Diarrhea [Finding]

Phrase: "and"

Phrase: "muscle cramps"
Meta Candidates (Total=7; Excluded=4; Pruned=0; Remaining=3)
  1000   C0026821:Muscle cramps [Sign or Symptom]
           Cramps
   861   C0026845:Muscle [Tissue]
   827 E C1413106:CRAMP [Gene or Genome]
   789 E C0442025:Muscular [Spatial Concept]
   777 E C0270814:Crampy [Disease or Syndrome]
   777 E C1446787:Crampy [Sign or Symptom]

Phrase: "were"

Phrase: "common,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205214:Common [Quantitative Concept]
  1000   C1522138:Common [Functional Concept]
  1000   C3245511:common [Intellectual Product]

Phrase: "but"

Phrase: "not more frequent than what"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0332183:Frequent [Temporal Concept]

Phrase: "has"

Phrase: "been"

Phrase: "reported with standard-dose imatinib."
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
   760   C0178602:Dose [Quantitative Concept]
   760   C0684224:Reported [Intellectual Product]
   760   C0700287:Reported [Health Care Activity]
   760   C0869039:Dose [Quantitative Concept]
   760   C0935989:imatinib [Organic Chemical,Pharmacologic Substance]
   760   C1114758:Dose # [Clinical Attribute]
   760   C1442989:Standard [Qualitative Concept]
   760   C2828392:Standard [Intellectual Product]
   760   C3496591:Reported [Clinical Attribute]
   726 E C3273238:Report [Intellectual Product]
Processing 00000000.tx.110: Grade 3 or higher nonhematologic adverse events were uncommon, with skin rash (n = 3, 8%), fatigue (n = 1, 3%), liver toxicity (n = 1, 3%), and bone pain (n = 1, 3%) being the most common. 

Phrase: "Grade 3"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0205617:Grade III [Qualitative Concept]
  1000   C0450094:Grade 3 [Qualitative Concept]
  1000   C0687697:grade 3 [Intellectual Product]
   861   C0441800:Grade [Classification]
   861   C0919553:Grade [Classification]
   861   C3244287:grade [Finding]

Phrase: "or"

Phrase: "higher nonhematologic adverse events"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0877248:adverse events [Finding]
   861   C1705413:Adverse Events [Idea or Concept]
   812   C0441471:Events [Event]
   812   C3541888:Events [Classification]

Phrase: "were"

Phrase: "uncommon,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0522498:Uncommon [Qualitative Concept]

Phrase: "with skin rash"
Meta Candidates (Total=9; Excluded=4; Pruned=0; Remaining=5)
  1000   C0015230:Skin Rash [Disease or Syndrome]
           Rash
   861   C0444099:Skin [Body Substance]
   861   C1123023:Skin [Body System]
   861   C1278993:Skin [Body System]
   805 E C0221912:Cutaneous [Spatial Concept]
   805 E C0221928:Dermal [Qualitative Concept]
   805 E C1522447:Cutaneous [Functional Concept]
   738 E C0011646:Dermis [Tissue]

Phrase: "(n = 3,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441922:N+ [Intellectual Product]
   861   C1553036:[n] [Quantitative Concept]

Phrase: "8%"

Phrase: ")"

Phrase: ","

Phrase: "fatigue"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0015672:Fatigue [Sign or Symptom]

Phrase: "(n = 1,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441922:N+ [Intellectual Product]
   861   C1553036:[n] [Quantitative Concept]

Phrase: "3%"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]

Phrase: ")"

Phrase: ","

Phrase: "liver toxicity"
Meta Candidates (Total=6; Excluded=4; Pruned=0; Remaining=2)
   861   C0040539:toxicity [Qualitative Concept]
   861   C0600688:Toxicity [Injury or Poisoning]
   789 E C1407029:Toxic [Qualitative Concept]
   768 E C0032346:Poison [Hazardous or Poisonous Substance]
   768 E C1548769:Poison [Intellectual Product]
   768 E C1550590:poison [Idea or Concept]

Phrase: "(n = 1,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441922:N+ [Intellectual Product]
   861   C1553036:[n] [Quantitative Concept]

Phrase: "3%"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "bone pain"
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
  1000   C0151825:Bone pain [Sign or Symptom]
  1000   C1963077:Bone pain [Finding]
   861   C0030193:Pain [Sign or Symptom]
   861   C0262950:Bone, NOS [Body Part, Organ, or Organ Component]
   861   C0391978:Bone [Tissue]
   861   C1266908:Bone [Body Part, Organ, or Organ Component]
   861   C1266909:Bone [Body System]
   861   C1962977:Pain NOS [Finding]
   789 E C0443157:Bony [Functional Concept]

Phrase: "(n = 1,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441922:N+ [Intellectual Product]
   861   C1553036:[n] [Quantitative Concept]

Phrase: "3%"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]

Phrase: ")"

Phrase: "being"

Phrase: "the most common."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205214:Common [Quantitative Concept]
   861   C1522138:Common [Functional Concept]
   861   C3245511:common [Intellectual Product]
Processing 00000000.tx.111: Hematologic toxicity is also shown in Table 3. 

Phrase: "Hematologic toxicity"
Meta Candidates (Total=6; Excluded=4; Pruned=0; Remaining=2)
   861   C0040539:toxicity [Qualitative Concept]
   861   C0600688:Toxicity [Injury or Poisoning]
   789 E C1407029:Toxic [Qualitative Concept]
   768 E C0032346:Poison [Hazardous or Poisonous Substance]
   768 E C1548769:Poison [Intellectual Product]
   768 E C1550590:poison [Idea or Concept]

Phrase: "is"

Phrase: "also"

Phrase: "shown in Table 3."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0039224:Table [Manufactured Object]
   770   C1706073:Table [Medical Device]
   770   C1706074:Table [Intellectual Product]
   737   C1547282:Show [Intellectual Product]
Processing 00000000.tx.112: Grade 3 or higher neutropenia occurred in 11 patients (31%) and thrombocytopenia in 8 patients (22%). 

Phrase: "Grade 3"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0205617:Grade III [Qualitative Concept]
  1000   C0450094:Grade 3 [Qualitative Concept]
  1000   C0687697:grade 3 [Intellectual Product]
   861   C0441800:Grade [Classification]
   861   C0919553:Grade [Classification]
   861   C3244287:grade [Finding]

Phrase: "or"

Phrase: "higher neutropenia"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0027947:Neutropenia [Finding]
   861   C0853697:Neutropenia [Finding]

Phrase: "occurred in 11 patients"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   770   C0030705:Patients [Patient or Disabled Group]
   770   C1709305:Occurred [Activity]
   737 E C2745955:OCCUR [Temporal Concept]

Phrase: "(31%"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450355:31 [Intellectual Product]

Phrase: ")"

Phrase: "and"

Phrase: "thrombocytopenia in 8 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0040034:Thrombocytopenia [Finding]

Phrase: "(22%"

Phrase: ")."
Processing 00000000.tx.113: Anemia was observed in only 3 patients (8%). 

Phrase: "Anemia"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0002871:Anaemia [Disease or Syndrome]
  1000   C1000483:Anemia [Plant]
   928 E C0857322:anaemic [Finding]

Phrase: "was"

Phrase: "observed in only 3 patients"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0030705:Patients [Patient or Disabled Group]
   760   C0205171:Only [Quantitative Concept]
   760   C1441672:Observed [Functional Concept]
   760   C1720467:Only [Intellectual Product]

Phrase: "(8%"

Phrase: ")."
Processing 00000000.tx.114: View this table: [in this window] [in a new window]  Table 3. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "this table"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039224:Table [Manufactured Object]
  1000   C1706073:Table [Medical Device]
  1000   C1706074:Table [Intellectual Product]

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Table 3."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]
Processing 00000000.tx.115: Side effects with high-dose imatinib (n = 36)  After 3 months of therapy, 18 patients (50%) were receiving the planned dose; 

Phrase: "Side effects with high-dose imatinib"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   790   C0001688:side effects [Functional Concept]
   756 E C0879626:Side Effect [Pathologic Function]
   753   C0441987:Side [Spatial Concept]
   753   C1280500:effects [Qualitative Concept]
   719 E C2348382:Effect [Qualitative Concept]

Phrase: "(n = 36"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441922:N+ [Intellectual Product]
   861   C1553036:[n] [Quantitative Concept]

Phrase: ")"

Phrase: "After 3 months"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C1442461:3 Months [Temporal Concept]
   861   C0439231:months [Temporal Concept]
   827 E C0439507:/month [Temporal Concept]

Phrase: "of therapy,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039798:therapy [Functional Concept]
  1000   C0087111:Therapy [Therapeutic or Preventive Procedure]
  1000   C1363945:Therapy [Finding]

Phrase: "18 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "(50%"

Phrase: ")"

Phrase: "were"

Phrase: "receiving"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1514756:Receive [Qualitative Concept]

Phrase: "the planned dose"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C2826283:Planned Dose [Research Activity]
   861   C0178602:Dose [Quantitative Concept]
   861   C0869039:Dose [Quantitative Concept]
   861   C1114758:Dose # [Clinical Attribute]

Phrase: ";"
Processing 00000000.tx.116: 3 had discontinued therapy because of lack of compliance and 15 had dose reduced for toxicity. 

Phrase: "3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]

Phrase: "had"

Phrase: "discontinued therapy because of lack of compliance"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   774   C1321605:therapy compliance [Individual Behavior]
   748   C0039798:therapy [Functional Concept]
   748   C0087111:Therapy [Therapeutic or Preventive Procedure]
   748   C1363945:Therapy [Finding]

Phrase: "and"

Phrase: "15"

Phrase: "had"

Phrase: "dose"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0178602:Dose [Quantitative Concept]
  1000   C0869039:Dose [Quantitative Concept]
  1000   C1114758:Dose # [Clinical Attribute]

Phrase: "reduced for toxicity."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   790   C0040539:toxicity [Qualitative Concept]
   790   C0392756:Reduced [Qualitative Concept]
   790   C0600688:Toxicity [Injury or Poisoning]
   718 E C1407029:Toxic [Qualitative Concept]
Processing 00000000.tx.117: Corresponding values at 6 and 9 months were 44% (14 of 32 evaluable) and 41% (12 of 29 evaluable), respectively. 

Phrase: "Corresponding values at 6"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C0042295:Values [Qualitative Concept]
   737 E C1522609:Value [Quantitative Concept]

Phrase: "and"

Phrase: "9 months"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0439231:months [Temporal Concept]
   827 E C0439507:/month [Temporal Concept]

Phrase: "were"

Phrase: "44%"

Phrase: "(14 of 32 evaluable"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1516986:Evaluable [Disease or Syndrome]

Phrase: ")"

Phrase: "and"

Phrase: "41%"

Phrase: "(12 of 29 evaluable"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1516986:Evaluable [Disease or Syndrome]

Phrase: ")"

Phrase: ","

Phrase: "respectively."
Processing 00000000.tx.118: Dose reduction to 600 mg daily resolved the toxicity in most patients; 

Phrase: "Dose reduction to 600 mg daily"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0301630:Reduction [Natural Phenomenon or Process]
   753   C0392756:Reduction [Qualitative Concept]
   753   C0441610:Reduction [Therapeutic or Preventive Procedure]

Phrase: "resolved"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514893:Resolved [Idea or Concept]
  1000   C2699488:Resolved [Conceptual Entity]

Phrase: "the toxicity in most patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0040539:toxicity [Qualitative Concept]
   760   C0600688:Toxicity [Injury or Poisoning]

Phrase: ";"
Processing 00000000.tx.119: 10 patients (28%) have required further dose reductions to 400 mg daily or lower (300 mg is the lowest acceptable dose). 

Phrase: "10 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "(28%"

Phrase: ")"

Phrase: "have"

Phrase: "required"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514873:Required [Functional Concept]

Phrase: "further dose reductions to 400 mg"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   753   C0301630:reductions [Natural Phenomenon or Process]
   753   C0441610:reductions [Therapeutic or Preventive Procedure]
   719 E C0392756:Reduction [Qualitative Concept]

Phrase: "daily"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332173:Daily [Temporal Concept]

Phrase: "or"

Phrase: "lower"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0441994:Lower [Spatial Concept]
  1000   C1548802:Lower [Body Location or Region]
  1000   C2003888:Lower [Activity]

Phrase: "(300 mg"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0439269:mg% [Quantitative Concept]
   861   C1960952:mg % [Quantitative Concept]
   861   C2346927:Mg++ [Element, Ion, or Isotope,Pharmacologic Substance]

Phrase: "is"

Phrase: "the lowest acceptable dose"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   896   C0445550:Low dose [Quantitative Concept]
   896   C1708745:Low-Dose [Research Activity]
   827   C0178602:Dose [Quantitative Concept]
   827   C0869039:Dose [Quantitative Concept]
   827   C1114758:Dose # [Clinical Attribute]

Phrase: ")."
Processing 00000000.tx.120: Patients that required dose reductions for toxicity did so early; 

Phrase: "Patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "that required dose reductions for toxicity"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   753   C0301630:reductions [Natural Phenomenon or Process]
   753   C0441610:reductions [Therapeutic or Preventive Procedure]
   719 E C0392756:Reduction [Qualitative Concept]

Phrase: "did"

Phrase: "so early"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0037640:SO [Geographic Area]
   861   C1279919:Early [Temporal Concept]

Phrase: ";"
Processing 00000000.tx.121: only 3 patients have required dose reductions after 4 months of therapy (after 20 [2 patients] and 64 [1 patient] weeks of therapy). 

Phrase: "only 3 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0030705:Patients [Patient or Disabled Group]

Phrase: "have"

Phrase: "required dose reductions after 4 months of therapy"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   744   C0301630:reductions [Natural Phenomenon or Process]
   744   C0441610:reductions [Therapeutic or Preventive Procedure]
   711 E C0392756:Reduction [Qualitative Concept]

Phrase: "("

Phrase: "after 20"

Phrase: "[2 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "]"

Phrase: "and"

Phrase: "64"

Phrase: "[1 patient"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:*^patient [Patient or Disabled Group]

Phrase: "] weeks of therapy"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   790   C0439230:weeks [Temporal Concept]
   756 E C0332174:/week [Temporal Concept]

Phrase: ")."
Processing 00000000.tx.122: The most common causes for dose reduction were myelosuppression in 7 patients (thrombocytopenia [n = 2], neutropenia [n = 2], both [n = 3]; 19%), skin rash (n = 5, 14%), fatigue (n = 3, 8%), and bone pain (n = 2 [1 recurrent grade 2, 1 grade 3], 6%).  

Phrase: "The most common causes for dose reduction"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   748   C0015127:causes [Functional Concept]
   748   C1314792:Causes [Functional Concept]
   714 E C1524003:Cause [Conceptual Entity]

Phrase: "were"

Phrase: "myelosuppression in 7 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0854467:Myelosuppression [Disease or Syndrome]

Phrase: "(thrombocytopenia"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0040034:Thrombocytopenia [Finding]

Phrase: "[n = 2],"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441922:N+ [Intellectual Product]
   861   C1553036:[n] [Quantitative Concept]

Phrase: "neutropenia"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0027947:Neutropenia [Finding]
  1000   C0853697:Neutropenia [Finding]

Phrase: "[n = 2],"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441922:N+ [Intellectual Product]
   861   C1553036:[n] [Quantitative Concept]

Phrase: "both"

Phrase: "[n = 3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441922:N+ [Intellectual Product]
   861   C1553036:[n] [Quantitative Concept]

Phrase: "]"

Phrase: "; 19%"

Phrase: ")"

Phrase: ","

Phrase: "skin rash"
Meta Candidates (Total=9; Excluded=4; Pruned=0; Remaining=5)
  1000   C0015230:Skin Rash [Disease or Syndrome]
           Rash
   861   C0444099:Skin [Body Substance]
   861   C1123023:Skin [Body System]
   861   C1278993:Skin [Body System]
   805 E C0221912:Cutaneous [Spatial Concept]
   805 E C0221928:Dermal [Qualitative Concept]
   805 E C1522447:Cutaneous [Functional Concept]
   738 E C0011646:Dermis [Tissue]

Phrase: "(n = 5,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0129575:N 5' [Organic Chemical,Pharmacologic Substance]
   861   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441922:N+ [Intellectual Product]
   861   C1553036:[n] [Quantitative Concept]

Phrase: "14%"

Phrase: ")"

Phrase: ","

Phrase: "fatigue"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0015672:Fatigue [Sign or Symptom]

Phrase: "(n = 3,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441922:N+ [Intellectual Product]
   861   C1553036:[n] [Quantitative Concept]

Phrase: "8%"

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "bone pain"
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
  1000   C0151825:Bone pain [Sign or Symptom]
  1000   C1963077:Bone pain [Finding]
   861   C0030193:Pain [Sign or Symptom]
   861   C0262950:Bone, NOS [Body Part, Organ, or Organ Component]
   861   C0391978:Bone [Tissue]
   861   C1266908:Bone [Body Part, Organ, or Organ Component]
   861   C1266909:Bone [Body System]
   861   C1962977:Pain NOS [Finding]
   789 E C0443157:Bony [Functional Concept]

Phrase: "(n = 2 [1 recurrent grade 2,"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   799   C0441800:Grade [Classification]
   799   C0919553:Grade [Classification]
   799   C2945760:Recurrent [Temporal Concept]
   799   C3244287:grade [Finding]
   727 E C0034897:Recurrence [Phenomenon or Process]
   727 E C1458156:recurrence [Neoplastic Process]
   727 E C2825055:Recurrence [Pathologic Function]

Phrase: "1 grade 3"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   901   C0205617:Grade III [Qualitative Concept]
   901   C0450094:Grade 3 [Qualitative Concept]
   901   C0687697:grade 3 [Intellectual Product]
   827   C0441800:Grade [Classification]
   827   C0919553:Grade [Classification]
   827   C3244287:grade [Finding]

Phrase: "],"

Phrase: "6%"

Phrase: ")."
Processing 00000000.tx.123: Discussion Top Abstract Introduction Patients and methods Results Discussion References  In this study we report high rates of major and complete CG responses with high-dose imatinib (800 mg daily) in patients whose CML has failed to respond to IFN- therapy. 

Phrase: "Discussion Top Abstract Introduction Patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C0030705:Patients [Patient or Disabled Group]

Phrase: "and"

Phrase: "methods Results Discussion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0557061:Discussion [Therapeutic or Preventive Procedure]
   827   C2584313:Discussion [Social Behavior]

Phrase: "References  In this study"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   819   C2985663:Study Reference [Intellectual Product]
   770   C0557651:Study [Manufactured Object]
   770   C1514811:Reference [Idea or Concept]
   770   C1706462:Reference [Conceptual Entity]
   770   C2603343:Study [Research Activity]

Phrase: "we"

Phrase: "report"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0684224:Report [Intellectual Product]
  1000   C0700287:Report [Health Care Activity]
  1000   C3273238:Report [Intellectual Product]

Phrase: "high rates of major"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0205250:High [Qualitative Concept]
   770   C1299351:High [Qualitative Concept]
   770   C2700149:HIGH [Intellectual Product]
   737   C0871208:Rate [Activity]
   737   C1521828:Rate [Quantitative Concept]

Phrase: "and"

Phrase: "complete CG responses with high-dose imatinib"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   757   C0677874:Complete Response [Finding]
   748   C0871261:responses [Organism Attribute]
   714 E C1704632:Response [Finding]
   714 E C1706817:Response [Intellectual Product]
   714 E C2911692:Response [Mental Process]

Phrase: "(800 mg daily"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0439269:mg% [Quantitative Concept]
   827   C1960952:mg % [Quantitative Concept]
   827   C2346927:Mg++ [Element, Ion, or Isotope,Pharmacologic Substance]

Phrase: ")"

Phrase: "in patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "whose CML"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0023473:Chronic myeloid leukaemia [Neoplastic Process]
  1000   C2984277:Chronic myeloid leukemia [Functional Concept]
   913   C1279296:Chronic leukaemia [Neoplastic Process]
   901   C0023470:Myeloid Leukemia [Neoplastic Process]
   827   C0023418:Leukaemia [Neoplastic Process]
   827   C0205191:chronic [Temporal Concept]
   827   C0439677:Myeloid [Qualitative Concept]

Phrase: "has"

Phrase: "failed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0231175:Failed [Functional Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "respond to IFN- therapy."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0039798:therapy [Functional Concept]
   770   C0087111:Therapy [Therapeutic or Preventive Procedure]
   770   C1363945:Therapy [Finding]
Processing 00000000.tx.124: Of the patients, 56% achieved very low levels of BCR-ABL/ABL percentage ratios, including 41% who achieved complete molecular remissions. 

Phrase: "Of the patients,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "56%"

Phrase: "achieved"

Phrase: "very low levels of BCR-ABL/ABL percentage ratios,"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   742   C0441889:Levels [Qualitative Concept]
   708 E C0456079:Level [Classification]
   708 E C1547707:Level [Geographic Area]
   708 E C2946261:Level [Pharmacologic Substance]

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "41%"

Phrase: "who"

Phrase: "achieved"

Phrase: "complete molecular remissions."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   896   C0677874:Complete Remission [Finding]
   827   C0544452:remissions [Finding]
   827   C0687702:remissions [Neoplastic Process]
Processing 00000000.tx.125: Higher-dose imatinib was well tolerated, with infrequent grade 3 or higher toxicity. 

Phrase: "Higher-dose imatinib"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0935989:imatinib [Organic Chemical,Pharmacologic Substance]
   717   C0444956:High dose [Quantitative Concept]

Phrase: "was"

Phrase: "well tolerated,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0205170:Well [Qualitative Concept]
   861   C3146287:Well [Manufactured Object]

Phrase: "with infrequent grade 3"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   901   C0205617:Grade III [Qualitative Concept]
   901   C0450094:Grade 3 [Qualitative Concept]
   901   C0687697:grade 3 [Intellectual Product]
   827   C0441800:Grade [Classification]
   827   C0919553:Grade [Classification]
   827   C3244287:grade [Finding]

Phrase: "or"

Phrase: "higher toxicity."
Meta Candidates (Total=6; Excluded=4; Pruned=0; Remaining=2)
   861   C0040539:toxicity [Qualitative Concept]
   861   C0600688:Toxicity [Injury or Poisoning]
   789 E C1407029:Toxic [Qualitative Concept]
   768 E C0032346:Poison [Hazardous or Poisonous Substance]
   768 E C1548769:Poison [Intellectual Product]
   768 E C1550590:poison [Idea or Concept]
Processing 00000000.tx.126: These results suggest that higher doses of imatinib may be more effective in Ph-positive CML. 

Phrase: "These results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "suggest"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that higher doses of imatinib"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   773   C0444956:High dose [Quantitative Concept]
   760   C0178602:Doses [Quantitative Concept]
   726 E C0869039:Dose [Quantitative Concept]
   726 E C1114758:Dose # [Clinical Attribute]
   726 E C1428722:DOS [Gene or Genome]

Phrase: "may"

Phrase: "be"

Phrase: "more effective in Ph-positive CML."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C1280519:effective [Qualitative Concept]
   744   C1704419:Effective [Qualitative Concept]
Processing 00000000.tx.127: The response rate achieved with higher-dose imatinib is remarkable. 

Phrase: "The response rate"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0237629:Response Rate [Temporal Concept]
   861   C0871208:Rate [Activity]
   861   C0871261:Response [Organism Attribute]
   861   C1521828:Rate [Quantitative Concept]
   861   C1704632:Response [Finding]
   861   C1706817:Response [Intellectual Product]
   861   C2911692:Response [Mental Process]

Phrase: "achieved with higher-dose imatinib"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   790   C0444956:High dose [Quantitative Concept]
   760   C0178602:Dose [Quantitative Concept]
   760   C0869039:Dose [Quantitative Concept]
   760   C0935989:imatinib [Organic Chemical,Pharmacologic Substance]
   760   C1114758:Dose # [Clinical Attribute]
   726   C0205250:High [Qualitative Concept]
   726   C1299351:High [Qualitative Concept]
   726   C2700149:HIGH [Intellectual Product]

Phrase: "is"

Phrase: "remarkable."
Processing 00000000.tx.128: The major CG response rate was 90% (95% confidence interval [CI], 70%-99%). 

Phrase: "The major CG response rate"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0237629:Response Rate [Temporal Concept]
   812   C0871208:Rate [Activity]
   812   C1521828:Rate [Quantitative Concept]

Phrase: "was"

Phrase: "90%"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439083:>90 [Quantitative Concept]
  1000   C0439087:<90 [Quantitative Concept]

Phrase: "(95% confidence interval [CI],"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   901   C0009667:Confidence Interval [Quantitative Concept]
   827   C0237529:Confidence [Mental Process]
   827   C1272706:Interval [Temporal Concept]
   827   C1552654:Interval [Idea or Concept]
   827   C1552713:Interval [Intellectual Product]
   827   C1704725:Confidence [Qualitative Concept]
   827   C1704726:Confidence [Mental Process]
   755 E C0558095:Confident [Individual Behavior]
   727 E C0009669:confidentiality [Idea or Concept]

Phrase: "70%-99%"

Phrase: ")."
Processing 00000000.tx.129: Most CG responses were complete (89%; 95% CI, 71%-98%). 

Phrase: "Most CG responses"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   827   C0871261:responses [Organism Attribute]
   793 E C1704632:Response [Finding]
   793 E C1706817:Response [Intellectual Product]
   793 E C2911692:Response [Mental Process]

Phrase: "were"

Phrase: "complete"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0205197:Complete [Qualitative Concept]
  1000   C0725685:COMPLEAT [Food]
   928 E C0439812:Completeness [Qualitative Concept]

Phrase: "(89%"

Phrase: "; 95% CI,"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   901   C0009667:Confidence Interval [Quantitative Concept]
   827   C0237529:Confidence [Mental Process]
   827   C1272706:Interval [Temporal Concept]
   827   C1552654:Interval [Idea or Concept]
   827   C1552713:Interval [Intellectual Product]
   827   C1704725:Confidence [Qualitative Concept]
   827   C1704726:Confidence [Mental Process]
   755 E C0558095:Confident [Individual Behavior]
   727 E C0009669:confidentiality [Idea or Concept]

Phrase: "71%-98%"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0450389:71 [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.130: These results compare favorably with those reported with standard-dose imatinib. 

Phrase: "These results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "compare"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707455:Compare [Activity]

Phrase: "favorably with those"

Phrase: "reported with standard-dose imatinib."
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
   760   C0178602:Dose [Quantitative Concept]
   760   C0684224:Reported [Intellectual Product]
   760   C0700287:Reported [Health Care Activity]
   760   C0869039:Dose [Quantitative Concept]
   760   C0935989:imatinib [Organic Chemical,Pharmacologic Substance]
   760   C1114758:Dose # [Clinical Attribute]
   760   C1442989:Standard [Qualitative Concept]
   760   C2828392:Standard [Intellectual Product]
   760   C3496591:Reported [Clinical Attribute]
   726 E C3273238:Report [Intellectual Product]
Processing 00000000.tx.131: At 3 months, 85% of the patients have achieved a major CG response, compared with 44% reported with standard-dose imatinib. 

Phrase: "At 3 months,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C1442461:3 Months [Temporal Concept]
   861   C0439231:months [Temporal Concept]
   827 E C0439507:/month [Temporal Concept]

Phrase: "85% of the patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0030705:Patients [Patient or Disabled Group]

Phrase: "have"

Phrase: "achieved"

Phrase: "a major CG response,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   827   C0010802:Cytogenetic [Biomedical Occupation or Discipline]
   827   C0205164:Major [Qualitative Concept]
   827   C0871261:Response [Organism Attribute]
   827   C1704632:Response [Finding]
   827   C1706817:Response [Intellectual Product]
   827   C2911692:Response [Mental Process]

Phrase: "compared with 44%"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1707455:Compared [Activity]

Phrase: "reported with standard-dose imatinib."
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
   760   C0178602:Dose [Quantitative Concept]
   760   C0684224:Reported [Intellectual Product]
   760   C0700287:Reported [Health Care Activity]
   760   C0869039:Dose [Quantitative Concept]
   760   C0935989:imatinib [Organic Chemical,Pharmacologic Substance]
   760   C1114758:Dose # [Clinical Attribute]
   760   C1442989:Standard [Qualitative Concept]
   760   C2828392:Standard [Intellectual Product]
   760   C3496591:Reported [Clinical Attribute]
   726 E C3273238:Report [Intellectual Product]
Processing 00000000.tx.132: Early response to imatinib has been shown to have significant prognostic implications.3,4,11 Kantarjian et al reported a landmark analysis of 343 patients treated with standard-dose imatinib in chronic phase after IFN- failure with evaluable CG studies after 3 months of therapy.4 With a median treatment duration of 18 months, 5 (3%) of 152 patients who had achieved a major CG response at 3 months had progressed, compared with 22 (12%) of 191 without such a response (P = .005). 

Phrase: "Early response to imatinib"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0871261:Response [Organism Attribute]
   770   C1704632:Response [Finding]
   770   C1706817:Response [Intellectual Product]
   770   C2911692:Response [Mental Process]

Phrase: "has"

Phrase: "been"

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "have"

Phrase: "significant prognostic implications.3,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   812   C0220901:prognostic [Intellectual Product]
   812   C0237881:significant [Quantitative Concept]
   812   C0750502:Significant [Idea or Concept]
   812   C1546944:Significant [Qualitative Concept]

Phrase: "4,"

Phrase: "11 Kantarjian et al"

Phrase: "reported"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0684224:Reported [Intellectual Product]
  1000   C0700287:Reported [Health Care Activity]
  1000   C3496591:Reported [Clinical Attribute]
   966 E C3273238:Report [Intellectual Product]

Phrase: "a landmark analysis of 343 patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0002778:Analysis [Laboratory Procedure]
   753   C0936012:Analysis [Research Activity]
   753   C1524024:analysis [Functional Concept]

Phrase: "treated with standard-dose imatinib"
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
   806   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   760   C0178602:Dose [Quantitative Concept]
   760   C0869039:Dose [Quantitative Concept]
   760   C0935989:imatinib [Organic Chemical,Pharmacologic Substance]
   760   C1114758:Dose # [Clinical Attribute]
   760   C1442989:Standard [Qualitative Concept]
   760   C1522326:Treated [Functional Concept]
   760   C2828392:Standard [Intellectual Product]
   726 E C1292734:TREAT [Functional Concept]

Phrase: "in chronic phase"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0457343:Chronic phase [Temporal Concept]
   861   C0205191:chronic [Temporal Concept]
   861   C0205390:Phase [Temporal Concept]

Phrase: "after IFN- failure"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0231174:Failure [Functional Concept]
   861   C0680095:failure [Individual Behavior]

Phrase: "with evaluable CG studies"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   901   C0200896:Cytogenetic Studies [Laboratory Procedure]
   827   C0010802:Cytogenetic [Biomedical Occupation or Discipline]
   827   C0947630:studies [Laboratory Procedure]
   793 E C0557651:Study [Manufactured Object]
   793 E C2603343:Study [Research Activity]

Phrase: "after 3 months"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C1442461:3 Months [Temporal Concept]
   861   C0439231:months [Temporal Concept]
   827 E C0439507:/month [Temporal Concept]

Phrase: "of therapy.4"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039798:therapy [Functional Concept]
   861   C0087111:Therapy [Therapeutic or Preventive Procedure]
   861   C1363945:Therapy [Finding]

Phrase: "With a median treatment duration"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C0444921:treatment duration [Temporal Concept]
   827   C0449238:Duration [Temporal Concept]
   827   C2926735:Duration [Pharmacologic Substance]

Phrase: "of 18 months,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0439231:months [Temporal Concept]
   827 E C0439507:/month [Temporal Concept]

Phrase: "5"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439084:>5 [Quantitative Concept]
  1000   C0728893:+5 [Quantitative Concept]

Phrase: "(3%"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]

Phrase: ")"

Phrase: "of 152 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "who"

Phrase: "had"

Phrase: "achieved"

Phrase: "a major CG response at 3 months"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   748   C0010802:Cytogenetic [Biomedical Occupation or Discipline]
   748   C0205164:Major [Qualitative Concept]
   748   C0871261:Response [Organism Attribute]
   748   C1704632:Response [Finding]
   748   C1706817:Response [Intellectual Product]
   748   C2911692:Response [Mental Process]

Phrase: "had"

Phrase: "progressed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1272688:progressed [Functional Concept]
   966 E C1280477:Progress [Functional Concept]

Phrase: ","

Phrase: "compared with 22"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1707455:Compared [Activity]

Phrase: "(12%"

Phrase: ")"

Phrase: "of 191"

Phrase: "without such"

Phrase: "a response"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0871261:Response [Organism Attribute]
  1000   C1704632:Response [Finding]
  1000   C1706817:Response [Intellectual Product]
  1000   C2911692:Response [Mental Process]

Phrase: "(P = .005"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C2603361:P' [Clinical Attribute]

Phrase: ")."
Processing 00000000.tx.133: Early response was also associated with a survival advantage.3 Since few patients in our series did not achieve a major CG response even at this early time point, we cannot compare our results with that analysis. 

Phrase: "Early response"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0871261:Response [Organism Attribute]
   861   C1704632:Response [Finding]
   861   C1706817:Response [Intellectual Product]
   861   C2911692:Response [Mental Process]

Phrase: "was"

Phrase: "also"

Phrase: "associated with a survival advantage.3"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   790   C0332281:Associated with [Qualitative Concept]
           Associated
   753   C0038952:Survival [Activity]
   753   C0220921:survival [Functional Concept]
   719 E C0750490:Associate [Idea or Concept]
   719 E C1706221:Associate [Professional or Occupational Group]

Phrase: "Since"

Phrase: "few patients in our series"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0030705:Patients [Patient or Disabled Group]

Phrase: "did"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "achieve"

Phrase: "a major CG response even at this early time point,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   757   C0034746:Response Time [Temporal Concept]
   739   C0010802:Cytogenetic [Biomedical Occupation or Discipline]
   739   C0205164:Major [Qualitative Concept]
   739   C0871261:Response [Organism Attribute]
   739   C1704632:Response [Finding]
   739   C1706817:Response [Intellectual Product]
   739   C2911692:Response [Mental Process]

Phrase: "we"

Phrase: "cannot"

Phrase: "compare"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707455:Compare [Activity]

Phrase: "our results with"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   756   C1274040:Result [Functional Concept]
   756   C1546471:Result [Idea or Concept]
   756   C2825142:Result [Finding]

Phrase: "that analysis."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0002778:Analysis [Laboratory Procedure]
  1000   C0936012:Analysis [Research Activity]
  1000   C1524024:analysis [Functional Concept]
Processing 00000000.tx.134: However, it is hoped that the early response observed in our patients would have similar implications. 

Phrase: "However,"

Phrase: "it"

Phrase: "is"

Phrase: "hoped"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0392347:Hope [Mental Process]

Phrase: "that"

Phrase: "the early response"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0871261:Response [Organism Attribute]
   861   C1704632:Response [Finding]
   861   C1706817:Response [Intellectual Product]
   861   C2911692:Response [Mental Process]

Phrase: "observed in our patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0030705:Patients [Patient or Disabled Group]
   770   C1441672:Observed [Functional Concept]

Phrase: "would"

Phrase: "have"

Phrase: "similar implications."
Processing 00000000.tx.135: Despite having similar eligibility criteria, the study group included in this study is not necessarily comparable with that reported in studies using standard-dose imatinib. 

Phrase: "Despite"

Phrase: "having"

Phrase: "similar eligibility criteria,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C1512693:eligibility criteria [Qualitative Concept]
   827   C0243161:criteria [Intellectual Product]

Phrase: "the study group"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   861   C0441833:Group [Idea or Concept]
   861   C0557651:Study [Manufactured Object]
   861   C0687744:group [Population Group]
   861   C1257890:Group [Population Group]
   861   C1552516:Group [Health Care Related Organization]
   861   C1705428:Group [Conceptual Entity]
   861   C1705429:Group [Population Group]
   861   C2603343:Study [Research Activity]

Phrase: "included in this study"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   770   C0332257:included [Functional Concept]
   770   C0557651:Study [Manufactured Object]
   770   C2603343:Study [Research Activity]
   770   C3538986:INCLUDED [Gene or Genome]
   737 E C1552866:include [Idea or Concept]
   737 E C2700399:Include [Activity]

Phrase: "is"

Phrase: "not necessarily comparable with that"

Phrase: "reported in studies"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   824   C1317750:Study report [Intellectual Product]
   824   C1831145:Study report [Clinical Attribute]
   790   C0684224:Reported [Intellectual Product]
   790   C0700287:Reported [Health Care Activity]
   790   C0947630:studies [Laboratory Procedure]
   790   C3496591:Reported [Clinical Attribute]
   756 E C0557651:Study [Manufactured Object]
   756 E C2603343:Study [Research Activity]
   756 E C3273238:Report [Intellectual Product]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "standard-dose imatinib."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0935989:imatinib [Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.136: A noticeable difference is the paucity of patients with hematologic failure to IFN- (n = 1). 

Phrase: "A noticeable difference"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C1705241:*Difference [Quantitative Concept]
   861   C1705242:Difference [Qualitative Concept]
   789 E C0443199:Differential [Qualitative Concept]

Phrase: "is"

Phrase: "the paucity of patients"

Phrase: "with hematologic failure"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0231174:Failure [Functional Concept]
   861   C0680095:failure [Individual Behavior]

Phrase: "to IFN- (n = 1"

Phrase: ")."
Processing 00000000.tx.137: These patients have been reported to have a low response rate to imatinib.3,4 Still, within each category of IFN- failure, the response rate to high-dose imatinib was equally high, and the results appear to be particularly significant in patients with intolerance or CG resistance to IFN-. 

Phrase: "These patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "have"

Phrase: "been"

Phrase: "reported"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0684224:Reported [Intellectual Product]
  1000   C0700287:Reported [Health Care Activity]
  1000   C3496591:Reported [Clinical Attribute]
   966 E C3273238:Report [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "have"

Phrase: "a low response rate to imatinib.3,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   778   C0237629:Response Rate [Temporal Concept]
   748   C0871208:Rate [Activity]
   748   C0871261:Response [Organism Attribute]
   748   C1521828:Rate [Quantitative Concept]
   748   C1704632:Response [Finding]
   748   C1706817:Response [Intellectual Product]
   748   C2911692:Response [Mental Process]

Phrase: "4 Still,"

Phrase: "within each category"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0683312:Category [Intellectual Product]
  1000   C1555713:category [Idea or Concept]

Phrase: "of IFN- failure,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0231174:Failure [Functional Concept]
   861   C0680095:failure [Individual Behavior]

Phrase: "the response rate to high-dose imatinib"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   778   C0237629:Response Rate [Temporal Concept]
   774   C1512044:Dose Rate [Quantitative Concept]
   748   C0871208:Rate [Activity]
   748   C0871261:Response [Organism Attribute]
   748   C1521828:Rate [Quantitative Concept]
   748   C1704632:Response [Finding]
   748   C1706817:Response [Intellectual Product]
   748   C2911692:Response [Mental Process]

Phrase: "was"

Phrase: "equally high,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205250:High [Qualitative Concept]
   861   C1299351:High [Qualitative Concept]
   861   C2700149:HIGH [Intellectual Product]

Phrase: "and"

Phrase: "the results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "appear"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0700364:APPEAR [Qualitative Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "particularly significant in patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0237881:significant [Quantitative Concept]
   770   C0750502:Significant [Idea or Concept]
   770   C1546944:Significant [Qualitative Concept]

Phrase: "with intolerance"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0231199:Intolerance [Organism Function]
  1000   C1744706:intolerance [Intellectual Product]
  1000   C2355652:Intolerance [Organism Attribute]
   928 E C0231200:Intolerant [Functional Concept]

Phrase: "or"

Phrase: "CG resistance to IFN-."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   797   C0332325:Resistant to [Functional Concept]
   770   C0237834:Resistance [Mental Process]
   770   C1514892:Resistance [Physiologic Function]
Processing 00000000.tx.138: A direct comparison with standard-dose imatinib would be required to better define the magnitude of these differences. 

Phrase: "A direct comparison with standard-dose imatinib"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C1707455:Comparison [Activity]

Phrase: "would"

Phrase: "be"

Phrase: "required"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514873:Required [Functional Concept]

Phrase: "to better"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   861   C0332272:Better [Qualitative Concept]
   861   C1883351:To [Qualitative Concept]
   827 E C0205170:Well [Qualitative Concept]
   827 E C3146287:Well [Manufactured Object]

Phrase: "define"

Phrase: "the magnitude of these differences."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0449286:magnitude [Quantitative Concept]
   760   C1704240:Magnitude [Quantitative Concept]
Processing 00000000.tx.139: The molecular response rates with high-dose imatinib were significant. 

Phrase: "The molecular response rates with high-dose imatinib"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   767   C0237629:rates response [Temporal Concept]
   750   C1512044:Dose Rate [Quantitative Concept]
   744   C0871261:Response [Organism Attribute]
   744   C1704632:Response [Finding]
   744   C1706817:Response [Intellectual Product]
   744   C2911692:Response [Mental Process]
   711   C0871208:Rate [Activity]
   711   C1521828:Rate [Quantitative Concept]

Phrase: "were"

Phrase: "significant."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0237881:significant [Quantitative Concept]
  1000   C0750502:Significant [Idea or Concept]
  1000   C1546944:Significant [Qualitative Concept]
Processing 00000000.tx.140: Of the patients, 56% (95 CI, 38%-74%) achieved BCR-ABL/ABL percentage ratios lower than 0.045%. 

Phrase: "Of the patients,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "56%"

Phrase: "(95 CI,"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   901   C0009667:Confidence Interval [Quantitative Concept]
   827   C0237529:Confidence [Mental Process]
   827   C1272706:Interval [Temporal Concept]
   827   C1552654:Interval [Idea or Concept]
   827   C1552713:Interval [Intellectual Product]
   827   C1704725:Confidence [Qualitative Concept]
   827   C1704726:Confidence [Mental Process]
   755 E C0558095:Confident [Individual Behavior]
   727 E C0009669:confidentiality [Idea or Concept]

Phrase: "38%-74%"

Phrase: ")"

Phrase: "achieved BCR-ABL/ABL percentage ratios"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   799   C0456603:Ratios [Quantitative Concept]
   799   C1610540:*Ratios [Quantitative Concept]
   766 E C1547037:Ratio [Intellectual Product]

Phrase: "lower than 0.045%."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0441994:Lower [Spatial Concept]
   770   C1548802:Lower [Body Location or Region]
   770   C2003888:Lower [Activity]
Processing 00000000.tx.141: This threshold was clinically meaningful, as demonstrated by Hochhaus et al,18 in 54 patients who had achieved complete CG response with IFN- therapy. 

Phrase: "This threshold"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449864:Threshold [Qualitative Concept]

Phrase: "was"

Phrase: "clinically meaningful,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   789   C0876919:Meaning [Idea or Concept]

Phrase: "as"

Phrase: "demonstrated by Hochhaus et al,18"

Phrase: "in 54 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "who"

Phrase: "had"

Phrase: "achieved complete CG response with IFN- therapy."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   774   C0677874:Complete Response [Finding]
   748   C0871261:Response [Organism Attribute]
   748   C1704632:Response [Finding]
   748   C1706817:Response [Intellectual Product]
   748   C2911692:Response [Mental Process]
Processing 00000000.tx.142: Of the 27 patients who did not reach ratios lower than 0.045%, 13 (48%) eventually relapsed, compared with 1 (4%) of 27 patients who achieved these levels or lower.18 Furthermore, 13 (41%; 95 CI, 24%-59%) patients treated with high-dose imatinib in this study had undetectable transcripts, with a median follow-up of only 14 months. 

Phrase: "Of the 27 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "who"

Phrase: "did"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "reach"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2584321:Reach [Organism Function]

Phrase: "ratios"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0456603:Ratios [Quantitative Concept]
  1000   C1610540:*Ratios [Quantitative Concept]
   966 E C1547037:Ratio [Intellectual Product]

Phrase: "lower than 0.045%,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0441994:Lower [Spatial Concept]
   770   C1548802:Lower [Body Location or Region]
   770   C2003888:Lower [Activity]

Phrase: "13"

Phrase: "(48%"

Phrase: ")"

Phrase: "eventually"

Phrase: "relapsed"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0205336:relapsed [Temporal Concept]
   966 E C0035020:Relapse [Phenomenon or Process]
   966 E C0277556:Relapse [Disease or Syndrome]

Phrase: ","

Phrase: "compared with 1"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1707455:Compared [Activity]

Phrase: "(4%"

Phrase: ")"

Phrase: "of 27 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "who"

Phrase: "achieved"

Phrase: "these levels"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0441889:Levels [Qualitative Concept]
   966 E C0456079:Level [Classification]
   966 E C1547707:Level [Geographic Area]
   966 E C2946261:Level [Pharmacologic Substance]

Phrase: "or"

Phrase: "lower.18 Furthermore,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0441994:Lower [Spatial Concept]
   827   C1548802:Lower [Body Location or Region]
   827   C2003888:Lower [Activity]

Phrase: "13"

Phrase: "(41%"

Phrase: "; 95 CI,"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   901   C0009667:Confidence Interval [Quantitative Concept]
   827   C0237529:Confidence [Mental Process]
   827   C1272706:Interval [Temporal Concept]
   827   C1552654:Interval [Idea or Concept]
   827   C1552713:Interval [Intellectual Product]
   827   C1704725:Confidence [Qualitative Concept]
   827   C1704726:Confidence [Mental Process]
   755 E C0558095:Confident [Individual Behavior]
   727 E C0009669:confidentiality [Idea or Concept]

Phrase: "24%-59%"

Phrase: ")"

Phrase: "patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "treated with high-dose imatinib"
Meta Candidates (Total=12; Excluded=1; Pruned=0; Remaining=11)
   806   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   806   C0444956:High dose [Quantitative Concept]
   760   C0178602:Dose [Quantitative Concept]
   760   C0205250:High [Qualitative Concept]
   760   C0869039:Dose [Quantitative Concept]
   760   C0935989:imatinib [Organic Chemical,Pharmacologic Substance]
   760   C1114758:Dose # [Clinical Attribute]
   760   C1299351:High [Qualitative Concept]
   760   C1522326:Treated [Functional Concept]
   760   C2700149:HIGH [Intellectual Product]
   726 E C1292734:TREAT [Functional Concept]

Phrase: "in this study"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0557651:Study [Manufactured Object]
  1000   C2603343:Study [Research Activity]

Phrase: "had"

Phrase: "undetectable transcripts,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1519595:Transcripts [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "with a median"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0549183:Median [Spatial Concept]
  1000   C0876920:Median [Quantitative Concept]
  1000   C2347635:Median [Quantitative Concept]
  1000   C2348144:Median [Quantitative Concept]
  1000   C2939193:Median [Spatial Concept]

Phrase: "follow-up of only 14 months."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C0589120:Follow-up [Finding]
   790   C1522577:follow-up [Health Care Activity]
   790   C1704685:FOLLOW-UP [Intellectual Product]
   790   C3274571:FOLLOW-UP [Health Care Activity]
   753   C0332283:follow [Temporal Concept]
   753   C1719822:Follow [Intellectual Product]
Processing 00000000.tx.143: Molecular remissions have been reported infrequently with late standard-dose imatinib. 

Phrase: "Molecular remissions"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0544452:remissions [Finding]
   861   C0687702:remissions [Neoplastic Process]

Phrase: "have"

Phrase: "been"

Phrase: "reported"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0684224:Reported [Intellectual Product]
  1000   C0700287:Reported [Health Care Activity]
  1000   C3496591:Reported [Clinical Attribute]
   966 E C3273238:Report [Intellectual Product]

Phrase: "infrequently with late standard-dose imatinib."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   753   C0178602:Dose [Quantitative Concept]
   753   C0205087:Late [Temporal Concept]
   753   C0521114:Infrequently [Temporal Concept]
   753   C0869039:Dose [Quantitative Concept]
   753   C0935989:imatinib [Organic Chemical,Pharmacologic Substance]
   753   C1114758:Dose # [Clinical Attribute]
   753   C1442989:Standard [Qualitative Concept]
   753   C2828392:Standard [Intellectual Product]
Processing 00000000.tx.144: Hochhaus et al analyzed 300 patients with CML treated with imatinib, including 135 patients with late chronic phase.9 All 55 patients in complete CG remission remained PCR positive with a median follow-up of 1.3 years. 

Phrase: "Hochhaus et al"

Phrase: "analyzed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0936012:Analyzed [Research Activity]

Phrase: "300 patients with CML"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0030705:Patients [Patient or Disabled Group]

Phrase: "treated with imatinib,"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   882   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   790   C0935989:imatinib [Organic Chemical,Pharmacologic Substance]
   790   C1522326:Treated [Functional Concept]
   756 E C1292734:TREAT [Functional Concept]

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "135 patients with late chronic phase.9"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0030705:Patients [Patient or Disabled Group]

Phrase: "All 55 patients in complete CG remission"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   793   C1277626:Patient in remission [Finding]
           patients remission
   748   C0030705:Patients [Patient or Disabled Group]

Phrase: "remained"

Phrase: "PCR positive with a median"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   748   C0439178:% Positive [Quantitative Concept]
   748   C1446409:Positive [Qualitative Concept]
   748   C1514241:Positive [Finding]
   748   C2825490:Positive [Qualitative Concept]

Phrase: "follow-up of 1.3 years."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   843   C0420338:Follow-up 1 year [Finding]
   790   C0589120:Follow-up [Finding]
   790   C1522577:follow-up [Health Care Activity]
   790   C1704685:FOLLOW-UP [Intellectual Product]
   790   C3274571:FOLLOW-UP [Health Care Activity]
   753   C0332283:follow [Temporal Concept]
   753   C1719822:Follow [Intellectual Product]
Processing 00000000.tx.145: In our experience, 32 (29%; 95 CI, 21%-38%) of 111 patients with chronic-phase CML treated with 400 mg imatinib daily after IFN- failure have achieved BCR-ABL/ABL ratios lower than 0.045% after a median follow-up of 32 months; 

Phrase: "In our experience,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0237607:experience [Mental Process]
  1000   C0596545:Experience [Mental Process]

Phrase: "32"

Phrase: "(29%"

Phrase: "; 95 CI,"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   901   C0009667:Confidence Interval [Quantitative Concept]
   827   C0237529:Confidence [Mental Process]
   827   C1272706:Interval [Temporal Concept]
   827   C1552654:Interval [Idea or Concept]
   827   C1552713:Interval [Intellectual Product]
   827   C1704725:Confidence [Qualitative Concept]
   827   C1704726:Confidence [Mental Process]
   755 E C0558095:Confident [Individual Behavior]
   727 E C0009669:confidentiality [Idea or Concept]

Phrase: "21%-38%"

Phrase: ")"

Phrase: "of 111 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "with chronic-phase CML"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
  1000   C0023474:Chronic phase chronic myeloid leukaemia [Neoplastic Process]
           Leukemia, Myeloid, Chronic-Phase
   911   C0023473:Chronic myeloid leukaemia [Neoplastic Process]
   911   C2984277:Chronic myeloid leukemia [Functional Concept]
   897   C1279296:Chronic leukaemia [Neoplastic Process]
   840   C0023470:Myeloid Leukemia [Neoplastic Process]
   840   C0457343:Chronic phase [Temporal Concept]
   804   C0023418:Leukaemia [Neoplastic Process]
   804   C0205191:chronic [Temporal Concept]
   804   C0205390:Phase [Temporal Concept]
   804   C0439677:Myeloid [Qualitative Concept]

Phrase: "treated with 400 mg imatinib daily"
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
   820   C1331284:imatinib 400 MG [Clinical Drug]
   790   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   753   C0332173:Daily [Temporal Concept]
   753   C0439269:mg% [Quantitative Concept]
   753   C0935989:imatinib [Organic Chemical,Pharmacologic Substance]
   753   C1522326:Treated [Functional Concept]
   753   C1960952:mg % [Quantitative Concept]
   753   C2346927:Mg++ [Element, Ion, or Isotope,Pharmacologic Substance]
   719 E C1292734:TREAT [Functional Concept]

Phrase: "after IFN- failure"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0231174:Failure [Functional Concept]
   861   C0680095:failure [Individual Behavior]

Phrase: "have"

Phrase: "achieved BCR-ABL/ABL ratios"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   804   C0456603:Ratios [Quantitative Concept]
   804   C1610540:*Ratios [Quantitative Concept]
   771 E C1547037:Ratio [Intellectual Product]

Phrase: "lower than 0.045%"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0441994:Lower [Spatial Concept]
   770   C1548802:Lower [Body Location or Region]
   770   C2003888:Lower [Activity]

Phrase: "after a median"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0549183:Median [Spatial Concept]
  1000   C0876920:Median [Quantitative Concept]
  1000   C2347635:Median [Quantitative Concept]
  1000   C2348144:Median [Quantitative Concept]
  1000   C2939193:Median [Spatial Concept]

Phrase: "follow-up of 32 months"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   806   C0589120:Follow-up [Finding]
   806   C1522577:follow-up [Health Care Activity]
   806   C1704685:FOLLOW-UP [Intellectual Product]
   806   C3274571:FOLLOW-UP [Health Care Activity]
   760   C0332283:follow [Temporal Concept]
   760   C1719822:Follow [Intellectual Product]

Phrase: ";"
Processing 00000000.tx.146: 14 patients (13%; 95 CI, 7%-20%) have undetectable transcripts. 

Phrase: "14 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "(13%"

Phrase: "; 95 CI,"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   901   C0009667:Confidence Interval [Quantitative Concept]
   827   C0237529:Confidence [Mental Process]
   827   C1272706:Interval [Temporal Concept]
   827   C1552654:Interval [Idea or Concept]
   827   C1552713:Interval [Intellectual Product]
   827   C1704725:Confidence [Qualitative Concept]
   827   C1704726:Confidence [Mental Process]
   755 E C0558095:Confident [Individual Behavior]
   727 E C0009669:confidentiality [Idea or Concept]

Phrase: "7%-20%"

Phrase: ")"

Phrase: "have"

Phrase: "undetectable transcripts."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1519595:Transcripts [Nucleic Acid, Nucleoside, or Nucleotide]
Processing 00000000.tx.147: The percentage of patients who achieve undetectable transcripts appear to be higher with high-dose imatinib, even with the shorter median follow-up time of therapy. 

Phrase: "The percentage of patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0439165:Percentage [Quantitative Concept]
   770   C1549488:Percentage [Idea or Concept]
   770   C1561533:Percentage [Idea or Concept]

Phrase: "who"

Phrase: "achieve"

Phrase: "undetectable transcripts"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1519595:Transcripts [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "appear"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0700364:APPEAR [Qualitative Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "higher with high-dose imatinib,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   781   C0444956:High dose [Quantitative Concept]
   726   C0205250:High [Qualitative Concept]
   726   C1299351:High [Qualitative Concept]
   726   C2700149:HIGH [Intellectual Product]

Phrase: "even with the shorter median follow-up time of therapy."
Meta Candidates (Total=19; Excluded=0; Pruned=0; Remaining=19)
   760   C0589120:Follow-up [Finding]
   760   C1522577:follow-up [Health Care Activity]
   760   C1704685:FOLLOW-UP [Intellectual Product]
   760   C3274571:FOLLOW-UP [Health Care Activity]
   739   C0039798:therapy [Functional Concept]
   739   C0040223:Time [Temporal Concept]
   739   C0087111:Therapy [Therapeutic or Preventive Procedure]
   739   C0332283:follow [Temporal Concept]
   739   C0549183:Median [Spatial Concept]
   739   C0876920:Median [Quantitative Concept]
   739   C1363945:Therapy [Finding]
   739   C1719822:Follow [Intellectual Product]
   739   C2347635:Median [Quantitative Concept]
   739   C2348144:Median [Quantitative Concept]
   739   C2939193:Median [Spatial Concept]
   739   C3541383:Time [Temporal Concept]
   706   C1282927:short [Qualitative Concept]
   706   C1806781:Short [Quantitative Concept]
   706   C2350002:Short [Quantitative Concept]
Processing 00000000.tx.148: It is important however to recognize that the methodology for molecular analysis varies in different studies, and some techniques reported in the literature may be more sensitive.19 Also, the long-term outcome of patients with undetectable transcripts after imatinib remains to be determined with longer follow-up. 

Phrase: "It"

Phrase: "is"

Phrase: "important however to"

Phrase: "recognize"

Phrase: "that"

Phrase: "the methodology for molecular analysis"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0969625:methodology [Intellectual Product]
   760   C3266812:Methodology [Idea or Concept]

Phrase: "varies in different studies,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   770   C0947630:studies [Laboratory Procedure]
   770   C1548673:Varies [Intellectual Product]
   770   C1705242:Different [Qualitative Concept]
   737 E C0557651:Study [Manufactured Object]
   737 E C2603343:Study [Research Activity]

Phrase: "and"

Phrase: "some techniques"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0025664:techniques [Intellectual Product]
  1000   C0449851:Techniques [Functional Concept]

Phrase: "reported in the literature"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   770   C0023866:Literature [Intellectual Product]
   770   C0034036:LITERATURE [Intellectual Product,Manufactured Object]
   770   C0684224:Reported [Intellectual Product]
   770   C0700287:Reported [Health Care Activity]
   770   C3496591:Reported [Clinical Attribute]
   737 E C3273238:Report [Intellectual Product]

Phrase: "may"

Phrase: "be"

Phrase: "more sensitive.19 Also,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0205172:More [Functional Concept]
   812   C0332324:Sensitive [Functional Concept]
   812   C1550474:sensitive [Idea or Concept]

Phrase: "the long-term outcome of patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   767   C1547647:Patient Outcome [Idea or Concept]
   753   C1274040:Outcome [Functional Concept]

Phrase: "with undetectable transcripts"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1519595:Transcripts [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "after imatinib"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0935989:imatinib [Organic Chemical,Pharmacologic Substance]

Phrase: "remains"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "determined with longer follow-up."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   806   C0589120:Follow-up [Finding]
   806   C1522577:follow-up [Health Care Activity]
   806   C1704685:FOLLOW-UP [Intellectual Product]
   806   C3274571:FOLLOW-UP [Health Care Activity]
   760   C0332283:follow [Temporal Concept]
   760   C1719822:Follow [Intellectual Product]
   726   C0205166:Long [Qualitative Concept]
   726   C1706317:Long [Qualitative Concept]
Processing 00000000.tx.149: In our series, with a median follow-up time of 14 months, all patients who achieved a complete molecular response continue in molecular remission. 

Phrase: "In our series,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205549:Series [Quantitative Concept]
  1000   C2348044:Series [Intellectual Product]

Phrase: "with a median follow-up time"
Meta Candidates (Total=11; Excluded=3; Pruned=0; Remaining=8)
   861   C0589120:Follow-up [Finding]
   861   C1522577:follow-up [Health Care Activity]
   861   C1704685:FOLLOW-UP [Intellectual Product]
   861   C3274571:FOLLOW-UP [Health Care Activity]
   812   C0040223:Time [Temporal Concept]
   812   C0332283:follow [Temporal Concept]
   812   C1719822:Follow [Intellectual Product]
   812   C3541383:Time [Temporal Concept]
   756 E C0442043:Temporal [Spatial Concept]
   756 E C2362314:Temporal [Temporal Concept]
   729 E C1632851:Times [Quantitative Concept]

Phrase: "of 14 months,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0439231:months [Temporal Concept]
   827 E C0439507:/month [Temporal Concept]

Phrase: "all patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "who"

Phrase: "achieved"

Phrase: "a complete molecular response"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   913   C0677874:Complete Response [Finding]
   827   C0871261:Response [Organism Attribute]
   827   C1704632:Response [Finding]
   827   C1706817:Response [Intellectual Product]
   827   C2911692:Response [Mental Process]

Phrase: "continue in molecular remission."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0544452:Remission [Finding]
   770   C0549178:Continue [Idea or Concept]
   770   C0687702:remission [Neoplastic Process]
   770   C1521991:Molecular [Qualitative Concept]
Processing 00000000.tx.150: High-dose imatinib therapy was not associated with significantly more toxicity compared with standard-dose imatinib. 

Phrase: "High-dose imatinib therapy"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0039798:therapy [Functional Concept]
   812   C0087111:Therapy [Therapeutic or Preventive Procedure]
   812   C1363945:Therapy [Finding]

Phrase: "was"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "associated with significantly more toxicity"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   806   C0332281:Associated with [Qualitative Concept]
           Associated
   760   C0040539:toxicity [Qualitative Concept]
   760   C0600688:Toxicity [Injury or Poisoning]
   726 E C0750490:Associate [Idea or Concept]
   726 E C1706221:Associate [Professional or Occupational Group]

Phrase: "compared with standard-dose imatinib."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   760   C0178602:Dose [Quantitative Concept]
   760   C0869039:Dose [Quantitative Concept]
   760   C0935989:imatinib [Organic Chemical,Pharmacologic Substance]
   760   C1114758:Dose # [Clinical Attribute]
   760   C1442989:Standard [Qualitative Concept]
   760   C1707455:Compared [Activity]
   760   C2828392:Standard [Intellectual Product]
Processing 00000000.tx.151: These results are not unexpected. 

Phrase: "These results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "are"

Phrase: "not unexpected."
Processing 00000000.tx.152: In a phase 1 trial of imatinib in a similar population, patients were treated with escalating doses of 25 mg to 1000 mg daily.10 A maximum tolerated dose was not defined, and further dose escalations were not pursued because of evidence of biologic and clinical activity. 

Phrase: "In a phase 1 trial"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0008976:Trial [Research Activity]
   734   C0439559:Phase 1 [Temporal Concept]

Phrase: "of imatinib"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0935989:imatinib [Organic Chemical,Pharmacologic Substance]

Phrase: "in a similar population,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0032659:Population [Quantitative Concept]
   861   C1257890:Population [Population Group]

Phrase: "patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "were"

Phrase: "treated with escalating doses of 25 mg"
Meta Candidates (Total=11; Excluded=4; Pruned=0; Remaining=7)
   778   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   748   C0178602:Doses [Quantitative Concept]
   748   C0439269:mg% [Quantitative Concept]
   748   C1522326:Treated [Functional Concept]
   748   C1960952:mg % [Quantitative Concept]
   748   C2346927:Mg++ [Element, Ion, or Isotope,Pharmacologic Substance]
   714 E C0869039:Dose [Quantitative Concept]
   714 E C1114758:Dose # [Clinical Attribute]
   714 E C1292734:TREAT [Functional Concept]
   714 E C1428722:DOS [Gene or Genome]

Phrase: "to 1000 mg daily.10"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   812   C0332173:Daily [Temporal Concept]
   812   C0439269:mg% [Quantitative Concept]
   812   C1960952:mg % [Quantitative Concept]
   812   C2346927:Mg++ [Element, Ion, or Isotope,Pharmacologic Substance]

Phrase: "A maximum tolerated dose"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
  1000   C0752079:Maximum Tolerated Dose [Quantitative Concept]
   827   C0178602:Dose [Quantitative Concept]
   827   C0806909:Maximum [Quantitative Concept]
   827   C0869039:Dose [Quantitative Concept]
   827   C1114758:Dose # [Clinical Attribute]
   827   C1552615:maximum [Quantitative Concept]
   827   C2826546:MAXIMUM [Quantitative Concept]
   755 E C0205289:Maximal [Qualitative Concept]

Phrase: "was"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "defined"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1704788:Defined [Conceptual Entity]
  1000   C3539106:Defined [Intellectual Product]

Phrase: ","

Phrase: "and"

Phrase: "further dose escalations"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0178602:Dose [Quantitative Concept]
   827   C0869039:Dose [Quantitative Concept]
   827   C1114758:Dose # [Clinical Attribute]

Phrase: "were"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "pursued because of evidence of biologic"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   783   C0332120:Evidence of [Functional Concept]
           Evidence
   753   C0205460:Biologic [Qualitative Concept]
   753   C2979985:BIOLOGIC [Biologically Active Substance,Pharmacologic Substance]

Phrase: "and"

Phrase: "clinical activity."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0205177:Activity [Functional Concept]
   861   C0439167:% activity [Quantitative Concept]
   861   C0441655:Activity [Activity]
   861   C1561536:*Activity [Idea or Concept]
Processing 00000000.tx.153: In patients with accelerated-phase CML, there was no significant difference in grade 3 or higher hematologic or nonhematologic toxicity among patients treated with 400 mg or 600 mg daily.11 In our trial, fluid retention was more likely to require therapy (ie, grade 2 according to the NCI CTC), but grade 3 edema was rare. 

Phrase: "In patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "with accelerated-phase CML,"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C0023472:Accelerated phase chronic myeloid leukaemia [Neoplastic Process]
           Leukemia, Myeloid, Accelerated Phase
   884   C0023473:Chronic myeloid leukaemia [Neoplastic Process]
   884   C2984277:Chronic myeloid leukemia [Functional Concept]
   853   C1279296:Chronic leukaemia [Neoplastic Process]
   840   C0023470:Myeloid Leukemia [Neoplastic Process]
   804   C0023418:Leukaemia [Neoplastic Process]
   804   C0205191:chronic [Temporal Concept]
   804   C0439677:Myeloid [Qualitative Concept]

Phrase: "there"

Phrase: "was"

Phrase: "no significant difference in grade 3"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C1705241:*Difference [Quantitative Concept]
   753   C1705242:Difference [Qualitative Concept]

Phrase: "or"

Phrase: "higher hematologic"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0018943:Hematologic [Biomedical Occupation or Discipline]
   861   C0205488:Haematologic [Functional Concept]
   789 E C0200627:HEMATOLOGY [Laboratory Procedure]

Phrase: "or"

Phrase: "nonhematologic toxicity among patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0040539:toxicity [Qualitative Concept]
   770   C0600688:Toxicity [Injury or Poisoning]

Phrase: "treated with 400 mg"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   833   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   770   C0439269:mg% [Quantitative Concept]
   770   C1522326:Treated [Functional Concept]
   770   C1960952:mg % [Quantitative Concept]
   770   C2346927:Mg++ [Element, Ion, or Isotope,Pharmacologic Substance]
   737 E C1292734:TREAT [Functional Concept]

Phrase: "or"

Phrase: "600 mg daily.11 In our trial,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   748   C0008976:Trial [Research Activity]
   748   C0332173:Daily [Temporal Concept]
   748   C0439269:mg% [Quantitative Concept]
   748   C1960952:mg % [Quantitative Concept]
   748   C2346927:Mg++ [Element, Ion, or Isotope,Pharmacologic Substance]

Phrase: "fluid retention"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
  1000   C0268000:fluid retention [Pathologic Function]
   861   C0005889:FLUID [Body Substance]
   861   C0035280:Retention [Mental Process]
   861   C0302908:fluid [Substance]
   861   C0333117:Retention [Functional Concept]
   861   C0444611:Fluid [Qualitative Concept]
   861   C1704353:Fluid [Substance]
   861   C1753315:retention [Cell Function]

Phrase: "was"

Phrase: "more likely to"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0205172:More [Functional Concept]
   827   C0332148:Likely [Qualitative Concept]
   827   C0750492:Likely [Idea or Concept]

Phrase: "require"

Phrase: "therapy"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039798:therapy [Functional Concept]
  1000   C0087111:Therapy [Therapeutic or Preventive Procedure]
  1000   C1363945:Therapy [Finding]

Phrase: "("

Phrase: "ie"

Phrase: ","

Phrase: "grade 2 according to the NCI CTC"
Meta Candidates (Total=22; Excluded=0; Pruned=0; Remaining=22)
   775   C1513882:National Cancer Institute [Health Care Related Organization]
   775   C1516728:Common Toxicity Criteria [Intellectual Product]
   756   C0687696:grade 2 [Intellectual Product]
   756   C1522446:Grade 2 [Qualitative Concept]
   754   C0804646:Grade Cancer [Clinical Attribute]
   754   C2826262:Toxicity Grade [Quantitative Concept]
   738   C0006826:Cancer [Neoplastic Process]
   738   C0021622:institute [Organization]
   738   C0040539:toxicity [Qualitative Concept]
   738   C0205214:Common [Quantitative Concept]
   738   C0243161:criteria [Intellectual Product]
   738   C0441800:Grade [Classification]
   738   C0600688:Toxicity [Injury or Poisoning]
   738   C0680240:according [Social Behavior]
   738   C0919553:Grade [Classification]
   738   C0998265:Cancer [Eukaryote]
   738   C1272753:Institute [Idea or Concept]
   738   C1306459:Cancer [Finding]
   738   C1522138:Common [Functional Concept]
   738   C3244287:grade [Finding]
   738   C3245503:national [Intellectual Product]
   738   C3245511:common [Intellectual Product]

Phrase: ")"

Phrase: ","

Phrase: "but"

Phrase: "grade 3 edema"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   827   C0013604:Edema [Pathologic Function]
   827   C1717255:Edema [Clinical Attribute]
   734   C0205617:Grade III [Qualitative Concept]
   734   C0450094:Grade 3 [Qualitative Concept]
   734   C0687697:grade 3 [Intellectual Product]

Phrase: "was"

Phrase: "rare."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0521114:Rare [Temporal Concept]
  1000   C0522498:Rare [Qualitative Concept]
  1000   C1514917:RARE [Gene or Genome]
Processing 00000000.tx.154: The only nonhematologic grade 3 or higher adverse event that was more common with high-dose imatinib was skin rash. 

Phrase: "The only nonhematologic grade 3"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   861   C0205617:Grade III [Qualitative Concept]
   861   C0450094:Grade 3 [Qualitative Concept]
   861   C0687697:grade 3 [Intellectual Product]
   812   C0441800:Grade [Classification]
   812   C0919553:Grade [Classification]
   812   C3244287:grade [Finding]

Phrase: "or"

Phrase: "higher adverse event"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C0877248:Adverse event [Finding]
   827   C0441471:Event [Event]

Phrase: "that"

Phrase: "was"

Phrase: "more common with high-dose imatinib"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0205214:Common [Quantitative Concept]
   753   C1522138:Common [Functional Concept]
   753   C3245511:common [Intellectual Product]

Phrase: "was"

Phrase: "skin rash."
Meta Candidates (Total=9; Excluded=4; Pruned=0; Remaining=5)
  1000   C0015230:Skin Rash [Disease or Syndrome]
           Rash
   861   C0444099:Skin [Body Substance]
   861   C1123023:Skin [Body System]
   861   C1278993:Skin [Body System]
   805 E C0221912:Cutaneous [Spatial Concept]
   805 E C0221928:Dermal [Qualitative Concept]
   805 E C1522447:Cutaneous [Functional Concept]
   738 E C0011646:Dermis [Tissue]
Processing 00000000.tx.155: Although myelosuppression was observed, this was not more common with high-dose imatinib. 

Phrase: "Although"

Phrase: "myelosuppression"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0854467:Myelosuppression [Disease or Syndrome]

Phrase: "was"

Phrase: "observed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1441672:Observed [Functional Concept]

Phrase: ","

Phrase: "this"

Phrase: "was"

Phrase: "not more common with high-dose imatinib."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0205214:Common [Quantitative Concept]
   748   C1522138:Common [Functional Concept]
   748   C3245511:common [Intellectual Product]
Processing 00000000.tx.156: We conclude that high-dose imatinib may be more effective than standard doses of imatinib in patients with chronic-phase CML and failure on IFN- therapy. 

Phrase: "We"

Phrase: "conclude"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0917903:conclude [Biomedical or Dental Material,Organic Chemical]

Phrase: "that high-dose imatinib"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0935989:imatinib [Organic Chemical,Pharmacologic Substance]
   734   C0444956:High dose [Quantitative Concept]

Phrase: "may"

Phrase: "be"

Phrase: "more effective than standard doses of imatinib"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C1280519:effective [Qualitative Concept]
   748   C1704419:Effective [Qualitative Concept]

Phrase: "in patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "with chronic-phase CML"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
  1000   C0023474:Chronic phase chronic myeloid leukaemia [Neoplastic Process]
           Leukemia, Myeloid, Chronic-Phase
   911   C0023473:Chronic myeloid leukaemia [Neoplastic Process]
   911   C2984277:Chronic myeloid leukemia [Functional Concept]
   897   C1279296:Chronic leukaemia [Neoplastic Process]
   840   C0023470:Myeloid Leukemia [Neoplastic Process]
   840   C0457343:Chronic phase [Temporal Concept]
   804   C0023418:Leukaemia [Neoplastic Process]
   804   C0205191:chronic [Temporal Concept]
   804   C0205390:Phase [Temporal Concept]
   804   C0439677:Myeloid [Qualitative Concept]

Phrase: "and"

Phrase: "failure on IFN- therapy."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0231174:Failure [Functional Concept]
   770   C0680095:failure [Individual Behavior]
Processing 00000000.tx.157: These doses are well tolerated, and molecular remissions can be achieved in a significant percent of patients. 

Phrase: "These doses"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0178602:Doses [Quantitative Concept]
   966 E C0869039:Dose [Quantitative Concept]
   966 E C1114758:Dose # [Clinical Attribute]
   966 E C1428722:DOS [Gene or Genome]

Phrase: "are"

Phrase: "well tolerated,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0205170:Well [Qualitative Concept]
   861   C3146287:Well [Manufactured Object]

Phrase: "and"

Phrase: "molecular remissions"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0544452:remissions [Finding]
   861   C0687702:remissions [Neoplastic Process]

Phrase: "can"

Phrase: "be"

Phrase: "achieved in a significant percent of patients."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   748   C0030705:Patients [Patient or Disabled Group]
   748   C0237881:significant [Quantitative Concept]
   748   C0439165:Percent [Quantitative Concept]
   748   C0750502:Significant [Idea or Concept]
   748   C1546944:Significant [Qualitative Concept]
Processing 00000000.tx.158: A direct comparison of high-dose imatinib with standard-dose imatinib is warranted.  

Phrase: "A direct comparison of high-dose imatinib"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C1707455:Comparison [Activity]

Phrase: "with standard-dose imatinib"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0935989:imatinib [Organic Chemical,Pharmacologic Substance]

Phrase: "is"

Phrase: "warranted."
Processing 00000000.tx.159: Footnotes  Submitted January 6, 2003; 

Phrase: "Footnotes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2825232:Footnote [Intellectual Product]

Phrase: "Submitted January 6,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1515023:Submitted [Functional Concept]

Phrase: "2003"

Phrase: ";"
Processing 00000000.tx.160: accepted February 27, 2003. 

Phrase: "accepted February 27,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1272684:Accepted [Qualitative Concept]
   827   C1548435:Accepted [Idea or Concept]

Phrase: "2003."
Processing 00000000.tx.161: Prepublished online as Blood First Edition Paper, March 13, 2003; 

Phrase: "Prepublished online as Blood First Edition Paper,"

Phrase: "March 13,"

Phrase: "2003"

Phrase: ";"
Processing 00000000.tx.162: DOI 10.1182/blood-2003-01-0025. 

Phrase: "DOI 10.1182/blood-2003-01-0025."
Meta Candidates (Total=9; Excluded=5; Pruned=0; Remaining=4)
   795   C0005767:Blood [Tissue]
   795   C0005768:blood [Body Substance]
   795   C0229664:Blood [Body Substance]
   795   C2348291:DOI [Classification]
   724 E C0333275:Bloody [Qualitative Concept]
   712 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   712 E C0392895:Bloods [Population Group]
   712 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   712 E C1511228:VESSEL, BLOOD [Tissue]
Processing 00000000.tx.163: J.C. is a Clinical Research Scholar for the Leukemia & Lymphoma Society. 

Phrase: "J.C."

Phrase: "is"

Phrase: "a Clinical Research Scholar for the Leukemia & Lymphoma Society."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C0684017:scholar [Professional or Occupational Group]
Processing 00000000.tx.164: The publication costs of this article were defrayed in part by page charge payment. 

Phrase: "The publication"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0034036:Publication [Intellectual Product,Manufactured Object]
  1000   C0034037:Publication [Occupational Activity]
  1000   C1704324:Publication [Intellectual Product]

Phrase: "costs of this article"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0010186:Cost [Quantitative Concept]
   770   C0220812:Costs [Quantitative Concept]
   770   C1706852:Article [Intellectual Product]

Phrase: "were"

Phrase: "defrayed in part"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0449719:Part [Spatial Concept]
   790   C1709471:Part [Quantitative Concept]

Phrase: "by page charge payment."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0220808:payment [Quantitative Concept]
   827   C0680264:payment [Quantitative Concept]
Processing 00000000.tx.165: Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734. 

Phrase: "Therefore,"

Phrase: "and"

Phrase: "solely to"

Phrase: "indicate"

Phrase: "this fact,"

Phrase: "this article"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1706852:Article [Intellectual Product]

Phrase: "is"

Phrase: "hereby"

Phrase: "marked"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0522501:Marked [Qualitative Concept]
  1000   C1706089:Marked [Qualitative Concept]

Phrase: """advertisement"""
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0949214:advertisement [Intellectual Product]

Phrase: "in accordance with 18 U.S.C. section 1734."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   827   C0041703:U S [Geographic Area]
   799   C0205155:Section [Spatial Concept]
   799   C1293097:Section, NOS [Therapeutic or Preventive Procedure]
   799   C1522472:Section [Substance]
   799   C1552923:Section [Quantitative Concept]
   799   C1705191:Section [Physical Object]
Processing 00000000.tx.166: Reprints: Jorge Cortes, Department of Leukemia, M. 

Phrase: "Reprints"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C3273171:Reprint [Intellectual Product]

Phrase: ":"

Phrase: "Jorge Cortes,"

Phrase: "Department of Leukemia,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1704729:Department [Organization]

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.167: D. 

Phrase: "D."
Processing 00000000.tx.168: Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030; 

Phrase: "Anderson Cancer Center,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C1513817:Cancer Center [Health Care Related Organization]
   827   C0205099:Center [Spatial Concept]

Phrase: "1515 Holcombe Blvd,"

Phrase: "Box 428,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0179400:Box [Manufactured Object]
   861   C1533124:Box [Medical Device]

Phrase: "Houston,"

Phrase: "TX 77030"

Phrase: ";"
Processing 00000000.tx.169: e-mail: jcortes{at}mdanderson.org .  References Top Abstract Introduction Patients and methods Results Discussion References  Druker BJ, Tamura S, Buchdunger E, et al. 

Phrase: "e-mail"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0013849:E-Mail [Intellectual Product]
  1000   C1705961:E-mail [Intellectual Product]
   861   C0024492:Mail [Manufactured Object]
   861   C1538057:MAIL [Gene or Genome]
   861   C1547565:Mail [Idea or Concept]

Phrase: ":"

Phrase: "jcortes{at}mdanderson.org ."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C1522486:ORG [Professional or Occupational Group]

Phrase: "References"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Top Abstract Introduction Patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0030705:Patients [Patient or Disabled Group]

Phrase: "and"

Phrase: "methods Results Discussion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0557061:Discussion [Therapeutic or Preventive Procedure]
   827   C2584313:Discussion [Social Behavior]

Phrase: "References"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Druker BJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0005005:BJ [Geographic Area]

Phrase: "Tamura S,"

Phrase: "Buchdunger E,"

Phrase: "et al."
Processing 00000000.tx.170: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. 

Phrase: "Effects of a selective inhibitor of the Abl tyrosine kinase"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   739   C1280500:effects [Qualitative Concept]
   706 E C2348382:Effect [Qualitative Concept]

Phrase: "on the growth"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0018270:'growth' NOS [Organism Function]
  1000   C0220844:growth [Physiologic Function]
  1000   C1621966:Growth [Organ or Tissue Function]
  1000   C2911660:Growth [Activity]

Phrase: "of Bcr-Abl positive cells."
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   861   C0439178:% positive cells [Quantitative Concept]
   812   C0007634:Cells [Cell]
   812   C3282337:Cells [Cell]
   779 E C1269647:Cell [Cell]
   779 E C1704653:Cell [Medical Device]
   779 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.171: Nat Med. 

Phrase: "Nat Med."
Processing 00000000.tx.172: 1996;2: 561-566.[Medline] [OrderarticleviaInfotrieve] Beran M, Cao X, Estrov Z, et al. 

Phrase: "1996"

Phrase: ";2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: ":"

Phrase: "561-566."

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] Beran M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Cao X,"

Phrase: "Estrov Z,"

Phrase: "et al."
Processing 00000000.tx.173: Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). 

Phrase: "Selective inhibition of cell proliferation"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   926   C1156236:Inhibition of Cell Proliferation [Cell Function]
   760   C0021467:Inhibition [Mental Process]
   760   C0021469:Inhibition [Molecular Function]
   760   C1628982:% inhibition [Quantitative Concept]
   760   C3463820:Inhibition [Activity]

Phrase: "and"

Phrase: "BCR-ABL phosphorylation in acute lymphoblastic leukemia cells"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0031715:Phosphorylation [Molecular Function]
   744   C1158886:Phosphorylation [Molecular Function]

Phrase: "expressing"

Phrase: "Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   809   C0004891:BCR-ABL Protein Tyrosine Kinase [Amino Acid, Peptide, or Protein,Biologically Active Substance]
           BCR-ABL protein
   792   C1268567:Protein-tyrosine kinase inhibitor [Pharmacologic Substance]
   786   C0243459:Protein Kinase A Inhibitor [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   772   C0033681:Protein Tyrosine Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   772   C1449702:Protein kinase inhibitor [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   770   C0010531:Protein Kinase A [Amino Acid, Peptide, or Protein,Enzyme]
   754   C0033640:PROTEIN KINASE [Amino Acid, Peptide, or Protein,Enzyme]
   754   C0038164:Protein A [Amino Acid, Peptide, or Protein,Immunologic Factor,Indicator, Reagent, or Diagnostic Aid]
   754   C0105421:BCR Protein [Amino Acid, Peptide, or Protein,Enzyme]
   738   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "(CGP-57148"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0385728:CGP 57148 [Organic Chemical,Pharmacologic Substance]

Phrase: ")."
Processing 00000000.tx.174: Clin Cancer Res. 

Phrase: "Clin Cancer Res."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C2347379:RES [Finding]
Processing 00000000.tx.175: 1998;4: 1661-1672.[Abstract] Kantarjian HM, Talpaz M, O'Brien S, et al. 

Phrase: "1998"

Phrase: ";4"

Phrase: ":"

Phrase: "1661-1672."

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Kantarjian HM,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0262500:hm [Health Care Activity]
   861   C1512358:HM [Geographic Area]
   861   C3538713:HM [Idea or Concept]

Phrase: "Talpaz M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "O'Brien S,"

Phrase: "et al."
Processing 00000000.tx.176: Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. 

Phrase: "Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0939537:Imatinib mesilate [Organic Chemical,Pharmacologic Substance]
   739   C0025619:Mesilate [Organic Chemical]
   739   C0066087:mesilate [Organic Chemical]
   739   C0935989:imatinib [Organic Chemical,Pharmacologic Substance]
   739   C3645051:mesylate [Organic Chemical]

Phrase: "after failure"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0231174:Failure [Functional Concept]
  1000   C0680095:failure [Individual Behavior]

Phrase: "of interferon-alpha"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C0002199:Interferon Alfa [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
  1000   C0751598:Interferon Alfa [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
  1000   C1610033:Interferon Alpha [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2825023:Interferon alfa [Pharmacologic Substance]
   861   C0021747:Interferon [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0439095:Alpha [Intellectual Product]
   861   C0733470:Interferon [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C2003941:Alpha [Intellectual Product]
   861   C2350010:Alpha [Qualitative Concept]

Phrase: ":"

Phrase: "follow-up results."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   793   C1274040:Result [Functional Concept]
   793   C1546471:Result [Idea or Concept]
   793   C2825142:Result [Finding]
   734   C0589120:Follow-up [Finding]
   734   C1522577:follow-up [Health Care Activity]
   734   C1704685:FOLLOW-UP [Intellectual Product]
   734   C3274571:FOLLOW-UP [Health Care Activity]
Processing 00000000.tx.177: Clin Cancer Res. 

Phrase: "Clin Cancer Res."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C2347379:RES [Finding]
Processing 00000000.tx.178: 2002;8: 2177-2187.[Abstract/Free FullText] Kantarjian H, Sawyers C, Hochhaus A, et al. 

Phrase: "2002"

Phrase: ";8"

Phrase: ":"

Phrase: "2177-2187."

Phrase: "[Abstract/Free FullText"

Phrase: "] Kantarjian H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Sawyers C,"

Phrase: "Hochhaus"

Phrase: "A,"

Phrase: "et al."
Processing 00000000.tx.179: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. 

Phrase: "Hematologic"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0018943:Hematologic [Biomedical Occupation or Discipline]
  1000   C0205488:Haematologic [Functional Concept]
   928 E C0200627:HEMATOLOGY [Laboratory Procedure]

Phrase: "and"

Phrase: "cytogenetic responses to imatinib mesylate"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   760   C0871261:responses [Organism Attribute]
   726 E C1704632:Response [Finding]
   726 E C1706817:Response [Intellectual Product]
   726 E C2911692:Response [Mental Process]

Phrase: "in chronic myelogenous leukemia."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0023473:Chronic myelogenous leukaemia [Neoplastic Process]
   913   C1279296:Chronic leukaemia [Neoplastic Process]
   901   C0023470:Myelogenous Leukemia [Neoplastic Process]
   827   C0023418:Leukaemia [Neoplastic Process]
   827   C0205191:chronic [Temporal Concept]
   827   C0439677:Myelogenous [Qualitative Concept]
Processing 00000000.tx.180: N Engl J Med. 

Phrase: "N Engl J Med."
Processing 00000000.tx.181: 2002;346: 645-652.[Abstract/Free FullText] Kantarjian HM, O'Brien S, Smith TL, et al. 

Phrase: "2002"

Phrase: ";346"

Phrase: ":"

Phrase: "645-652."

Phrase: "[Abstract/Free FullText"

Phrase: "] Kantarjian HM,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0262500:hm [Health Care Activity]
   861   C1512358:HM [Geographic Area]
   861   C3538713:HM [Idea or Concept]

Phrase: "O'Brien S,"

Phrase: "Smith TL,"

Phrase: "et al."
Processing 00000000.tx.182: Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. 

Phrase: "Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   770   C0814494:early treatment phase [Health Care Activity]
   738   C0039798:treatment [Functional Concept]
   738   C0087111:Treatment [Therapeutic or Preventive Procedure]
   738   C1522326:Treatment [Functional Concept]
   738   C1533734:Treatment [Therapeutic or Preventive Procedure]
   738   C1705169:Treatment [Conceptual Entity]
   738   C3538994:TREATMENT [Research Activity]

Phrase: "with daily doses"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   966   C2348070:Daily Dose [Quantitative Concept]
   861   C0178602:Doses [Quantitative Concept]
   861   C0332173:Daily [Temporal Concept]
   827 E C0869039:Dose [Quantitative Concept]
   827 E C1114758:Dose # [Clinical Attribute]
   827 E C1428722:DOS [Gene or Genome]

Phrase: "of interferon alpha"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C0002199:Interferon Alfa [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
  1000   C0751598:Interferon Alfa [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
  1000   C1610033:Interferon Alpha [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2825023:Interferon alfa [Pharmacologic Substance]
   861   C0021747:Interferon [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0439095:Alpha [Intellectual Product]
   861   C0733470:Interferon [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C2003941:Alpha [Intellectual Product]
   861   C2350010:Alpha [Qualitative Concept]

Phrase: "and"

Phrase: "low-dose cytarabine."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   827   C0010711:Cytarabine [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]
   771 E C0591320:Cytosar [Hazardous or Poisonous Substance,Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]
   734   C0445550:Low dose [Quantitative Concept]
   734   C1708745:Low-Dose [Research Activity]
Processing 00000000.tx.183: J Clin Oncol. 

Phrase: "J Clin Oncol."
Processing 00000000.tx.184: 1999;17: 284-292.[Abstract/Free FullText] Guilhot F, Chastang C, Michallet M, et al. 

Phrase: "1999"

Phrase: ";17"

Phrase: ":"

Phrase: "284-292."

Phrase: "[Abstract/Free FullText"

Phrase: "] Guilhot F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Chastang C,"

Phrase: "Michallet M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "et al."
Processing 00000000.tx.185: Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia: French Chronic Myeloid Leukemia Study Group [see comments]. 

Phrase: "Interferon alfa-2b"
Meta Candidates (Total=13; Excluded=0; Pruned=0; Remaining=13)
  1000   C0021735:Interferon Alfa-2b [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
  1000   C1334080:interferon alpha 2b [Gene or Genome]
   901   C0002199:Interferon Alfa [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   901   C0751598:Interferon Alfa [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   901   C1610033:Interferon Alpha [Amino Acid, Peptide, or Protein,Immunologic Factor]
   901   C2825023:Interferon alfa [Pharmacologic Substance]
   827   C0021747:Interferon [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   827   C0439095:Alpha [Intellectual Product]
   827   C0450354:2b [Intellectual Product]
   827   C0733470:Interferon [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   827   C1706096:2B [Research Activity]
   827   C2003941:Alpha [Intellectual Product]
   827   C2350010:Alpha [Qualitative Concept]

Phrase: "combined with cytarabine"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   790   C0010711:Cytarabine [Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]
   790   C0205195:Combined [Qualitative Concept]
   756 E C0336789:Combine [Manufactured Object]
   734 E C0591320:Cytosar [Hazardous or Poisonous Substance,Nucleic Acid, Nucleoside, or Nucleotide,Pharmacologic Substance]

Phrase: "versus"

Phrase: "interferon"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0021747:Interferon [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
  1000   C0733470:Interferon [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "alone in chronic myelogenous leukemia"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0205171:Alone [Quantitative Concept]
   760   C0439044:alone [Finding]
   760   C0679994:alone [Group Attribute]

Phrase: ":"

Phrase: "French Chronic Myeloid Leukemia Study Group"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   799   C0441833:Group [Idea or Concept]
   799   C0557651:Study [Manufactured Object]
   799   C0687744:group [Population Group]
   799   C1257890:Group [Population Group]
   799   C1552516:Group [Health Care Related Organization]
   799   C1705428:Group [Conceptual Entity]
   799   C1705429:Group [Population Group]
   799   C2603343:Study [Research Activity]

Phrase: "["

Phrase: "see"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0042789:see [Organism Function]
  1000   C1947903:See [Activity]

Phrase: "comments"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0282411:Comments [Intellectual Product]
  1000   C0947611:comments [Intellectual Product]
  1000   C1705247:Comments [Conceptual Entity]

Phrase: "]."
Processing 00000000.tx.186: N Engl J Med. 

Phrase: "N Engl J Med."
Processing 00000000.tx.187: 1997;337: 223-229.[Abstract/Free FullText] Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia: the Italian Cooperative Study Group on Chronic Myeloid Leukemia. 

Phrase: "1997"

Phrase: ";337"

Phrase: ":"

Phrase: "223-229."

Phrase: "[Abstract/Free FullText"

Phrase: "] Interferon alfa-2a"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
  1000   C0021734:Interferon Alfa-2a [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   901   C0002199:Interferon Alfa [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   901   C0751598:Interferon Alfa [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   901   C1610033:Interferon Alpha [Amino Acid, Peptide, or Protein,Immunologic Factor]
   901   C2825023:Interferon alfa [Pharmacologic Substance]
   827   C0021747:Interferon [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   827   C0439095:Alpha [Intellectual Product]
   827   C0733470:Interferon [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   827   C2003941:Alpha [Intellectual Product]
   827   C2350010:Alpha [Qualitative Concept]

Phrase: "as"

Phrase: "compared with conventional chemotherapy"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0013216:Chemotherapy [Therapeutic or Preventive Procedure]
   770   C0013217:chemotherapy [Functional Concept]
   770   C0392920:Chemotherapy [Therapeutic or Preventive Procedure]
   770   C0439858:Conventional [Qualitative Concept]
   770   C1707455:Compared [Activity]

Phrase: "for the treatment"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0039798:treatment [Functional Concept]
  1000   C0087111:Treatment [Therapeutic or Preventive Procedure]
  1000   C1522326:Treatment [Functional Concept]
  1000   C1533734:Treatment [Therapeutic or Preventive Procedure]
  1000   C1705169:Treatment [Conceptual Entity]
  1000   C3538994:TREATMENT [Research Activity]

Phrase: "of chronic myeloid leukemia"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0023473:Chronic myeloid leukaemia [Neoplastic Process]
  1000   C2984277:Chronic myeloid leukemia [Functional Concept]
   913   C1279296:Chronic leukaemia [Neoplastic Process]
   901   C0023470:Myeloid Leukemia [Neoplastic Process]
   827   C0023418:Leukaemia [Neoplastic Process]
   827   C0205191:chronic [Temporal Concept]
   827   C0439677:Myeloid [Qualitative Concept]

Phrase: ":"

Phrase: "the Italian Cooperative Study Group on Chronic Myeloid Leukemia."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   762   C1521808:Cooperative Group [Professional or Occupational Group]
   742   C0441833:Group [Idea or Concept]
   742   C0687744:group [Population Group]
   742   C1257890:Group [Population Group]
   742   C1552516:Group [Health Care Related Organization]
   742   C1705428:Group [Conceptual Entity]
   742   C1705429:Group [Population Group]
Processing 00000000.tx.188: N Engl J Med. 

Phrase: "N Engl J Med."
Processing 00000000.tx.189: 1994;330: 820-825.[Abstract/Free FullText] Kantarjian HM, Smith T, O'Brien S, Beran M, Pierce S, Talpaz M. 

Phrase: "1994"

Phrase: ";330"

Phrase: ":"

Phrase: "820-825."

Phrase: "[Abstract/Free FullText"

Phrase: "] Kantarjian HM,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0262500:hm [Health Care Activity]
   861   C1512358:HM [Geographic Area]
   861   C3538713:HM [Idea or Concept]

Phrase: "Smith T,"

Phrase: "O'Brien S,"

Phrase: "Beran M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Pierce S,"

Phrase: "Talpaz M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.190: Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy: the Leukemia Service. 

Phrase: "Prolonged survival in chronic myelogenous leukemia"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0038952:Survival [Activity]
   753   C0220921:survival [Functional Concept]

Phrase: "after cytogenetic response"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0871261:Response [Organism Attribute]
   861   C1704632:Response [Finding]
   861   C1706817:Response [Intellectual Product]
   861   C2911692:Response [Mental Process]

Phrase: "to interferon-alpha therapy"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   913   C0279030:interferon therapy [Therapeutic or Preventive Procedure]
   827   C0039798:therapy [Functional Concept]
   827   C0087111:Therapy [Therapeutic or Preventive Procedure]
   827   C1363945:Therapy [Finding]
   734   C0002199:Interferon Alfa [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   734   C0751598:Interferon Alfa [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   734   C1610033:Interferon Alpha [Amino Acid, Peptide, or Protein,Immunologic Factor]
   734   C2825023:Interferon alfa [Pharmacologic Substance]

Phrase: ":"

Phrase: "the Leukemia Service."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557854:Service [Occupational Activity]
   861   C2825316:Service [Manufactured Object]
   861   C3245478:service [Idea or Concept]
Processing 00000000.tx.191: Ann Intern Med. 

Phrase: "Ann Intern Med."
Processing 00000000.tx.192: 1995;122: 254-261.[Abstract/Free FullText] Hochhaus A, Lahaye T, Kreil S, et al. 

Phrase: "1995"

Phrase: ";122"

Phrase: ":"

Phrase: "254-261."

Phrase: "[Abstract/Free FullText"

Phrase: "] Hochhaus"

Phrase: "A,"

Phrase: "Lahaye T,"

Phrase: "Kreil S,"

Phrase: "et al."
Processing 00000000.tx.193: Interim analysis of imatinib treatment in 300 patients with chronic myelogenous leukemia (CML): evaluation of response and resistance [abstract]. 

Phrase: "Interim analysis of imatinib treatment"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0002778:Analysis [Laboratory Procedure]
   760   C0936012:Analysis [Research Activity]
   760   C1524024:analysis [Functional Concept]

Phrase: "in 300 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "with chronic myelogenous leukemia"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0023473:Chronic myelogenous leukaemia [Neoplastic Process]
   913   C1279296:Chronic leukaemia [Neoplastic Process]
   901   C0023470:Myelogenous Leukemia [Neoplastic Process]
   827   C0023418:Leukaemia [Neoplastic Process]
   827   C0205191:chronic [Temporal Concept]
   827   C0439677:Myelogenous [Qualitative Concept]

Phrase: "(CML"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0023473:Chronic myeloid leukaemia [Neoplastic Process]
  1000   C2984277:Chronic myeloid leukemia [Functional Concept]
   913   C1279296:Chronic leukaemia [Neoplastic Process]
   901   C0023470:Myeloid Leukemia [Neoplastic Process]
   827   C0023418:Leukaemia [Neoplastic Process]
   827   C0205191:chronic [Temporal Concept]
   827   C0439677:Myeloid [Qualitative Concept]

Phrase: ")"

Phrase: ":"

Phrase: "evaluation of response"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0220825:Evaluation [Functional Concept]
   790   C1261322:Evaluation [Health Care Activity]

Phrase: "and"

Phrase: "resistance"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0237834:Resistance [Mental Process]
  1000   C1514892:Resistance [Physiologic Function]
   928 E C0332325:Resistant [Functional Concept]
   928 E C1550464:resistent [Idea or Concept]
   928 E C2827757:RESISTANT [Laboratory or Test Result]

Phrase: "[abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "]."
Processing 00000000.tx.194: Proc ASCO. 

Phrase: "Proc ASCO."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1515948:ASCO [Professional Society]
Processing 00000000.tx.195: 2002;21: 262a. 

Phrase: "2002"

Phrase: ";21"

Phrase: ":"

Phrase: "262a."
Processing 00000000.tx.196: Druker BJ, Talpaz M, Resta DJ, et al. 

Phrase: "Druker BJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0005005:BJ [Geographic Area]

Phrase: "Talpaz M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Resta DJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0012836:DJ [Geographic Area]

Phrase: "et al."
Processing 00000000.tx.197: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. 

Phrase: "Efficacy"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1280519:Efficacy [Qualitative Concept]
  1000   C1707887:EFFICACY [Research Activity]

Phrase: "and"

Phrase: "safety of a specific inhibitor of the BCR-ABL tyrosine kinase"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   738   C0036043:Safety [Human-caused Phenomenon or Process]
   738   C1705187:SAFETY [Research Activity]

Phrase: "in chronic myeloid leukemia."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0023473:Chronic myeloid leukaemia [Neoplastic Process]
  1000   C2984277:Chronic myeloid leukemia [Functional Concept]
   913   C1279296:Chronic leukaemia [Neoplastic Process]
   901   C0023470:Myeloid Leukemia [Neoplastic Process]
   827   C0023418:Leukaemia [Neoplastic Process]
   827   C0205191:chronic [Temporal Concept]
   827   C0439677:Myeloid [Qualitative Concept]
Processing 00000000.tx.198: N Engl J Med. 

Phrase: "N Engl J Med."
Processing 00000000.tx.199: 2001;344: 1031-1037.[Abstract/Free FullText] Talpaz M, Silver RT, Druker BJ, et al. 

Phrase: "2001"

Phrase: ";344"

Phrase: ":"

Phrase: "1031-1037."

Phrase: "[Abstract/Free FullText"

Phrase: "] Talpaz M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Silver RT,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C0035380:Reverse Transcription [Genetic Function]
   827   C0040649:Transcription [Genetic Function]
   827   C1555029:Reverse [Idea or Concept]

Phrase: "Druker BJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0005005:BJ [Geographic Area]

Phrase: "et al."
Processing 00000000.tx.200: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. 

Phrase: "Imatinib"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0935989:imatinib [Organic Chemical,Pharmacologic Substance]

Phrase: "induces"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205263:Induce [Functional Concept]

Phrase: "durable hematologic"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0018943:Hematologic [Biomedical Occupation or Discipline]
   861   C0205488:Haematologic [Functional Concept]
   789 E C0200627:HEMATOLOGY [Laboratory Procedure]

Phrase: "and"

Phrase: "cytogenetic responses in patients"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   770   C0871261:responses [Organism Attribute]
   737 E C1704632:Response [Finding]
   737 E C1706817:Response [Intellectual Product]
   737 E C2911692:Response [Mental Process]

Phrase: "with accelerated phase chronic myeloid leukemia"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C0023472:Accelerated phase chronic myeloid leukaemia [Neoplastic Process]
           Leukemia, Myeloid, Accelerated Phase
   884   C0023473:Chronic myeloid leukaemia [Neoplastic Process]
   884   C2984277:Chronic myeloid leukemia [Functional Concept]
   853   C1279296:Chronic leukaemia [Neoplastic Process]
   840   C0023470:Myeloid Leukemia [Neoplastic Process]
   804   C0023418:Leukaemia [Neoplastic Process]
   804   C0205191:chronic [Temporal Concept]
   804   C0439677:Myeloid [Qualitative Concept]

Phrase: ":"

Phrase: "results of a phase 2 study."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   783   C0683954:results study [Finding]
   719   C1274040:Result [Functional Concept]
   719   C1546471:Result [Idea or Concept]
   719   C2825142:Result [Finding]
Processing 00000000.tx.201: Blood. 

Phrase: "Blood."
Meta Candidates (Total=10; Excluded=7; Pruned=0; Remaining=3)
  1000   C0005767:Blood [Tissue]
  1000   C0005768:blood [Body Substance]
  1000   C0229664:Blood [Body Substance]
   928 E C0333275:Bloody [Qualitative Concept]
   916 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   916 E C0392895:Bloods [Population Group]
   916 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   916 E C1511228:VESSEL, BLOOD [Tissue]
   900 E C1558950:VASCULAR [Finding]
   900 E C1801960:Vascular [Qualitative Concept]
Processing 00000000.tx.202: 2002;99: 1928-1937.[Abstract/Free FullText] Weisberg E, Griffin JD. 

Phrase: "2002"

Phrase: ";99"

Phrase: ":"

Phrase: "1928-1937."

Phrase: "[Abstract/Free FullText"

Phrase: "] Weisberg E,"

Phrase: "Griffin JD."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1549972:JD [Intellectual Product]
Processing 00000000.tx.203: Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients. 

Phrase: "Mechanisms of resistance imatinib"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   802   C1522618:resistance mechanism [Clinical Attribute]
   770   C0441712:Mechanisms [Functional Concept]
   737 E C1706376:Mechanism [Manufactured Object]

Phrase: "(STI571"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0906802:STI-571 [Organic Chemical,Pharmacologic Substance]

Phrase: ")"

Phrase: "in preclinical models"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514292:Preclinical Models [Intellectual Product]
   861   C3161035:Models [Intellectual Product]

Phrase: "and in leukemia patients."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0023418:Leukaemia [Neoplastic Process]
   770   C0030705:Patients [Patient or Disabled Group]
   770   C1515981:And [Idea or Concept]
Processing 00000000.tx.204: Drug Resistance Updates. 

Phrase: "Drug Resistance Updates."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   793   C1519814:Update [Temporal Concept]
   734   C0013203:Drug resistance [Biologic Function]
Processing 00000000.tx.205: 2001;4: 22-28.[CrossRef][Medline] [OrderarticleviaInfotrieve] Weisberg E, Griffin JD. 

Phrase: "2001"

Phrase: ";4"

Phrase: ":"

Phrase: "22-28."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] Weisberg E,"

Phrase: "Griffin JD."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1549972:JD [Intellectual Product]
Processing 00000000.tx.206: Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. 

Phrase: "Mechanism of resistance"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   858   C1522618:resistance mechanism [Clinical Attribute]
   790   C0441712:Mechanism [Functional Concept]
   790   C1706376:Mechanism [Manufactured Object]

Phrase: "to the ABL tyrosine kinase inhibitor STI571"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   804   C0906802:STI-571 [Organic Chemical,Pharmacologic Substance]
   717   C1268567:Tyrosine Kinase Inhibitor [Pharmacologic Substance]
   717   C1439337:ABL Tyrosine Kinase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "in BCR/ABL-transformed hematopoietic cell lines."
Meta Candidates (Total=10; Excluded=2; Pruned=0; Remaining=8)
   867   C0007601:Transformed Cell Lines [Cell]
   827   C0007600:Cell lines [Cell]
   827   C2323499:Hematopoietic cell [Cell]
   799   C0007634:Cell [Cell]
   799   C0205132:lines [Spatial Concept]
   799   C1269647:Cell [Cell]
   799   C1704653:Cell [Medical Device]
   799   C1948049:Cell [Spatial Concept]
   766 E C1550648:Line [Substance]
   766 E C1552960:Line [Quantitative Concept]
Processing 00000000.tx.207: Blood. 

Phrase: "Blood."
Meta Candidates (Total=10; Excluded=7; Pruned=0; Remaining=3)
  1000   C0005767:Blood [Tissue]
  1000   C0005768:blood [Body Substance]
  1000   C0229664:Blood [Body Substance]
   928 E C0333275:Bloody [Qualitative Concept]
   916 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   916 E C0392895:Bloods [Population Group]
   916 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   916 E C1511228:VESSEL, BLOOD [Tissue]
   900 E C1558950:VASCULAR [Finding]
   900 E C1801960:Vascular [Qualitative Concept]
Processing 00000000.tx.208: 2000;95: 3498-3505.[Abstract/Free FullText] Mahon FX, Deininger MW, Schultheis B, et al. 

Phrase: "2000"

Phrase: ";95"

Phrase: ":"

Phrase: "3498-3505."

Phrase: "[Abstract/Free FullText"

Phrase: "] Mahon FX,"

Phrase: "Deininger MW,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0024548:MW [Geographic Area]
   861   C0026385:mw [Quantitative Concept]
   861   C0556966:mW [Quantitative Concept]

Phrase: "Schultheis B,"

Phrase: "et al."
Processing 00000000.tx.209: Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. 

Phrase: "Selection"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0036576:selection [Genetic Function]

Phrase: "and"

Phrase: "characterization of BCR-ABL positive cell lines"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C1880022:Characterization [Activity]

Phrase: "with differential sensitivity"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   861   C0036667:Sensitivity [Quantitative Concept]
   861   C0312418:Sensitivity [Mental Process]
   861   C0427965:Sensitivity [Finding]
   861   C1511883:Sensitivity [Quantitative Concept]
   861   C1522640:Sensitivity [Qualitative Concept]
   861   C2346484:SENSITIVITY [Phenomenon or Process]
   861   C2349185:Sensitivity [Qualitative Concept]
   789 E C0332324:Sensitive [Functional Concept]
   789 E C1550474:sensitive [Idea or Concept]

Phrase: "to the tyrosine kinase inhibitor STI571"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0906802:STI-571 [Organic Chemical,Pharmacologic Substance]
   756   C1268567:Tyrosine Kinase Inhibitor [Pharmacologic Substance]

Phrase: ":"

Phrase: "diverse mechanisms of resistance."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   802   C1522618:resistance mechanism [Clinical Attribute]
   770   C0441712:Mechanisms [Functional Concept]
   737 E C1706376:Mechanism [Manufactured Object]
Processing 00000000.tx.210: Blood. 

Phrase: "Blood."
Meta Candidates (Total=10; Excluded=7; Pruned=0; Remaining=3)
  1000   C0005767:Blood [Tissue]
  1000   C0005768:blood [Body Substance]
  1000   C0229664:Blood [Body Substance]
   928 E C0333275:Bloody [Qualitative Concept]
   916 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   916 E C0392895:Bloods [Population Group]
   916 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   916 E C1511228:VESSEL, BLOOD [Tissue]
   900 E C1558950:VASCULAR [Finding]
   900 E C1801960:Vascular [Qualitative Concept]
Processing 00000000.tx.211: 2000;96: 1070-1079.[Abstract/Free FullText] le Coutre P, Tassi E, Varella-Garcia M, et al. 

Phrase: "2000"

Phrase: ";96"

Phrase: ":"

Phrase: "1070-1079."

Phrase: "[Abstract/Free FullText"

Phrase: "] le Coutre P,"

Phrase: "Tassi E,"

Phrase: "Varella-Garcia M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C0441923:M+ [Intellectual Product]

Phrase: "et al."
Processing 00000000.tx.212: Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. 

Phrase: "Induction of resistance"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0205263:Induction [Functional Concept]
   790   C0857127:induction [Therapeutic or Preventive Procedure]

Phrase: "to the Abelson inhibitor STI571"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0906802:STI-571 [Organic Chemical,Pharmacologic Substance]

Phrase: "in human leukemic cells"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   913   C0427861:Human cells [Laboratory or Test Result]
   884   C1517806:Leukemic Cell [Cell]
   827   C0007634:Cells [Cell]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]

Phrase: "through gene amplification."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0017256:Gene Amplification [Genetic Function]
  1000   C1705759:Gene Amplification [Cell or Molecular Dysfunction]
           Amplification
   861   C0017337:Gene [Gene or Genome]
   861   C1517480:Amplification [Molecular Biology Research Technique]
   861   C1521871:Amplification [Phenomenon or Process]
Processing 00000000.tx.213: Blood. 

Phrase: "Blood."
Meta Candidates (Total=10; Excluded=7; Pruned=0; Remaining=3)
  1000   C0005767:Blood [Tissue]
  1000   C0005768:blood [Body Substance]
  1000   C0229664:Blood [Body Substance]
   928 E C0333275:Bloody [Qualitative Concept]
   916 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   916 E C0392895:Bloods [Population Group]
   916 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   916 E C1511228:VESSEL, BLOOD [Tissue]
   900 E C1558950:VASCULAR [Finding]
   900 E C1801960:Vascular [Qualitative Concept]
Processing 00000000.tx.214: 2000;95: 1758-1766.[Abstract/Free FullText] Faderl S, Talpaz M, Estrov Z, Kantarjian HM. 

Phrase: "2000"

Phrase: ";95"

Phrase: ":"

Phrase: "1758-1766."

Phrase: "[Abstract/Free FullText"

Phrase: "] Faderl S,"

Phrase: "Talpaz M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Estrov Z,"

Phrase: "Kantarjian HM."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0262500:hm [Health Care Activity]
   861   C1512358:HM [Geographic Area]
   861   C3538713:HM [Idea or Concept]
Processing 00000000.tx.215: Chronic myelogenous leukemia: biology and therapy. 

Phrase: "Chronic myelogenous leukemia"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0023473:Chronic myelogenous leukaemia [Neoplastic Process]
   913   C1279296:Chronic leukaemia [Neoplastic Process]
   901   C0023470:Myelogenous Leukemia [Neoplastic Process]
   827   C0023418:Leukaemia [Neoplastic Process]
   827   C0205191:chronic [Temporal Concept]
   827   C0439677:Myelogenous [Qualitative Concept]

Phrase: ":"

Phrase: "biology"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0005532:Biology [Biomedical Occupation or Discipline]
   928 E C0205460:Biologic [Qualitative Concept]
   928 E C2979985:BIOLOGIC [Biologically Active Substance,Pharmacologic Substance]

Phrase: "and"

Phrase: "therapy."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039798:therapy [Functional Concept]
  1000   C0087111:Therapy [Therapeutic or Preventive Procedure]
  1000   C1363945:Therapy [Finding]
Processing 00000000.tx.216: Ann Intern Med. 

Phrase: "Ann Intern Med."
Processing 00000000.tx.217: 1999;131: 207-219.[Abstract/Free FullText] Kantarjian HM, Talpaz M, Cortes J, et al. 

Phrase: "1999"

Phrase: ";131"

Phrase: ":"

Phrase: "207-219."

Phrase: "[Abstract/Free FullText"

Phrase: "] Kantarjian HM,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0262500:hm [Health Care Activity]
   861   C1512358:HM [Geographic Area]
   861   C3538713:HM [Idea or Concept]

Phrase: "Talpaz M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Cortes J,"

Phrase: "et al."
Processing 00000000.tx.218: Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; Gleevec) in chronic-phase chronic myelogenous leukemia. 

Phrase: "Quantitative polymerase chain reaction monitoring of BCR-ABL"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0150369:Monitoring [Health Care Activity]
   744   C1516647:monitoring [Research Activity]

Phrase: "during therapy"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039798:therapy [Functional Concept]
  1000   C0087111:Therapy [Therapeutic or Preventive Procedure]
  1000   C1363945:Therapy [Finding]

Phrase: "with imatinib mesylate"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0939537:Imatinib mesilate [Organic Chemical,Pharmacologic Substance]
   861   C0025619:Mesilate [Organic Chemical]
   861   C0066087:mesilate [Organic Chemical]
   861   C0935989:imatinib [Organic Chemical,Pharmacologic Substance]
   861   C3645051:mesylate [Organic Chemical]

Phrase: "(STI571"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0906802:STI-571 [Organic Chemical,Pharmacologic Substance]

Phrase: "; Gleevec"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0935987:Gleevec [Organic Chemical,Pharmacologic Substance]

Phrase: ")"

Phrase: "in chronic-phase chronic myelogenous leukemia."
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
  1000   C0023474:Myelogenous Leukemia, Chronic, Chronic-Phase [Neoplastic Process]
           Leukemia, Myelogenous, Chronic-Phase
   911   C0023473:Chronic myelogenous leukaemia [Neoplastic Process]
   897   C1279296:Chronic leukaemia [Neoplastic Process]
   840   C0023470:Myelogenous Leukemia [Neoplastic Process]
   840   C0457343:Chronic phase [Temporal Concept]
   804   C0023418:Leukaemia [Neoplastic Process]
   804   C0205191:chronic [Temporal Concept]
   804   C0205390:Phase [Temporal Concept]
   804   C0439677:Myelogenous [Qualitative Concept]
Processing 00000000.tx.219: Clin Cancer Res. 

Phrase: "Clin Cancer Res."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C2347379:RES [Finding]
Processing 00000000.tx.220: 2003;9: 160-166.[Abstract/Free FullText] Hochhaus A, Reiter A, Saussele S, et al. 

Phrase: "2003"

Phrase: ";9"

Phrase: ":"

Phrase: "160-166."

Phrase: "[Abstract/Free FullText"

Phrase: "] Hochhaus"

Phrase: "A,"

Phrase: "Reiter A,"

Phrase: "Saussele S,"

Phrase: "et al."
Processing 00000000.tx.221: Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission: German CML Study Group and the UK MRC CML Study Group. 

Phrase: "Molecular heterogeneity in complete cytogenetic responders"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0019409:Heterogeneity [Qualitative Concept]

Phrase: "after interferon-alpha therapy"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   913   C0279030:interferon therapy [Therapeutic or Preventive Procedure]
   827   C0039798:therapy [Functional Concept]
   827   C0087111:Therapy [Therapeutic or Preventive Procedure]
   827   C1363945:Therapy [Finding]
   734   C0002199:Interferon Alfa [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   734   C0751598:Interferon Alfa [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   734   C1610033:Interferon Alpha [Amino Acid, Peptide, or Protein,Immunologic Factor]
   734   C2825023:Interferon alfa [Pharmacologic Substance]

Phrase: "for chronic myelogenous leukemia"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0023473:Chronic myelogenous leukaemia [Neoplastic Process]
   913   C1279296:Chronic leukaemia [Neoplastic Process]
   901   C0023470:Myelogenous Leukemia [Neoplastic Process]
   827   C0023418:Leukaemia [Neoplastic Process]
   827   C0205191:chronic [Temporal Concept]
   827   C0439677:Myelogenous [Qualitative Concept]

Phrase: ":"

Phrase: "low levels of minimal residual disease"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   753   C0441889:Levels [Qualitative Concept]
   719 E C0456079:Level [Classification]
   719 E C1547707:Level [Geographic Area]
   719 E C2946261:Level [Pharmacologic Substance]

Phrase: "are"

Phrase: "associated with continuing remission"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   833   C0332281:Associated with [Qualitative Concept]
           Associated
   770   C0544452:Remission [Finding]
   770   C0549178:Continuing [Idea or Concept]
   770   C0687702:remission [Neoplastic Process]
   737 E C0750490:Associate [Idea or Concept]
   737 E C1706221:Associate [Professional or Occupational Group]

Phrase: ":"

Phrase: "German CML Study Group"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   799   C0441833:Group [Idea or Concept]
   799   C0557651:Study [Manufactured Object]
   799   C0687744:group [Population Group]
   799   C1257890:Group [Population Group]
   799   C1552516:Group [Health Care Related Organization]
   799   C1705428:Group [Conceptual Entity]
   799   C1705429:Group [Population Group]
   799   C2603343:Study [Research Activity]

Phrase: "and"

Phrase: "the UK MRC CML Study Group."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   795   C0441833:Group [Idea or Concept]
   795   C0557651:Study [Manufactured Object]
   795   C0687744:group [Population Group]
   795   C1257890:Group [Population Group]
   795   C1552516:Group [Health Care Related Organization]
   795   C1705428:Group [Conceptual Entity]
   795   C1705429:Group [Population Group]
   795   C2603343:Study [Research Activity]
Processing 00000000.tx.222: Blood. 

Phrase: "Blood."
Meta Candidates (Total=10; Excluded=7; Pruned=0; Remaining=3)
  1000   C0005767:Blood [Tissue]
  1000   C0005768:blood [Body Substance]
  1000   C0229664:Blood [Body Substance]
   928 E C0333275:Bloody [Qualitative Concept]
   916 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   916 E C0392895:Bloods [Population Group]
   916 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   916 E C1511228:VESSEL, BLOOD [Tissue]
   900 E C1558950:VASCULAR [Finding]
   900 E C1801960:Vascular [Qualitative Concept]
Processing 00000000.tx.223: 2000;95: 62-66.[Abstract/Free FullText] Merx K, Muller MC, Kreil S, et al. 

Phrase: "2000"

Phrase: ";95"

Phrase: ":"

Phrase: "62-66."

Phrase: "[Abstract/Free FullText"

Phrase: "] Merx K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Muller MC,"

Phrase: "Kreil S,"

Phrase: "et al."
Processing 00000000.tx.224: Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. 

Phrase: "Early reduction of BCR-ABL mRNA transcript levels"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   744   C0301630:Reduction [Natural Phenomenon or Process]
   744   C0392756:Reduction [Qualitative Concept]
   744   C0441610:Reduction [Therapeutic or Preventive Procedure]

Phrase: "predicts"

Phrase: "cytogenetic response in chronic phase CML patients"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   742   C0871261:Response [Organism Attribute]
   742   C1704632:Response [Finding]
   742   C1706817:Response [Intellectual Product]
   742   C2911692:Response [Mental Process]

Phrase: "treated with imatinib"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   882   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   790   C0935989:imatinib [Organic Chemical,Pharmacologic Substance]
   790   C1522326:Treated [Functional Concept]
   756 E C1292734:TREAT [Functional Concept]

Phrase: "after failure"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0231174:Failure [Functional Concept]
  1000   C0680095:failure [Individual Behavior]

Phrase: "of interferon alpha."
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C0002199:Interferon Alfa [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
  1000   C0751598:Interferon Alfa [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
  1000   C1610033:Interferon Alpha [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2825023:Interferon alfa [Pharmacologic Substance]
   861   C0021747:Interferon [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0439095:Alpha [Intellectual Product]
   861   C0733470:Interferon [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C2003941:Alpha [Intellectual Product]
   861   C2350010:Alpha [Qualitative Concept]
Processing 00000000.tx.225: Leukemia. 

Phrase: "Leukemia."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0023418:Leukaemia [Neoplastic Process]
Processing 00000000.tx.226: 2002;16: 1579-1583.[CrossRef][Medline] [OrderarticleviaInfotrieve]

Phrase: "2002"

Phrase: ";16"

Phrase: ":"

Phrase: "1579-1583."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "]"

